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Human cytomegalovirus (CMV) is associated with serious infections 
in immunocompromised hosts such as organ transplant recipients.  
Prolonged ganciclovir therapy for CMV infection and disease often 
results in the development of ganciclovir-resistant strains.  This 
thesis has addressed several issues relating to the clinical challenges 
that CMV infections pose to paediatric solid organ transplant 
recipients from a Singapore perspective.   
 
We hypothesized that that the high incidence of CMV diseases 
(28.6%) in the National University Hospital’s paediatric solid organ 
transplant recipients – despite the use of ganciclovir prophylaxis – 
was due to ganciclovir-resistant CMV mutant strains.  We sought to 
determine the frequency of CMV mutant strains recovered in both 
transplant and non-transplant populations.   
 
As antiviral susceptibility testing was not performed in Singapore 
before, we assessed the feasibility of available laboratory 
techniques; using PCR-based restriction analysis, DNA sequencing 
and plaque reduction assay, we screened both clinical isolates of 
CMV and samples obtained from pediatric renal and liver transplant 
 xxi
recipients for ganciclovir-resistance related mutations in the CMV 
viral genome.  Ganciclovir resistance was detected in 25% of renal 
and 40% of liver transplant recipients.  We were also the first to 
document a case of laboratory confirmed ganciclovir resistant CMV 
infection in Singapore – in a paediatric renal transplant recipient 
with clinically confirmed CMV disease and allograft dysfunction.   
 
Our data indicate that laboratory screening for antiviral resistance is 
warranted.  We fine-tuned current genotypic screening methods by 
developing several PCR-based assays (PCR-RFLP, discriminatory 
PCR and probe-based real time PCR) for detection of specific 
mutations in both the UL97 and UL54 genes of CMV that were rapid 
and which could be utilized directly on clinical samples.  Patients 
who harbored ganciclovir-resistant CMV strains may also contain 
wild type viruses so these new assays were designed to 
simultaneously detect wild type and mutant sequences.   
 
Risks and trends in CMV infections have implications for patient 
management strategies and treatment outcomes.  We sought to 
define the role of CMV infection in chronic allograft dysfunction in 
prospective study of 119 consecutive renal transplant patients at the 
two major transplant centers (National University Hospital and 
Singapore General Hospital) in Singapore.  Both univariate and 
 xxii
multivariate analyses of clinical data revealed a significant 
correlation between allograft dysfunction and presence of CMV 
DNAemia at five months post-transplant (P< 0.01; OR 3.578, 95% 
CI 1.417-0.031).  Our data provides argument that current strategies 
to improve long term outcomes after renal transplantation should 
also include serial post-transplant assessment of CMV infection 
using PCR amplification of viral DNA in sera.  We also discovered 
that at five months post-transplant, presence of IgG specific anti-
endothelial cell antibody (AECA) activity was significantly 
associated with CMV DNAemia (P < 0.01)  although there was no 
direct correlation between AECA activity and abnormal renal 
function at one year post-transplant.  We recommend further studies 
via histopathological assessment of donor kidneys to establish 
whether or not CMV-induced endothelial damage leads to the 
production of AECA and subsequent immune injury to the renal 
allograft.   
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1 INTRODUCTION AND OBJECTIVES OF THE THESIS 
 
 
The human cytomegaloviruses (CMV) are ubiquitous herpesviruses, 
found universally throughout all geographic locations and 
socioeconomic groups. CMV resides in the host throughout life 
without causing any symptoms in healthy, immunocompetent 
individuals, and 50–90% of the population have become seropositive 
by adulthood (Scholz et al, 2003).   
 
They are responsible for generally asymptomatic and persistent 
infections in healthy people.  While inapparent infection is common 
during childhood and adolescence, severe disease frequently occurs in 
the absence of an effective immune response, as in immunologically 
immature and immunocompromised individuals.   
 
CMV has significant impact on certain high-risk groups. Of concern 
is the risk of infection to the unborn baby during pregnancy and the 
risk of infection to immunocompromised persons, such as organ 
transplant recipients and persons infected with human 
immunodeficiency virus (HIV).   
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This chapter provides an overview of the general characteristics of 
the virus, as well as the pathogenesis, epidemiology, and diagnosis of 
infections associated with human CMV.  
 
 
1.1 Properties of the virus 
 
1.1.1 Virus structure and genome 
 
CMV is designated human herpesvirus 5 (HHV-5) in the 
herpesviridae family, which includes herpes simplex virus types 
(HSV) 1 and 2, Epstein-Barr virus, varicella-zoster virus (VZV), and 
human herpesvirus 5, 6, 7 and 8. 
 
Its virion structure, kinetics of viral gene expression, and persistence 
of the lifetime of their host are typical of the herpesviruses.  As a 
member of the betaherpesvirinae subfamily, it is slow growing, has a 
propensity for massive enlargement of infected cells and becomes 
latent in secretory glands and kidneys.  
 
The virion consists of a 100 nm diameter icosahedral nucleocapsid 
containing a 230 kbp, double-stranded linear DNA genome, 
surrounded by an envelope that is derived from the nuclear membrane 
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of the infected cell and contains viral glycoproteins.  An amorphous 
proteinaceous layer between the capsid and envelope is termed the 
tegument or matrix.  The enveloped form measures 150-200 nm. 
 
The CMV genome is the largest of all herpesviruses, and, as with all 
herpesvirus DNAs, possesses unique terminal and internal repeated 
sequences.  The laboratory CMV AD169 strain has been the best 
studied and was the first strain to be completely sequenced CMV.  
Analysis of its genome has shown that it encodes 225 Open Reading 
Frames (ORFs) of approximately 100 or more amino acids (Chee et 
al, 1990; Novotny et al, 2001).  The Towne and Toledo laboratory 
strains also contain additional ORFs (Cha et al, 1996).  Sequence 
homology searches and experimental biochemical and/or genetic 
studies have assigned functional roles to only some of the more than 
200 CMV ORFs (Novotny et al, 2001).  Many ORFs await functional 
characterization, and their role in infection, including dissemination, 
growth in target tissues and pathogenesis, and in counteracting host 
immune response is yet to be elucidated (Mocarski and Courcelle, 
2001).  
 
More than 200 proteins are produced in three overlapping phases 
(immediate early (IE), early, and late). The predominant proteins 
critical for virion production are envelope proteins gB, gH, gM, and 
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gL and the matrix proteins pp65/pp150/pp71 and pp28 (Landolfo et 
al, 2003).  
 
The human CMV genome contains a single origin of replication and 
encodes a DNA polymerase gene and a complete set of genes needed 
for its own DNA replication.  Current therapies for CMV disease 
inhibit viral DNA polymerase as the final target.  CMV DNA 
polymerase is encoded by a CMV ORF designated UL54.   
 
The CMV genome also encodes a protein phosphotransferase enzyme, 
the product of UL97, but its role in CMV DNA replication is not well 
elucidated (Chee et al, 1989).  Recent work has shown that this 
phosphotransferase enzyme is able to phosphorylate serine residues 
(He et al, 1997), as well as to phosphorylate ganciclovir to form 
ganciclovir monophosphate, necessary for the drug to become an 
effective inhibitor of CMV DNA replication (Sullivan et al, 1992; 
Littler et al, 1992).  Krosky et al (2003b) have also identified UL44 
as the natural substrate of UL97 in infected cells.  Genetic and 
pharmacological evidence, provided by experiments using a novel 
antiviral drug (maribavir), indicate that UL97 is required at the stage 
of infection when nucleocapsids exit from the nucleus (nuclear 
egress) (Krosky et al, 2003a).   
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1.1.2 Virus growth cycle 
 
CMV is very species-specific and cell type-specific.  While a number 
of animal CMVs exist, all of them are species-specific; likewise, all 
attempts to infect animals with human CMV have failed. 
 
Laboratory strains of CMV replicates in vitro only in human skin or 
lung fibroblasts, whereas clinical isolates replicate preferentially on 
endothelial cell cultures.  CMV replicates very slowly in cultured 
cells, with growth proceeding more slowly than that of herpesvirus 
such as HSV or VZV.  Very little virus becomes cell-free; infection is 
spread primarily cell-to-cell.  It usually takes several weeks for an 
entire monolayer to become entirely infected.    
 
CMV produces a characteristic cytopathic effect marked by cell 
rounding and enlargement with pronuclear cytoplasmic inclusions in 
addition to the intranuclear inclusions typical of herpesviruses.  The 
presence of this cytomegalic inclusion cell in clinical specimens is 
one of the classic hallmarks of CMV infection.  These massively 
enlarged cells (the property of cytomegaly from which CMV acquires 
its name) contain intranuclear inclusions, which histopathologically 
have the appearance of owl's eyes. The presence of these cells 
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indicates productive infection, although they may be absent even in 
actively infected tissues.   
 
The virus, however, is often isolated from a wide range of epithelial 
cells of the host.  The ductal epithelial cell is most frequently 
infected, and develops a typical cytopathology (Pass, 2001).  During 
natural infection, CMV replicates productively, in addition to 
epithelial cells, in endothelial cells, smooth muscle cells, 
mesenchymal cells, hepatocytes, granulocytes, and monocyte-derived 
macrophages (Pass, 2001; Landolfo et al, 2003).  Tissue types from 
which CMV has been isolated include the parenchymal organs, 
salivary glands, eye, gastrointestinal and genitourinary tract (Pass, 
2001).  The cellular receptor of CMV has yet to be identified but is 
thought to be widely distributed owing to the wide range of cells that 
the virus is able to infect (Mocarski and Courcelle, 2001).  Candidate 
receptors include CD13 surface molecules found on peripheral blood 
mononuclear cells (Larsson et al, 1998), cellular integrins (Feire et al, 
2004) and epidermal growth factor receptor (Wang et al, 2003) 
 
Infection leads to a co-coordinated sequence of events which results 
in to the synthesis of IE, early and late viral proteins (Mocarski and 
Courcelle, 2001).  After primary infection CMV establishes lifelong 
latency or persistence within the person, in which cells of the myeloid 
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lineage are an important reservoir.  Presence of the virus in a subset 
of CD34+ myeloid progenitor cells in bone marrow has been 
established, with a small proportion of these cells containing CMV 
genomic DNA without detectable viral IE gene expression, termed 
latent infections (Mocarski and Courcelle, 2001).  In healthy carriers, 
viral DNA is also present in a small proportion of CD14+ monocytes 
and in dendritic cells and megakaryocytes (Taylor-Wiedeman et al, 
1991; Crapnell et al, 2000).   
 
 
1.2 Pathogenesis and pathology 
 
1.2.1 Immunocompetent hosts – infections and immune responses 
 
CMV may be transmitted person-to-person in several different ways, 
all requiring close contact with virus-bearing material.  There is a 
four to eight week incubation period in normal older children and 
adults following viral exposure.  The virus causes a systemic 
infection – it has been isolated from lung, liver, esophagus, colon, 
kidneys, monocytes, and lymphocytes.  The disease is an infectious 
mononucleosis-like syndrome, although most infections are 
asymptomatic.  The unsuspecting host is thus able to spread the virus 
both vertically and horizontally.  For example, asymptomatic infected 
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children excrete CMV in their urine for several months and, from this 
source, the virus is able to spread rapidly in environments such as 
day-care centers (Weller, 2000). 
 
Virus can appear following primary infection, reinfection, or 
reactivation.  Following infection, the virus is excreted in body fluids 
(urine, saliva, tears, semen, breast milk and cervical secretions) for 
months to years, probably due to virus replication in glandular 
epithelial cells, accompanied by virus release into excretions.  
However, the levels of shedding and reactivation of the virus vary 
among individuals (Ling et al, 2003).  
 
Like all herpesviruses, CMV establishes lifelong latent infections.  
Cells in bone marrow and peripheral blood are the chief reservoirs for 
latent CMV infection.  CMV DNA is found in a small percentage of 
peripheral blood monocytes, and gene expression is limited to the 
early or E genes.  It has been proposed that bone marrow precursors 
of blood monocytes are the site of viral latency and provide a means 
of dissemination upon differentiation into circulating monocytes 
(Pass, 2001).  Differentiation of latently infected monocytes in 
macrophages leads to reactivation and productive infection.   
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Recurrent infections may consist of either reactivation of the virus 
strain causing primary infection or reinfection by a new virus strain.  
Recurrent infection can be defined as indefinite, but intermittent, 
excretion of the virus from single or multiple sites.  It should be 
distinguished from prolonged excretion typical of primary infection 
and also infection in the immunocompromised host (Pass 2001), 
where productive infection, as measured by viral excretion, is 
markedly increased.   
  
Cell mediated immunity is depressed with primary infections, and this 
may contribute to the persistence of viral infection.  It may take 
several months for cellular responses to recover.  
 
CMV cellular reservoirs are leukocytes, epithelial cells of salivary 
glands, and cervix.  Infectious CMV may be shed in body fluids of 
infected persons, and may be detected in urine, saliva, blood, tears, 
semen, and breast milk. Examination of organ tissues and of 
peripheral blood obtained from patients with CMV disease has 
suggested that peripheral blood mononuclear cells (PBMC) are also a 
viral reservoir, and further analyses of PBMC revealed monocytes as 
the predominant infected cell type (Sholz et al, 2003). 
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T cells are crucial for the control of CMV in infected individuals.  
More specifically, CMV is thought to be controlled by antigen-
specific antiviral CD8 T cells. However, reactivation of CMV occurs 
often in certain high-risk groups such as immunocompromised hosts, 
and also in asymptomatically healthy individuals.  A series of 
mechanisms have been proposed to be responsible for CMV 
reactivation. These include stress (through catecholamine using the 
cAMP system), inflammation (through tumor necrosis factor (TNF)-α 
using nuclear factor κβ or through prostaglandins using the cAMP 
pathway), and some cAMP-elevating drugs.  This results in the 
activation of the CMV IE enhancer/promoter, which is responsible for 
initiation of virus replication (Reinke et al, 1999).  
 
The high frequency of CMV-specific effector CD8 T cells found in 
healthy individuals indicates that CMV is more frequently reactivated 
than previously expected (Reinke et al, 1999) but reactivation remains 
unnoticed and asymptomatic.  This is in contrast to most of the 
situations of reactivation associated with clinical CMV diseases 
which occur after transplantation or in immunocompromised hosts.  
Reactivation of CMV from latency results in serious morbidity and 
mortality in immunocompromised transplant recipients or 
immunodeficient individuals and has both direct and indirect effects. 
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The loss of immune control of CMV that is evidenced by the 
detection of antigenemia is closely associated with an impaired 
function of CMV-specific CD8 T cells.  In fact, it is the reduced 
cytokine production rather than a lower frequency or absolute number 
of CMV-specific CD4 or CD8 T cells that is thought to be responsible 
for the loss of immune control.  Reduced numbers of cytokine-
producing CMV-specific CD8 T cells were found in individuals with 
a higher risk of CMV reactivation.  The highest frequencies and 
absolute numbers of CMV-specific CD8 T cells were noted in those 
subjects who experienced early or late CMV reactivation.  CMV-
specific cytotoxic T lymphocyte (CTL) responses are generally lost in 
subjects undergoing allogeneic bone marrow transplantation (BMT) 
and restoration of those responses requires an extended period 
(Reusser et al, 1991).   
 
A series of genes are directly involved in these mechanisms of 
immune evasion (Ploegh, 1998).  The primary target of the proteins 
encoded by these genes is the class I antigen processing pathway: the 
unique short (US) region 3, which is expressed in the IE phase binds 
to and retains major histocompatibility complex (MHC) class I 
molecules in the endoplasmic reticulum (ER).  US2 and US11, both 
early gene products, cause the translocation of MHC class I to the 
cytosol where it is degraded. US6 blocks the transport of antigen-
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peptide into the ER.  CMV protein US2 contributes to the degradation 
of human leukocyte antigen (HLA)-Drα and HLA-Dmα through the 
inhibition of class II transactivator.  The inhibitory effects on T-cell 
antigen recognition is active when viral or self-antigens are 
synthesized within the cells, but not if the specific epitope is given as 
a peptide (Ploegh, 1998).  These strategies may explain the 
immunodominance of CTL directed against viral antigens that can be 
presented before expression of the US genes.  In CMV infected cells, 
the expression of the viral phosphoprotein pp65 (pp65) inhibits the 
generation of CMV-specific T-cell epitopes (Ploegh, 1998). 
 
 
1.2.2 Congenital and perinatal infections 
 
Congenital CMV infection remains a major problem worldwide.  The 
virus can be transmitted in utero as the consequence of either a 
primary or recurrent maternal infection (Stagno et al, 1980).  The 
incidence of symptomatic congenital CMV infections in immune 
mothers has also been shown to be similar in primary and recurrent 
maternal infections (Boppana et al, 1999).  In addition, symptomatic 
congenital infections appear to be mostly caused by reinfection of 
immune mothers during pregnancy by a new CMV strain (Boppana, et 
al, 2001).  On the other hand, congenital infections following 
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reactivated maternal infection are mostly asymptomatic (Stagno et al, 
1982).  
 
CMV can also be acquired by the infant from exposure to virus in the 
mother’s genital tract during delivery, and from maternal breast milk 
(Stagno, 2001).  In these cases, the infants usually have received 
some maternal antibody, and the perinatally acquired CMV infections 
tend to be asymptomatic.  Transfusion-acquired CMV infections in 
newborns will vary, depending on the amount of virus received and 
the serological status of the blood donor.   
 
Fetal and newborn infections with CMV may be severe.  Congenital 
intrauterine infections have been associated with congenital 
abnormalities, intrauterine growth deficiency and intrauterine death 
of the fetus, in addition to developmental delay, blindness and 
deafness of the infected child.  The incidence of congenital infection 
has been estimated to be between 0.2 to 2% of all live births in 
different regions of the world.  In a 1994 study of 1,688 infants with 
congenital abnormalities in Malaysia, 11.4% showed evidence of 
congenital CMV infections, higher than congenital toxoplasma (1%) 
or congenital rubella infection (3.7%) (Balasubramaniam et al, 1994). 




1.2.3 Immunosuppressed hosts  
 
Primary CMV infection is always followed by a prolonged, 
inapparent infection during which the virus remains alive but usually 
dormant and resides in cells without causing detectable damage or 
clinical illness.  The occurrence of CMV disease is almost exclusively 
restricted to immunocompromised hosts. 
 
Primary CMV infection in immunosuppressed or immunodeficient 
hosts is much more severe than in normal hosts.  Individuals at 
greater risk for CMV disease are those receiving organ transplants, 
those with malignant tumors who are receiving chemotherapy, and 
those who are HIV-infected or with acquired immunodeficiency 
syndrome (AIDS).  Viral excretion is increased and prolonged, and 
the infection is more apt to become disseminated.  Pneumonia is the 
most common complication. 
 
The host immune response presumably maintains the virus in a latent 
state in seropositive individuals.  Reactivated infections are 
associated with disease much more often in the immunosuppressed 
patients than in normal hosts.  Although usually less severe, 
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reactivated infections may be as virulent as primary infections.  Long 
term immunosuppression can lead to uncontrolled replication and 
serious disease (Reinke et al, 1999). 
 
In the immunocompetent host, the virus remains efficiently controlled 
and several components of the immune system are shown to play a 
role. In mice it has been demonstrated that both T and B cells play a 
role in the control of CMV (Scholz et al, 2003; Van Lier, 2003).  In 
HIV and CMV co-infected patients, elevated and very stable CD4 and 
CD8 T-cell responses to CMV have been observed (Harari et al, 2003; 
Van Lier, 2003).  The majority of CMV-specific CD8 T cells in 
peripheral blood were able to produce a range of antiviral factors 
after stimulation with specific antigens (IFN-γ, macrophage 
inflammatory protein-1β, TNF-α) (Van Lier et al, 2003).  With regard 
to CD4 T cells, CMV-specific lymphoproliferation and interleukin 
(IL)-2 secreting CD4 T-cell responses were present in healthy 
subjects (Harari et al, 2003); however, deficient CD4 T-cell responses 
were reported in BMT recipients (Scholz et al, 2003). 
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1.3 Clinical findings associated with human cytomegalovirus 
infections 
 
1.3.1 Infections in immunocompetent hosts 
 
CMV infection in normal immunocompetent hosts is usually 
asymptomatic but occasionally causes a spontaneous infectious 
mononucleosis syndrome.  CMV is estimated to cause 20-50% of non-
Epstein-Barr virus (EBV) associated mononucleosis cases (Klemola 
and von Essen, 1970).  The disease is characterized by malaise, 
myalgia, protracted fever, liver function abnormalities and non-
specific constitutional symptoms, which may persist for weeks.  The 
hematological hallmark is a relative lymphocytosis, in which greater 
than 50% of the peripheral white blood cell differential is composed 
of lymphocytes, of which, 10% or more are atypical lymphocytes.  At 
the time of occurrence of the mononucleosis syndrome, a variety of 
cutaneous manifestations also occur. All these clinical symptoms are 
not the direct consequence of proliferation of CMV in given tissues 
but indicative of the immunological response toward CMV (Kano et 
al, 2000).   
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Complications are rare and include pneumonia, myocarditis, 
hemolytic anemia, retinitis, gastrointestinal ulceration, hepatitis, 
central nervous system (CNS) involvement (Guillain-Barre syndrome) 
and peripheral neuropathy.  
 
 
1.3.2 Infections in the immunosuppressed host 
 
CMV is an important opportunistic pathogen in immunocompromised 
patients or immunologically immature hosts.  Primary infection, 
reactivation of latent virus, and reinfection are possible, and they 
cause a wide range of clinical manifestations, from asymptomatic 
infection to severe, potentially lethal disease.  In organ transplant 
patients, three potential mechanisms of CMV infection have been 
recognized: transmission by the donor organ, blood products or 
reactivation of latent virus in the recipient (Zamora, 2004).  Presence 
of antibody to CMV in the recipient, whether endogenous or passively 
transferred, provides partial protection against the development of 
serious and sometimes fatal disease.  Absent endogenous antibody 
protection in the recipient results in primary CMV infections, 
particularly CMV pneumonitis or gastrointestinal disease, which may 
be quite severe with mortality rates of 2 20% (Valentine, 1995). 
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The major clinical diseases related to the types of 
immunocompromised host are summarized in Table 1.1.   
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Table 1.1 Clinical syndromes associated with cytomegalovirus 
infection in the immunocompromised host (adapted from Griffiths 


















Retinitis + + + 
Pneumonitis + ++  
Myelosuppression  +  
Encephalopathy   + 
Polyradiculopathy   + 
Immunosuppression +   
Rejection/Graft versus 
host disease 
+   
Atherosclerosis +   
Death  + + 
 +, disease occurs; ++ disease most common 
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1.3.2.1 Cytomegalovirus infections in transplant patients 
 
All major transplantations (including kidney, liver, heart, heart-lung 
and bone marrow transplantation) are associated with an increased 
risk of CMV infection.  A survey of 16 studies of 1276 patients 
showed that the rate of infection after renal transplantation had a 
range of 59 to 70% (Ho, 1991).  The most important source for many 
patients is the transplanted organ or transfused blood.  Secondary 
infection after activation of latent virus is also an important source 
(Ho, 1977).  
 
The severity of end-organ disease caused by CMV is related to the 
degree of immune suppression and the type of transplant.  With 
immune suppression the most severe in bone marrow transplantation, 
CMV disease is also the greatest in BMT recipients.  
Immunosuppressive therapy, and in particular, the use of very high 
doses of corticosteroids plus azathioprine, also play a major role in 
reactivation of CMV (Ho, 1977; Rubin, 1981).  Preemptive therapy 
with mycophenolate mofetil, first introduced in 1994, has been 
associated with an increased risk of development of CMV diseases 
compared with azathioprine in cadaveric renal transplantation (Basic-
Jukic et al, 2000) but the disease course is less severe, and less 
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frequently accompanied with deterioration of renal function in 
comparison to the azathioprine group.  In a retrospective study of 
pediatric renal transplant recipients in Singapore, use of 
mycophenolic acid was significantly associated with CMV disease in 
the early post-transplant period (Sim et al, 1997). 
 
The main risk factors for CMV disease in recipients of allogeneic 
stem cell transplants are recipient CMV seropositivity and acute graft-
versus-host disease (Meijer et al, 2003).  In the era before 
introduction of ganciclovir (GCV), CMV infection and pneumonia 
developed in 38 and 17%, respectively, of recipients of allogeneic 
stem cell transplants, while mortality due to CMV interstitial 
pneumonia was 85% (Myers et al, 1986).  This very serious 
complication occurred mainly in CMV-seropositive patients, with 
acute graft-versus-host disease being the most important risk factor.  
Treatment of CMV pneumonia with GCV and immunoglobulin 
decreased mortality to 30 to 50% (Emmanuel et al, 1988; Reed et al, 
1988).  Currently, two antiviral strategies, prophylactic or preemptive 
antiviral treatment, are used for prevention of CMV disease.  
Nevertheless, CMV infection remains a life-threatening disease.   
 
CMV remains the most common pathogen isolated after solid organ 
transplantation, including liver transplantation (Patel et al, 1996; 
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Stratta et al, 1989).  CMV hepatitis occurs frequently, and the 
incidence is greatest after transplantation from a CMV-seropostive 
donor.  In managing liver transplant patients the signs of severe CMV 
hepatitis can be difficult to distinguish from graft rejection.  Liver 
biopsy is the only reliable way to distinguish rejection from CMV 
hepatitis (Demetris et al, 1985).  However, prophylaxis and antiviral 
treatment have been shown to result in a mild or moderate intensity of 
CMV infection, and among the immunosuppressive drugs, only anti-
IL-2Rab was proved to significantly reduce the incidence of CMV 
(Oldakowska-Jedynak et al, 2003). 
 
The morbidity due to CMV is lowest in kidney transplant recipients, 
and the most common manifestation of CMV-associated illness is 
termed CMV syndrome (Sia and Patel, 2000).  This usually presents 
insidiously with fever, anorexia, and malaise without additional signs 
or symptoms.  This viral syndrome may be self-limited or may 
progress to clinically evident organ involvement (Sia and Patel, 
2000). 
 
The association of CMV with allograft dysfunction is controversial. 
Infection with CMV has been associated with early-onset allograft 
rejection in renal transplant recipients (Fox et al, 1988).  In a cohort 
of 242 renal transplant patients, 65% developed CMV infection 
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(Pouteil-Noble et al, 1993).  The incidence of rejection was 
significantly higher in those with antecedent CMV infection: 45% 
among infected patients versus 11% among noninfected patients.  In 
another study, CMV-seropositive donor status was associated with 
lower graft survival rates than CMV-seronegative donor status (Hirata 





Virological and molecular detection of CMV and serological 
demonstration of a specific immune response are used for diagnosis, 
although acute infection is usually diagnosed through detection of the 
virus in body fluids.  There is no single best assay method for 
monitoring infection but molecular assays have a shorter turnaround 
time and can be automated, promise earlier treatment, and have 
reliable results.   
 
Table 1.2 summarizes the different laboratory diagnostic strategies.  
The diagnosis of invasive disease is not straightforward, since the 
presence of CMV in a diseased tissue does not necessarily imply a 
causal relation.  Diagnosis should be based on appropriate clinical 
signs and symptoms of disease in conjunction with detection of virus 
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from the appropriate involved tissue.  For the purpose of consistent 
reporting of CMV in clinical trials, definitions of infection and 
disease have been developed (Ljungman et al, 2002).   
 
The first laboratory test that was developed was viremia (detection of 
infectious virus in peripheral blood leukocytes) after 16 – 24 hours 
cocultivation with human fibroblasts in shell vials (Gregory and 
Mengus, 1983).  Quantification of CMV in blood was also made 
possible by inoculating a predetermined number of leukocytes onto 
shell vial monolayers (Gerna et al, 1995).  This approach was found 
to be the most reliable in evaluating the efficacy of antiviral 
treatment, because the test, as a rule, became negative 24 – 48 hours 
after initiation of therapy unless a drug-resistant strain emerged.  
 
Developed at the end of the 1980s, assay for antigenemia entails 
identification of peripheral blood leukocytes carrying a viral protein 
(pp65) in the nucleus within a few hours after blood collection (van 
der Bij et al, 1988).  Although representing only an indirect marker of 
virus replication, antigenemia has been very useful in monitoring 
CMV infection in immunocompromised patients for several years.  
However, problems arose in interpretation when rising levels of 
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antigenemia were observed in association with decreasing or stable 
levels of viremia and viral DNAemia after initiation of ganciclovir 
treatment in primary infections of both solid organ transplant 
recipients and hematopoietic stem cell transplant recipients.  This 
often prompted clinicians to change antiviral treatment with the 
erroneous assumption that a ganciclovir-resistant strain had been 
selected, though the efficacy of treatment was documented by the 
negative results of the viremia assay (Gerna et al, 2004).  
 
Polymerase chain reaction (PCR) methods were developed in the 
early 1990s for the qualitative and quantitative detection of viral 
DNA in blood (DNAemia) by either PCR or hybridization techniques, 
and has been reviewed extensively by Hodinka (1998) and Boeckh 
and Boivin (1998).  Aw et al (2000) have described the usefulness of 
a quantitative CMV PCR technique for monitoring peripheral blood 
CMV DNA in pediatric recipients of kidney and liver allografts who 
had recurrent CMV retinitis, particularly for the surveillance of 
disease resolution and recurrence as this group of patients may remain 
asymptomatic for a period of time, despite recurrences.  Gerna et al 
(1998; 2003) have reported that while viremia lacks sensitivity, 
quantitative DNAemia has been found to correlate with virus 
replication and clinical symptoms much more closely than 
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antigenemia, both during the natural history of HCMV infection and 
antiviral treatment.  Weinberg et al (2000) evaluated serial CMV 
blood cultures, antigenemia, and qualitative and quantitative plasma 
PCR tests for their value in predicting CMV disease and for guiding 
preemptive therapy after lung transplantation.  They found that PCR 
and antigenemia tests were the most effective predictors of 
symptomatic CMV infections and the response to therapy. 
 
Viral DNAemia, however, is possibly a result of virus latency. To this 
end, viral messenger RNAs are directly related to virus replication.  
Either IE or late mRNAs may be detected by using either reverse 
transcriptase PCR (RT-PCR) or the nucleic acid sequence-based 
amplification (NASBA) technique.  A randomized trial comparing 
antigenemia with NASBA for determination of CMV IE messenger 
RNA (IE mRNA) as the guiding assay for initiation of pre-emptive 
antiviral treatment showed that the NASBA technique applied to the 
detection of IE mRNA was found to be more sensitive than 
antigenemia in detecting earlier a greater number of infected patients 
(Gerna et al, 2003). 
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Table 1.2. Diagnosis of cytomegalovirus infection and disease 









Presence of CMV in tissue might simply 
be a bystander effect and does not 
necessarily imply causality.  CMV-
associated disease should be diagnosed 
on clinical grounds in combination with 
detection of virus. 
Viral cultures Requires at least 21 days to be reported 
negative.  Not routinely done, but can be 
useful in antiviral resistance testing. 
Detection of early 
antigen fluorescent foci 
Twenty-four hour turnaround.  Infected 
fibroblasts stained with fluorescent 
antibody specific for the antigen MIEp72 
(Gregory and Menegus, 1983).  
Insufficiently sensitive to be routinely 
recommended after allogeneic stem cell 
transplantation (Einsele et al, 1995).  
Antigenemia assay Quantitates leucocytes positive for pp65.  
Since uninfected cells can harbor CMV 
protein, this provides an indirect 
assessment of infection.  Reliable, rapid 
and sensitive.  In common use (Boeckh 
et al, 1996).  
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Qualitative PCR Can be used on whole blood, leucocytes 
and plasma.  Rapid and sensitive, easily 
automated.  Threshold needs careful 
calibrating to avoid over detection of 
CMV infection. 
Quantitative PCR Allows response to treatment to be 
monitored.  Useful as a surrogate marker 
of clinical or viral resistance.  
Correlation between high degrees of 
viral DNA and presence of clinical 
symptoms in transplant recipients and 
patients with AIDS and the congenital 
infection of pregnancy has been shown 
((Emery et al, 2000; Limaye et al, 2001, 
Trincado and Rawlinson.2001). 
Hybrid capture assay RNA probes used to detect viral DNA in 
an ELISA-type format.  Can be used on 
whole blood stored for up to 48 hours.  
Limited experience but results to date 
promising (Ho et al, 2000). 
Nucleic assay sequence-
based amplification 
Allows the specific nucleic assay 
sequence-based amplification of 
unspliced viral mRNAs in a background 
of DNA.  Experience in transplant and 
AIDS patients encouraging (Blank et al, 
2002; Gerna et al, 2003).  
Serology Highly specific and sensitive in 
immunocompetent individuals.  IgM 
titers rise 2-6 weeks after infection and 
can persist for 2 years and be detectable 
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during episodes of reactivation.  IgG 
seropositivity is usually lifelong 
although antibody concentrations can 
decline with age.  Unreliable and not 
used in monitoring of CMV reactivation 
in immunocompromised hosts.  IgG 
antibody avidity assays (low avidity 
suggests infection within 3 months) can 
be useful in identifying pregnant women 
at risk of transmitting intrauterine 
infection (Bodeus et al, 2002).   
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1.5 Objectives of the thesis 
 
Despite remarkable progress made in the fields of antiviral therapy 
and laboratory diagnosis, infections with the human CMV continues 
to pose serious problems and challenges in certain patient groups, in 
particular, those with suppressed or impaired immune systems.   
 
Data collection, statistics and publications with respect to CMV 
infections and routine or specialized laboratory testing (such as 
detection of antiviral resistance) are almost exclusively from non-
Asian sources.  There is also a paucity of information in Singapore 
regarding CMV infections in the general population, or in the 
immunocompromised groups of patients.  A PubMed index search 
(accessed June 2006) revealed only six such publications, excluding 
the recent publication of Yeo et al (2005) on molecular detection of 
ganciclovir resistant CMV.  There were two on CMV epidemiology in 
women and children (Sng and Tobin, 1977; Wong et al, 2000); two 
case reports on AIDS-related CMV retinitis and pneumonitis (Law et 
al, 1990; Eng et al, 1992, respectively); a survey of infections 
(including CMV disease) in paediatric renal transplantation (Sim et 
al, 1997), and a publication on the utility of quantitative PCR for 
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monitoring CMV retinitis in pediatric solid organ transplant 
recipients (Aw et al, 2000).   
 
The scope of this thesis is as follows: 
 
1 Elucidate the molecular epidemiology of CMV in 
Singapore: 
a. Molecular epidemiology studies of CMV infections in 
Asia have been limited to those carried out in Japan 
(Wada et al, 1997; Kawasaki et al, 1999; Numazaki et 
al, 2000; Kashiwagi et al, 2002), Taiwan (Shen et al, 
1996) and Hong Kong (Woo et al, 1997).  We analyzed 
the genomes of CMV strains recovered from 
immunocompromised patients (specifically, the solid 
organ transplant cohorts admitted to the National 
University Hospital (NUH), the designated pediatric 
liver and renal transplant center in Singapore).  To the 
best of our knowledge, this analysis of CMV interstrain 
variations to determine the types circulating in the 
country and their association, if any, to the different 
types of transplantation, represents the first such study 
in Singapore.   
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b. CMV serostatus is one of the traditional risk factors for 
early-onset CMV disease and now appears to also 
contribute to the occurrence of late-onset CMV disease 
during the first year after transplantation for both solid 
organ and hematopoietic stem cell recipients 
(Razonable, 2005).   As an adjunct to the molecular 
epidemiology study, we also determine the 
seroprevalence of antibodies to CMV in the apparently 
healthy, young adult male and female populations.  No 
previous study has also been reported for this age-
related cohort in Singapore who is potentially at risk as 
CMV seronegative organ transplant recipients. 
 
2 Screen for strains of CMV resistant to ganciclovir in 
Singapore.  Antiviral drug resistance in CMV is a major 
concern in transplantation.  While the majority of infections 
by antiviral resistant CMV have been described to occur in 
patients with AIDS receiving prolonged antiviral therapy 
for CMV end-organ disease, other immunocompromised 
individuals on antiviral prophylaxis and or therapy, 
including bone marrow and solid-organ transplant 
recipients, are also affected.  The frequency of active CMV 
disease seen in children from the Paediatric Renal and 
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Liver Transplant Programs at NUH is 30.8%, including one 
death, in renal allograft recipients (Sim et al, 1997) and 
25% in liver allograft recipients.  This is despite the routine 
use of ganciclovir prophylaxis.   
 
Our hypothesis is that the high incidence of active CMV 
disease, which includes pneumonitis, retinitis and colitis, is 
due to ganciclovir-resistant CMV mutant strains.  We 
sought to determine the frequency of CMV mutant strains 
in (i) CMV isolates from the non-transplant population sent 
to the Virology Laboratories of NUH and the Singapore 
General Hospital (SGH), where the culture-based detection 
of CMV areperformed and (ii) CMV DNA isolated directly 
from clinical samples such as blood, saliva and urine from a 
cohort of pediatric solid organ transplant patients from 
NUH.  Different laboratory methods currently available, 
including conventional drug susceptibility assay (plaque 
reduction assay) and previously published genotypic assays 
(PCR-RFLP, DNA sequencing) would be employed. 
 
3 Develop new PCR-based assays for rapid and improved 
detection of specific mutations in the CMV genome that 
are known to confer ganciclovir resistance and to 
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discover novel mutations.  Resistance of CMV to 
ganciclovir is related to mutations in the CMV UL97 gene 
and or mutations in the viral DNA polymerase (UL54 
gene).  Limitations of currently available laboratory tests 
for resistant strains of CMV include long turnaround time 
and wide interlaboratory variability owing to the slow and 
often variable growth patterns of CMV in the plaque 
reduction assay (Harmenberg and Brytting, 1999) and the 
fact that PCR-RFLP can detect CMV mutants only they 
reach approximately 10% of the viral population in a 
clinical isolate.  Nonetheless, genotypic tests that are PCR-
based and target specific change(s) in the genome have the 
advantage of being amenable to producing rapid results and 
automation.  We attempted to develop laboratory tests for 
detection of antiviral resistant CMV strains by employing 
new molecular-based strategies that could produced a short 
turnaround time for results and with improved detection 
limits.  
 
4 Define the role of CMV infection in allograft rejection.  
While infection has been shown to have a high association 
with chronic rejection in extra-renal transplants such as 
heart/lung transplants, there is conflicting evidence on the 
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role of CMV infection in chronic allograft rejection in renal 
transplantation.  In Singapore the seropositivity rate of 
CMV in kidney donors is approximately 90%.  Assessment 
of CMV infection of the renal allograft as well as other 
contributory factors to the process of chronic rejection is 
therefore important.  In this thesis, we attempted to answer 
the following questions: 
 
a. Does CMV infection contribute significantly to chronic 
allograft rejection in renal transplant recipients?  Upon 
recruitment of renal allograft recipients transplanted at 
two hospitals (i.e. NUH and SGH), clinical and 
laboratory parameters would be recorded to allow for 
statistical analysis of risk factors for development of 
chronic allograft rejection at one year post-transplant 
 
b. Is the mechanism of late allograft loss related to 
possible CMV-induced changes in the antigenic 
structure of the endothelial cells, namely via anti-
endothelial cell antibodies (AECA)? 
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2 METHODS AND MATERIALS 
 
2.1 Seroprevalence of cytomegalovirus infection in healthy  
young adults and paediatric transplant subjects in Singapore 
 
Randomly selected and apparently healthy volunteer subjects were 
approached in 2003 to 2004.  There were 151 subjects (aged 17 – 24 
years, mean age was 18.6 years), who were students studying in 
Singapore Polytechnic.  Whole blood was drawn by venipuncture; 
upon informed consent, and serum collected was stored at -20°C prior 
to batch analysis by immunoassay for serological evidence of CMV 
infection.  Commercially available enzyme-linked immunosorbent 
assay (ELISA) test kits (DRG Diagnostics Co, Germany) were used to 
test for the presence or absence of CMV IgG.  Microtiter well 
washing and absorbance readings utilized the Model 1575 
Immunowash and Model 680 Microplate Reader (both from Bio-Rad 
Laboratories, Hercules, CA, USA), respectively.  Determination of a 
positive or negative result was as per the manufacturer’s instructions.  
Data was statistically analyzed using the test for difference between 
two population proportions to see the relation between gender and 
CMV seropositivity.  P < 0.05 was considered statistically significant.  
Serostatus of the cohort of paediatric transplant subjects were 
obtained from the clinical database. 
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2.2 Molecular epidemiology of cytomegalovirus infection in 
Singapore 
 
This study examined a total of 200 clinical samples, comprising (a) 
96 clinical isolates of CMV propagated in human foreskin fibroblasts 
(MRC5) and saved in frozen storage and (b) CMV DNA isolated 
directly from 104 samples such as blood, saliva and bronchoalveolar 
lavage using a modified phenol-chloroform method (Ratnamohan et 
al, 1992).  DNA from the primary isolates in (a) were extracted using 
the DNeasy Tissue Kit (Qiagen GmbH, Germany) according to the 
manufacturer’s specifications.  All samples were from patients 
admitted to Singapore General Hospital (SGH) and the National 
University Hospital (NUH), Singapore, from the period July 1998 to 
2001.  Two laboratory strains, AD169 and Towne (both from 
American Type Culture Collection, Manassas, VA, USA), were used 
as reference viruses.   
 
Genotyping of CMV for interstrain variation was performed using a 
previously described PCR-RFLP method (Chou and Dennison, 1991).  
PCR amplification of part of the CMV envelope glycoprotein B (gB) 
gene that encodes a portion of gp55 using primers gB1319 (5’ 
TGGAACTGGAACGTTTGGC 3’) and gB1604 (5’ 
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GAAACGCGCGGCAATCGG 3’) yielded a 293 to 296 bp target 
(depending on the gB group).   
 
All the PCR primers were synthesized commercially (either by 
QIAGEN Operon, Alameda, CA, USA or Research Biolabs Pte Ltd, 
Singapore).  PCR reactions were performed in a final volume of 25µL 
with 2.0mM Mg2+, 200µM of each dNTP (Finnzymes Oy, Espoo, 
Finland), 1.5 units of Taq polymerase (QIAGEN GmbH, Germany) , 
standard buffer (QIAGEN GmbH) and 0.2µM of each primer.  
Amplification involved 1 cycle of denaturation for 5 minutes at 95°C 
and 37 programmed cycles (denaturation at 95°C for 1.5 minutes, 
annealing at 55°C for 2 minutes, and extension at 72°C for 1 minute) 
on the GeneAmp PCR System 9700 thermal cycler (Applied 
Biosystems, Foster City, CA, USA).  CMV AD169 and Towne strains 
were used as positive controls, and nuclease-free water (Promega 
Corporation, Madison, WI, USA) as the negative control.  
 
To identify the genotype to which a strain belonged, the amplified 
products were subjected to restriction analysis in separate reactions 
using HinfI and RsaI (both from New England Biolabs Inc, Ipswich, 
MA, USA).  Digested DNAs were subjected to electrophoresis on 6% 
polyacrylamide gels and ethidium bromide staining, and the images 
digitally captured on the Gel Doc 2000 (Bio-Rad Laboratories, 
 Cytomegalovirus infections in solid organ transplant recipients 
 39
Hercules, CA, USA).  Product sizes were measured against the 
AmpliSize and EZ load 20 bp molecular rulers (all from Bio-Rad 
Laboratories).  RFLP patterns obtained with the two restriction 
enzymes were used to classify the CMV isolates or DNAs according 
to one of four gB types (1 – 4).  
 
Data was statistically analyzed using pairwise comparisons of 
proportions, and statistical significance for all analyses was assumed 
at P < 0.05 level.  
 
 
2.3 Cytomegalovirus antiviral resistance  
 
Samples for this study comprised the same two cohorts as described 
in Section 2.2, namely (a) 96 clinical isolates of CMV propagated in 
human foreskin fibroblasts (MRC-5) and saved in frozen (-70°C) 
storage and (b) CMV DNA isolated directly from 104 clinical samples 
using a modified phenol-chloroform method (Ratnamohan et al, 
1992).  DNA from the primary isolates in (a) were extracted using the 
DNeasy Tissue Kit.  All the clinical samples were initially screened, 
and were shown positive for presence for CMV by quantitative 
conventional PCR of the immediate early gene (Jiwa et al, 1990; Aw 
et al, 2000).  The two cohorts were made up of patients admitted to 
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SGH and NUH hospitals from the period July 1998 to 2002.  Included 
in the study, as a wild-type positive control, was the laboratory CMV 
strain AD169. 
 
The clinical isolates (“live” cultures) of CMV were screened for 
ganciclovir resistance by a plaque reduction assay as described by 
Wentworth and French (1970).  In brief, each well in 24-well plates 
were inoculated with virus suspension when MRC-5 cells (from the 
human embryonic fibroblast cell line (American Type Culture 
Collection, Manassas, VA, USA)) were just confluent.  The virus 
suspensions were prepared from stocks consisting extracellular virus 
from infected monolayers (harvested when extensive cytopathology 
occurred in at least 90% of the cell layer).  After adsorption for 90 
minutes at 37°C, the wells were overlaid with 1.5mL of 0.4% agarose 
(FMC Bioproducts, Rockland, ME, USA) containing the appropriate 
concentration (0, 1.5, 3, 6, 12 and 24µM) of ganciclovir (Cymevene, 
F Hoffman-La Roche, Basel, Switzerland) and growth medium 
(Minimum Essential Medium, Gibco Invitrogen Corporation, 
Carlsbad, CA, USA) in triplicates.  The cultures are then observed for 
the presence of viral plaques over two weeks, with a second overlay 
of agarose after the first week of incubation.  Two mL of 10% 
formalin was added to each well to fix the monolayers and the 
monolayers then removed and discarded.  After staining with 0.03% 
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aqueous methylene blue for two minutes, the plaques were counted 
visually.   
 
The IC50 (50% inhibitory concentration) of the agent for the isolate is 
defined as the concentration of agent causing a 50% reduction in the 
number of plaques produced.  Sensitive, indeterminate and resistant 
ranges were as follows: IC50 ≤ 6µM of ganciclovir, sensitive; IC50 > 
6µM to 12µM, indeterminate; >12µM, resistant  
 
In addition, the clinical isolates were screened using genotypic 
methods for detection of mutations known to confer ganciclovir 
resistance in the CMV UL97 phosphotransferase and UL54 DNA 
polymerase genes.   
 
UL97 mutations were screened using PCR-RFLP, with primers and 
types of restriction enzymes as previously described (Chou et al 
1995a; Chou et al, 1995b; Hanson et al, 1995).  This nested PCR 
protocol enabled improved, specific amplification, and hence, direct 
detection of the virus in clinical samples.   
 
In brief, extracted CMV DNA was subjected to an initial round of 
PCR amplification using universal primers as previously described 
(Chou et al, 1997) to amplify the entire UL97.   
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Subsequently, regions within the UL97 gene flanking frequently 
encountered UL97 resistance mutations at codons 460 (Met to Val), 
594 (Ala to Val), 595 (Leu to Ser, or Leu to Phe) and 520 (His to Glu) 
were further amplified by PCR with the relevant primers.   
 
The sequences of the nested PCR primers for amplification of UL97 
are as follows: for the first round of PCR, universal primers CPT0 (5’ 
GTCGACGACGCCGTCTAA 3’) and CPT2096 (5’ 
CGTCAAGGTCCTCCTCGCA 3’) for the entire UL97 gene; for the 
second round, primer set CPT1088 (5’ ACGGTGCTCACGGTCTGG 
AT 3’) and CPT1619 (5’ AAACGCGCGTGCGGGTCGCAGA 3’) for 
region surrounding codon 460; primer set CPT1713 (5’ CGGTCT 
GGACGAGGTGCGCAT 3’) and CPT1830M (5’ AATG 
AGCAGACAGGCGTCGAAGCAGTGCGTGAGCTTGCCGTTCTT 
3’) for region surrounding codon 594 and 595; primer set CPT1088 
and CPT1587M (5’ CTGCAGCGGCATGGGTCGGAAA GCAAG 3’) 
for region surrounding codon 520 (Chou et al 1995a; Chou et al, 
1995b; Hanson et al, 1995). 
 
All the PCR primers were synthesized commercially (QIAGEN 
Operon or Research Biolabs).  PCR reactions were performed in a 
final volume of 25µL with 2.0mM Mg2+, 200µM of each dNTP 
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(Finnzymes Oy, Espoo, Finland), 1.5 units of Taq polymerase 
(QIAGEN GmbH, Germany) , standard buffer (QIAGEN GmbH) and 
0.2µM of each primer.  1×Q-solution (QIAGEN GmbH), a proprietary 
PCR additive, was included in amplification reactions for templates 
that had low copy numbers of CMV DNA.   
 
PCR amplification involved 1 cycle of denaturation for 15 minutes at 
95°C and 37 programmed cycles (denaturation at 95°C for 1.5 
minutes, annealing at 55°C for 1 minute, and extension at 7°2C for 1 
minute) on the GeneAmp PCR System 9700 thermal cycler (Applied 
Biosystems, Foster City, CA, USA).  CMV AD169 and Towne strains 
(both from American Type Culture Collection) were used as wild type 
positive controls, and nuclease-free water (Promega Corporation) as 
the negative control.  
 
PCR products obtained were then digested separately with restriction 
enzymes (NlaIII, HhaI, TaqI, MseI and AluI (all from New England 
Biolabs Inc, Ipswich, MA, USA)) in order to identify mutations in 
codons 460, 594, 595 (two different mutations) and 520, respectively.  
Digest conditions were according to the manufacturer’s instructions.  
The digest patterns were visualized upon electrophoresis on 8% or 
15% polyacrylamide gels and ethidium bromide staining, the images 
digitally captured on the Gel Doc 2000 (Bio-Rad Laboratories), and 
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compared against that for wild type laboratory CMV strain AD169 
DNA (Advanced Biotechnologies Inc, Columbia, MD, USA) and 
various molecular rulers (Table 2.1).  Mutations at codons 460 and 
594 result in the loss of naturally occurring restriction enzyme sites 
but mutations at codons 520 and 595 result in additional restriction 
sites (Table 2.1).   
 
Specific identification of mutations was by DNA sequence analyses 
of the PCR products using BigDye Terminator Cycle Sequencing kit 
(Applied Biosystems, Foster City, CA, USA) and the ABI Prism 310 
genetic analyzer (Applied Biosystems), and by comparison with 
reference strain AD169 sequence (EMBL accession no X17403).. 
 
CMV UL54 mutations were detected by sequencing the relevant 
portions of the polymerase-encoding gene, in particular, regions of 
the gene that have been shown to confer ganciclovir resistance (Chou 
et al, 2003).  PCR reactions were done under the following 
conditions: 37 cycles at 95°C for 1 minute, 55°C for 2minutes and 
72°C for 1 minute on the GeneAmp PCR System 9700 thermal cycler 
(Applied Biosystems).  Sequencing reactions were carried out using 
the BigDye Terminator Cycle Sequencing kit and the ABI Prism 310 
genetic analyzer.  PCR primers specific for codons 300 to 1000 (as 
previously described by Erice et al, 1997) were as follows: Z4957F 
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(5’ GCTGCACTTCGGAGGGTGTGA 3’), Z4958R (5’ TGCC 
GCTTAAAACCCACGGCG 3’), Z3583F (5’ GGGCTCGAAACATCG 
TCAGG 3’), Z3584R (5’ CGTGGCACGCCGTACTTCTT 3’), 
Pol1474F (5’ GTGATATCGAGGTAGACTGCGATG 3’), Pol2536R 
(5’ GCGGCGGTAGAGATGATAGC 3’), Pol2401F (5’ GTATCT 
ACACCTCGCTGCTG 3’) and Pol3895 (5’ ACGGCAATGT 
GCGGCAGGTTAG 3’).  Comparison of UL54 sequences obtained 
was undertaken with reference strain AD169 sequence, based on the 
published strain AD169 reference sequence (EMBL Accession 
number X17403).  
 
 
2.4 CMV UL97 mutation analysis by discriminatory PCR 
 
This study involved the development of discriminatory PCR assays 
for mutation analysis of CMV UL97 codons 594 and 595.  Wild type 
laboratory CMV strain AD169 DNA was obtained commercially 
(Advanced Biotechnologies Inc).   
 
(The newly developed discriminatory PCR assays were subsequently 
used to prospectively screen samples received in the Dept of 
Paediatrics, NUS for anti-ganciclovir resistance testing, in parallel 
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with conventional PCR-RFLP methods for mutation analysis in the 
UL97 gene) 
 
A total of 40 clinical samples (phenol-chloroform extracted and 
purified DNAs) from a cohort of pediatric solid organ transplant 
patients admitted to the National University Hospital, Singapore or 
the Dept of Paediatrics, National University of Singapore (NUS) was 
studied.  Samples from these renal (n = 12) and liver (n = 5) 
transplant recipients were previously analyzed for the presence of 
CMV by quantitative conventional PCR and the wild type and or 
mutant genotype determined using PCR-RFLP, as previously 
described (Section 2.3).  Mutations at the two codons of interest 
(namely CMV UL97 codons 594 and 595) were confirmed by DNA 
sequence analyses of the PCR products.   
 
New PCR primers were designed using Primer3 software program 
(Rozen and Skaletsky, 2000), again based on the published strain 
AD169 reference sequence (EMBL Accession number X17403).   
 
All the PCR primers were synthesized commercially (QIAGEN 
Operon or Research Biolabs).  Optimized PCR reactions were 
performed in a final volume of 25µL with 2.0mM Mg2+, 200µM of 
each dNTP (Finnzymes Oy, Espoo, Finland), 1.5 units of HotStarTaq 
 Cytomegalovirus infections in solid organ transplant recipients 
 47
DNA polymerase (QIAGEN GmbH, Germany) , standard PCR buffer 
(QIAGEN GmbH), 1×Q-solution, 0.2µM of each primer and 1µg of 
total DNA.  Samples with low copy number of CMV were subjected 
to a nested PCR protocol and 2uL of PCR product from the first round 
of amplification using universal primers (as previously described 
(Chou et al, 1997) to amplify the entire UL97)) were used for the 
second round (discriminatory PCR) amplification.  
 
Controls included the CMV AD169 strain as the wild type positive 
control, and nuclease-free water (Promega Corporation) and DNAs 
from culture isolates of herpes simplex virus type 1 and adenovirus 
(American Type Culture Collection) as the negative controls.  
 
CMV UL97 mutation analysis of codon 594 involved a two-step PCR 
amplification profile as follows: 1 cycle of denaturation for 15 
minutes at 95°C and 37 programmed cycles (denaturation at 95°C for 
1.5 minutes, and annealing/extension at 58°C for 0.5 minute).  For 
mutation analysis of codon 595, the profile was similar except that 
the annealing/extension were at 60°C for 0.5 minute.  The iCycler 
thermal cycler (Bio-Rad Laboratories, Hercules, CA, USA) was 
utilized.   
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PCR products obtained were resolved by electrophoresis on 8% 
polyacrylamide gels and ethidium bromide staining, the images 
digitally captured on the Gel Doc 2000 (Bio-Rad Laboratories), and 
compared against that for the wild type CMV strain and various 
molecular rulers (Bio-Rad Laboratories).  
 
 
2.5 CMV UL97 mutation analysis by real time PCR using 
molecular beacons  
 
2.5.1 Real time PCR using molecular beacons 
 
The aim of this study was to develop a PCR-based protocol using the 
real time platform for mutation analysis.  As proof of concept, the 
mutation in the CMV UL97 codon 460 gene served as the focus of the 
study.  An A to G change at position 1378 of the gene leads to amino 
acid changes (Met to Val) which have previously been shown to 
confer ganciclovir resistance (Chou et al, 1995a).   
 
DNA extraction was performed directly from blood samples using a 
modified phenol-chloroform method, and spectrophotometrically 
quantified as previously described.  The 40 samples were randomly 
selected from a cohort of pediatric solid organ transplant patients 
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(renal (n = 12) and liver (n = 5)) admitted to NUH.  Prior to coding 
for unbiased reexamination, all samples were analyzed for the 
presence of CMV by quantitative conventional PCR, as previously 
described (Aw et al, 2000).  This was followed by codon 460 
mutation analysis via PCR-RFLP (that is, conventional nested PCR, 
NlaIII restriction enzyme digestion and polyacrylamide gel 
electrophoresis), also as previously described (Chou et al, 1995a).  
Included in the study, as a calibrated wild-type positive control, is the 
laboratory CMV strain AD169 DNA, obtained commercially 
(Advanced Biotechnologies Inc) in the form of quantitated viral DNA 
(104 DNA copies/µL).   
 
The PCR primers and molecular beacons were also synthesized 
commercially (Proligo SAS, France or QIAGEN Operon), and both 
primers and beacons were designed using the Beacon Designer 2 
version 2.06 software (Premier Biosoft International, Palo Alto, CA, 
USA).  PCR primers were designed to amplify a portion of the UL97 
CMV gene region flanking codon 460, based on the published strain 
AD169 reference sequence (EMBL Accession number X17403).  The 
product generated by these primers is 321 bp long.  The molecular 
beacons were constructed following criteria first described by Tyagi 
and Kramer (1996).  They consisted of probe sequences 16 
nucleotides long that anneal either to the wild-type or to mutant 
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sequences, 5-nucleotide arm sequences, the fluorophores FAM 
(carboxy-fluorescein) and HEX (hexachlorofluorescein) covalently 
linked to the 5’ ends of the wild-type and mutant beacons, 
respectively, and the quencher DABCYL (4-[4’-
dimethylaminophenylazo]benzoic acid) linked to the 3’ ends of both 
beacons.  The sequences of the primers and molecular beacons are 
summarized in Table 2.4. 
 
Using the iCycler iQ detection system (Bio-Rad Laboratories, 
Hercules, CA, USA), PCR conditions were optimized by varying 
molecular beacon (100 – 500 nM), primer (200 – 1000 nM), and 
magnesium (4 – 6 mM) concentrations and the annealing temperature 
(50 - 60°C).   
 
Optimal PCR reactions contained 25µL of 2× QuantiTect Probe PCR 
Master Mix (QIAGEN GmbH, Germany), 200nM of primers, 200nM 
of molecular beacon for the wild-type or mutant sequence, and 1µg of 
total DNA in a 50µL final volume.  The thermal cycling program 
consisted of 15 minutes at 95°C to activate the HotStarTaq DNA 
polymerase, followed by 40 cycles of 15 seconds at 95°C, 30 seconds 
at 60°C and 30 seconds at 72°C.  Fluorescence was monitored during 
the 60°C annealing phases. 
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2.5.2 Generation of CMV UL97 M460V mutants by PCR mutagenesis 
 
Whilst wild type CMV DNA are readily available through commercial 
sources (for instance, American Type Culture Collection, or 
Advanced Biotechnologies, Inc), DNA from ganciclovir-resistant 
strains of CMV has to be sourced by screening clinical samples or 
isolates from patients.  Using an in vitro PCR mutagenesis protocol, 
we aimed to generate CMV DNA containing mutant sequence arising 
from ATG to GTG change (methionine to valine amino acid 
substitution) at codon 460 of the UL97 gene.  These mutants would 
serve either as controls for PCR assays or for use in generating mixed 
populations of known proportions of wild type and mutant sequences.   
 
By means of mismatched primer mutagenesis first described by 
Higuchi (1990), new primers were designed (using the Beacon 
Designer 2 version 2.06 software (Premier Biosoft International)) to 
be only partially complementary to the target site but in such a way 
that it will still bind specifically to the target (Table 2.3).  Two 
mutagenic reactions were carried out, generating two separate PCR 
products which have partially overlapping sequences containing the 
M460V mutation.  These reactions were carried out as asymmetric 
PCR assays, in order to preferentially amplify the designed strand 
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containing the mutant sequence.  A symmetric PCR results in 
exponentially grown double stranded DNA whereas an asymmetric 
PCR generates one of the strands by linear amplification and a 
fraction of its total product as double-stranded DNA limited by the 
concentration ratio of the primers used (Poddar, 2000).  The 
denatured products were then combined in a final PCR reaction (using 
outer primers previously described by Chou et al, 1995a) to generate 
a larger product with the mutation in a more central location.   
 
All PCR reactions were carried out in 50µL volumes consisting of 
2.0mM Mg2+, 200µM of each dNTP (Finnzymes Oy), 1.5 units of 
HotStarTaq DNA polymerase (QIAGEN GmbH), standard PCR buffer 
(QIAGEN GmbH), 1×Q-solution, 0.2µM of outer primers CPT1088 
and CPT1619 or 0.3µM of inner primers 460_F and 460_R and 1µg of 
CMV AD169 DNA (for first round of PCR) or 2µL of PCR product.  
Cycling conditions were 1 cycle of 95°C for 15 minutes; 37 cycles 
with denaturation at 94°C for30 seconds, annealing at 55°C for 30 
seconds and extension at 72°C for 30 seconds.  Amplification was 
carried out on the iCycler thermal cycler (Bio-Rad Laboratories). 
 
Electrophoresis on 1% agarose gel and ethidium bromide staining 
were used to size the desired PCR products.  The M460V mutation 
was confirmed by DNA sequence analysis of the PCR products.   
 Cytomegalovirus infections in solid organ transplant recipients 
 53
 
2.6 CMV UL54 mutation analysis 
 
PCR-based assays - either involving restriction analysis (PCR-RFLP) 
or discriminatory PCR primers - were developed for detection of a 
mutation at codon 412 of the CMV UL54 gene, occurring at a 
conserved region in the codons 300 to 1000 of the polymerase genes 
where the majority of mutations leading to ganciclovir resistance are 
known to occur (Chou, 1999).   
 
Primers for PCR were designed using the Jellyfish version 1.4 for 
Windows software (Biowire.com, Inc.).  A nested PCR strategy was 
adopted to increase the sensitivity and specificity of amplification.  
For the first round of PCR, universal primers were selected to amplify 
the entire CMV UL54 gene sequence (NCBI, Human CMV strain 
AD169 complete genome Accession and Version No: 59591, 
Sequence feature view of the region: gi|59591:c80631-76903). 
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2.6.1 Analysis of CMV UL54 F412C mutation by PCR-RFLP 
 
For the second round of PCR, primers were designed to amplify the 
gene region surrounding codon 412 within UL54.   Also taken into 
account during primer design and selection was the number of 
restriction site (and thus the number and size of fragment generated) 
as well as the commercial availability of the restriction enzymes.  
These newly designed primers and corresponding restriction enzymes 
are listed in Table 2.5.  All primers were synthesized commercially 
by QIAGEN Operon or Research Biolabs Pte Ltd.  
 
Optimized conditions for the first (universal) round of amplification 
of the nested PCR protocol were as follows: 2.0mM Mg2+, 200µM of 
each dNTP (Finnzymes Oy), 1.5 units of HotStarTaq DNA 
polymerase (QIAGEN GmbH), standard PCR buffer (QIAGEN 
GmbH), 1×Q-solution, 0.2µM of each universal primer (TJ54N_F1 
and TJ54N_B1) and 1µg of total DNA to a total volume of 25µL.  
Cycling conditions were 1 cycle of 95°C for 15 minutes; 37 cycles 
with denaturation at 94°C for 2 minutes, annealing at 50°C for 2 
minutes and extension at 72°C for 2 minutes; to ensure the complete 
synthesis of all strands, the samples were further extended at 72°C for 
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5 minutes.  Amplification was carried out on the iCycler thermal 
cycler (Bio-Rad Laboratories).  
 
PCR-RFLP involved a second round of PCR amplification as above 
except that the universal primers were replaced by specific primers 
(RJ54_412F and RJ54_412R) designed to amplify the region 
surrounding codon 412 and 2 – 3µL of the first round PCR product 
were used as test template.   
 
Validation of the assay involved the use of control templates, with 
CMV AD169 strain as the wild type positive control, DNAs from 
culture isolates of herpes simplex virus type 1 and adenovirus 
(American Type Culture Collection) as the negative template controls 
as well as nuclease-free water (Promega Corporation) as the negative 
no template control.   
 
Sensitivity of assay was determined by using two-fold serial dilutions 
of calibrated wild type laboratory CMV strain AD169 DNA, obtained 
commercially (Advanced Biotechnologies Inc) in the form of 
quantitated viral DNA (stock concentration = 104 DNA copies/µL).   
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Cycling conditions were similar to the initial round of amplification 
above and also carried out on the iCycler thermal cycler (Bio-Rad 
Laboratories).   
 
Restriction enzyme digestion using MboII (New England Biolabs Inc) 
was under conditions as specified by the manufacturer.  
Electrophoresis on 8% polyacrylamide gels and ethidium bromide 
staining were followed by fragment analysis against the wild type 
laboratory CMV strain AD169 and the AmpliSize molecular ruler 
(Bio-Rad Laboratories).   
 
Upon optimization, the PCR-RFLP assay was used for a retrospective 
analysis of 52 randomly selected clinical samples (phenol-chloroform 
extracted and purified DNAs) from the same cohort of pediatric solid 
organ transplant patients admitted to NUH.  These patients were also 
determined to be positive for CMV and also genotyped for presence 
or absence of CMV UL97 mutations (see Section 2.3).  
 
 
2.6.2 Analysis of CMV UL54 F412C mutation by discriminatory PCR  
 
This discriminatory PCR strategy was based on that for our previous 
study on mutation analysis of UL97 codons 594 and 595.  Primer 
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pairs were designed with changes in the 3’ terminal sequence to 
anneal either to wild type or mutant sequences but not to both (Table 
2.5).  All primers were synthesized commercially by QIAGEN 
Operon or Research Biolabs Pte Ltd. 
 
Reagent mixture for PCR was also as previously described for UL97 
mutation analysis by this method, except that primer set 
CMV_412FW1 and CMV_412RW1 was used for the detection of wild 
type sequence and primer set CMV-412FW1 and CMV_412RM2 for 
the mutant.  Cycling conditions –with the optimal annealing 
temperature again determined by performing gradient PCR – were as 
follows: 1 cycle of 95°C for 15 minutes; 37 cycles with denaturation 
at 94°C for 1 minute, annealing at 64.7°C for 15 seconds minutes and 
extension at 72°C for 30 seconds.  Amplification was carried out on 
the iCycler thermal cycler (Bio-Rad Laboratories).  
 
Electrophoresis on 8% polyacrylamide gels and ethidium bromide 
staining enabled fragment sizing against that for various template 
controls and molecular ruler (Bio-Rad Laboratories).   
 
Upon optimization, a retrospective analysis of the 52 clinical samples 
from the same cohort of pediatric solid organ transplant patients for 
the PCR-RFLP study was made.  F412C mutations were confirmed by 
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DNA sequence analyses of the PCR products using BigDye 
Terminator Cycle Sequencing kit (Applied Biosystems) and the ABI 
Prism 310 genetic analyzer (Applied Biosystems), and by alignment 




2.7 Role of cytomegalovirus infection in the development of 
chronic allograft dysfunction 
 
2.7.1 Patient population 
 
A prospective study was done involving a total of 119 consecutive 
renal allograft recipients transplanted at the two major transplant 
centers in Singapore, i.e. NUH or SGH hospitals, recruited over a two 
year period.  Informed consent was obtained from all the patients 
enrolled in the study, which was approved by the Institutional Review 
Boards of both hospitals.   
 
Clinical data on all renal allograft recipients were obtained by chart 
review, case notes and the clinical database.  The standard induction 
immunosuppression regime used included methylprednisolone, 
azathioprine and cyclosporin A. Patients who were at high 
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immunological risk received induction with anti-thymocyte globulin 
(ATG) and/or anti-CD3 monoclonal antibodies (OKT3).  Patients who 
were seronegative prior to the transplantation and who received a 
kidney from a seropositive donor were treated prophylactically with 
intravenous ganciclovir as were patients with proven CMV infection.  
Chronic allograft dysfunction at one year post-transplant was defined 
as serum creatinine greater than 150 µmol/L.  Clinical and laboratory 
parameters recorded in the study included transplantation type 
(cadaveric or living-related or living-unrelated), the number of acute 
rejections, the degree of immunosuppression and the administration 
of ganciclovir.  Whole blood was obtained from each subject serially 
at the following time intervals: pre-transplant, day one, one month, 
three months and five months post-transplant.   
 
 
2.7.2 Determination of CMV DNAemia in the pre- and post-
transplant period 
 
To study the relationship between the presence of CMV DNA at 
various time intervals in the post-transplant period and subsequent 
allograft function at one year, nucleic acid was extracted from 
peripheral blood leucocytes by a modified phenol-chloroform 
procedure using protocols previously described (Jiwa et al, 1990; 
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Aw et al, 2000).  PCR amplification and quantitation of CMV 
were performed using primers specific for the CMV immediate 
early gene, namely 5’-AGC TGC ATG ATG TGA GCA AG and 
3’-GAA GGC TGA GTT CTT GGT AA (Jiwa et al, 1990).  The 
146bp PCR products were visualized upon electrophoresis with 
2% agarose gel and staining with 0.5µg/mL ethidium bromide; 
laser densitometric analysis carried out using a Bio-Rad GS-700 
imaging densitometer (Bio-Rad Laboratories, Hercules, CA, USA) 
at 260 nm.  Quantitation of the test CMV copy number was 
accomplished by comparison with a standard curve constructed 
from the densitometric analysis of the PCR amplicons obtained by 
running known copy numbers (10, 50, 100, 500 and 1000) of an 
external control plasmid containing CMV DNA.  The results were 
expressed as CMV copy number/µg of total DNA tested. 
 
 
2.7.3 Anti-endothelial cell antibodies activity (AECA) in sera 
 
Enzyme immunoassay (EIA) for AECA in sera was performed as 
previously described by Yap et al (1988), Jordan et al (1988) and 
Rappaport et al (1990),with minor modifications.   
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In brief, patient sera, diluted 1:10 for IgM specific and 1:50 for IgG 
specific AECA, were tested against human umbilical venous 
endothelial cells (American Type Culture Collection, Manassas, VA, 
USA) that were cultured in Clonetics endothelial cells basal medium 
(Cambrex Corp, Baltimore, MD, USA) supplemented with antibiotic 
and antimycotic and endothelial cell growth supplement (Sigma-
Aldrich Co, St Louis, MO, USA).  The cells were grown on 96-well 
microtiter well plates (Nunc A/S, Roskilde, Denmark) until they 
formed at least a 90% confluent monolayer.  After fixation with 0.2% 
gluteraldehyde and quenching with PBS-Tween 0.1%, the plates were 
ready for testing.  Sera were tested in quadruplicates.  .   
 
To standardize the AECA EIA, the relevant antibody levels were 
measured in 30 normal controls, and four controls were used to 
statistically represent the distribution of the normal controls, and 
were subsequently tested on every microtiter well plate.  A 
standardized score was derived based on the mean OD of the four 
standard controls (M) on each plate, expressed as follows: 
 
AECA score = OD of test serum - M 
 
The upper 95th percentile confidence limit (one-tailed test) of the 
control population was calculated to determine the upper limit of 
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normality; scores of greater than 0.06 for IgG specific AECA, and 
greater than 0.08 for IgG specific AECA were considered abnormal.   
 
 
2.7.4 Statistical analysis of risk factors for development of chronic 
allograft dysfunction at one year post-transplant 
 
Statistical analysis of risk factors for development of chronic 
allograft rejection at one year post-transplant were performed using 
SPSS for Windows, Rel. 13.0 2004 (SPSS Inc., Chicago, USA).  
Initially, univariate analyses employing a chi-square test for 
interdependence were performed.  P < 0.05 was considered 
statistically significant.  This was followed by logistic regression 
analyses considering chronic allograft rejection as the dependent 
variable.  Potentially significant variables identified in the univariate 
analysis were tested in this model.  The odds ratio (OR) for each 
variable, and their 95th percentile confidence intervals were 
calculated, and their significance were then determined.   
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Table 2.1. Screening for CMV UL97 mutations related to ganciclovir 
resistance based on distinctive restriction digestion patterns from 
PCR products (adapted from Erice, 1999). 
 








NlaIII 460 198, 168, 126, 9 324, 168, 9  
AluI 520 295, 189, 17 
268, 189, 
27, 17  
HhaI 594 50, 38, 18, 12 62, 38, 18  
MseI 595 76, 42 46, 42, 30  
TaqI 595 99, 19 71, 28, 19 
 
*Underlined fragments are normally seen in polyacrylamide gels after 
ethidium bromide staining. 
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Table 2.2. CMV UL97 mutation analysis by discriminatory PCR: 













UL97 codon 594 
  
 CMV_594R CGAATGTTACCACCCTGCTT 
 CMV_594LW CTTACCGTTCTCCAACG 
 
269 
 CMV_594LM CTTACCGTTCTCCAACA  
 
UL97 codon 595 
  
 CMV_595R TATTGCATGTCGGAGCTGTC 
 CMV_595LW GAGCTTACCGTTCTCCA 
 
159 
 CMV_595LM GAGCTTACCGTTCTCCG  
* underlined nucleotide indicates point mutation 
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Table 2.3. Generation of CMV UL97 mutants by PCR mutagenesis: 














a  previously described by Chou et al, 1995a 
* new primers 
**underlined nucleotide indicates site of mutation (A to G change) 
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Table 2.4. CMV UL97 mutation analysis by real time PCR using 
molecular beacons: sequences of primers and molecular beacons 









 Forward 5′-TGCATCGACAGCTACC-3′ 













a underlined sequences indicate stem sequences of the molecular 
beacon 
* indicates site of mutation 
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Table 2.5. CMV UL54 mutation analysis by PCR-RFLP and 
discriminatory PCR: sequences of primers for the entire UL54 gene, 











Complete UL54 gene 
 
 TJ54N_F1 TTTTTCAACCCGTATCTGAGC 







 RJ54_412F TCTCTTTACGATCGGCACCT 
 RJ54_412R GCCGGATTGTTGTGAGAAG 
 
318* 
 *Restriction enzyme MboII digest patterns for wild type (318 bp, i.e. 




 CMV_412FW1 TGTGCTACGAGACGGGGGG 
 CMV_412RW1 CGCGTGAGGATGTACTTCAAGTCAA 
 
280 
 CMV_412RM2 CGCGTGAGGATGTACTTCAAGTCTG**  
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CMV is endemic rather than epidemic in all parts of the world.  It is 
present throughout the year, with no seasonal variation seen in 
infection rates.  
 
Every mammal appears to be infected with its own species-specific 
CMV, and no evidence exists for infections across species in nature. 
Hence, humans are the only natural host for CMV infection. Although 
most adults eventually become infected with CMV, the epidemiology 
of this infection is complex, and the age at which an individual 
acquires CMV depends greatly on geographic location, 
socioeconomic status, cultural factors, and child-rearing practices.  
 
Although CMV is not noted for being highly communicable, any 
person with a CMV infection can pass it to others throughout life, 
chiefly via contact with infected secretions.  In developed countries 
congenital CMV infection is the leading cause of congenital viral 
infection, with a stable incidence in 0.4 to 2.2% of all live births 
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(Alford et al, 1990).  Intrauterine infection occurs in up to 50% of 
pregnancies following primary maternal infection, and 10% of the 
infected infants are symptomatic at birth (Stagno et al, 1986).  The 
virus may be transmitted readily to susceptible children via saliva, 
urine, and fomites; these children, in turn, may transmit infection to 
their parents. 
 
In adulthood, sexual activity is probably the most important route of 
acquisition of CMV, though the observation that virus is present in 
saliva, cervicovaginal secretions, and semen makes it unclear which 
route or routes of transmission are primarily responsible for 
establishment of infection.  Other important routes of transmission 
include blood transfusion and solid organ transplantation. 
 
The immune response to CMV in immunocompetent individuals 
involves synthesis of anti-CMV IgM antibodies several weeks after 
primary infection and which persist for 3-4 months; this is followed, a 
few weeks later, by the appearance of anti-CMV IgG antibodies that 
persist for life (Landolfo et al, 2003).  
 
In Singapore, very few studies have been conducted to estimate the 
seroprevalence rate for CMV infection.  To date, only two 
seroprevalence studies were conducted locally (Sng and Tobin, 1971; 
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Wong et al, 2000); these studies focused on and women and children 
in the former, and on pregnant women in the latter.   
 
Advances in the field of molecular biology have greatly augmented 
not only the laboratory's capability to detect nonculturable or slow-
growing microorganisms and detect antimicrobial resistance but also 
to monitor a variety of disease processes by quantitation of nucleic 
acid sequences, as well as evaluate the relatedness of organisms 
involved in epidemic and nosocomial infections.  Specifically, 
molecular strain characterization aids in the detection of infectious 
disease outbreaks and helps guide control efforts to protect public 
health, identify pseudo-outbreaks due to contamination events, and, in 
the case of a number of infectious diseases, distinguish between 
reactivation disease and reinfection (Arens, 1999 and 2001; Clarke 
and Bloor, 2002; Hungnes et al, 2000).  
 
A variety of typing methods have been used, including nucleotide 
sequencing, Southern blotting, oligonucleotide fingerprint analysis, 
single-strand conformation polymorphism (SSCP) analysis, 
heteroduplex mobility assay, or restriction fragment length 
polymorphisms (RFLP) (Arens, 1999).   
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PCR-based RFLP methods, in which amplification of selected 
segments of the viral genome is followed by restriction enzyme 
digestion of the amplicons, are most widely used in the elucidation of 
CMV epidemiology.   
 
The importance of CMV strain variability, recognized since 1976, is 
now receiving renewed interest (Rasmussen, 1999), in particular, as 
part of investigations into why in hosts with comparable levels of 
immunosuppression, some CMV infections result in symptomatic 
CMV disease while others are limited to asymptomatic virus shedding 
with no discernible clinical consequences.  
 
There has been no previous study on the molecular epidemiology of 
CMV infection in Singapore.  Therefore, in this chapter, we sought to 
determine the frequency distribution of the genotypes of clinical 
isolates of CMV directly from blood in Singapore on the basis of 
envelope glycoprotein gene sequences by PCR-RFLP (Chou and 
Dennison, 1991). 
 
Additionally, the seroprevalence rate for CMV infection was 
determined from a cohort of randomly selected and apparently healthy 
young adults (aged 17 to 24 years) by screening for serological 
evidence of CMV infection (presence of IgG antibodies) by 
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immunoassay (ELISA).  CMV serostatus is one of the traditional risk 
factors for early-onset CMV disease and now appears to also 
contribute to the occurrence of late-onset CMV disease during the 
first year after transplantation for both solid organ and hematopoietic 
stem cell recipients (Razonable, 2005).   No previous study has also 
been reported for this age-related cohort in Singapore.   
 




3.2.1 Cytomegalovirus seroprevalence in healthy young adults and 
pediatric solid organ transplant subjects 
 
Of the total number of 151 subjects (Table 3.1) tested for CMV 
antibodies by ELISA, 46.36% (70/151) were CMV IgG seropositive.  
With respect to gender, 42.47% (31/73) of males and 50.0% (39/78) 
of females were positive for CMV IgG antibody (P = 0.18) (Table 
3.2).   
 
Pre-transplant CMV seropositivity for the cohort of 17 pediatric solid 
organ transplant recipients was 23.52%; all 5 liver transplant subjects 
were CMV seronegative (Table 3.2).   
 
 
3.2.2 Molecular epidemiology of cytomegalovirus infection in 
Singapore  
 
A total of 200 clinical samples (104 from peripheral blood, saliva and 
bronchoalveolar lavage of 17 pediatric solid organ transplant 
subjects, and 96 clinical isolates of CMV, Table 3.3) were subjected 
to PCR amplification of the CMV gB gene.   
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Seven samples (from renal transplant subjects) did not yield any PCR 
product (possibly owing to DNA degradation from prolonged storage 
or amplification inhibition) and were therefore not typed.  Restriction 
enzyme digestion by HinfI and RsaI of the PCR products of the 
remaining 193 samples showed distinct patterns for gB types 1 – 3 
(Figure 3.1).  The correct gB type 1 and gB type 2 were obtained for 
the reference strains Towne and AD169, respectively.   
 
For the 193 clinical samples assayed, the overall frequency 
distribution of CMV strains on the basis of gB types 1, 2, 3, and 4 
was 58.5%, 19.1%, 14.1% and 0%, respectively, with 8.3% of 
samples containing mixed genotypes (Table 3.3).  Pairwise 
comparisons of the different genotypes were carried out; the 
percentage of gB type 1 was found to be statistically significant from 
the other types (P = 0.03) for the two cohorts (transplant and non-
transplant subjects) surveyed independently as well as when both are 
combined   
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subjects (n = 151) 
 
Sera from 73 males and 78 females; mean 




Pediatric solid organ 
transplant subjects with 




CMV DNAs isolated from peripheral 
whole blood, saliva and bronchoalveolar 
lavage of 4 males and 1 female 
Renal transplant  
(n = 12)
CMV DNAs isolated from peripheral 
whole blood, saliva and bronchoalveolar 
lavage of 12 males and 0 female 
Clinical isolates of 
CMV (n = 96) 
 
Viruses propagated in human foreskin 
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Table 3.2.  CMV serostatus of healthy young adults and pediatric 








Presence of CMV IgG antibody 
 
Healthy young adults 
Male 73 42.47% (31/73)* 
Female 78 50.0% (39/78) 
Total  151 46.36% (70/151) 
Pediatric solid organ transplant subjects (pre-transplant) 
Liver transplant 5 0% (0/5) 
Renal transplant 12 33.33% (4/12) 
Total 17 23.52% (4/17) 
* P = 0.18 











Figure 3.1.  Restriction digest profiles of PCR amplified part of CMV 
envelope glycoprotein B (gB) using (A) RsaI.  Lanes 1-2: Towne (gB 
type 1), AD169 (gB type 2); Lanes 3 – 5: CMV isolates types 1 – 3, 
respectively; Lane L, AmpliSize molecular ruler (Bio-Rad 
Laboratories, Hercules, CA, USA), and (B) HinfI.  Lanes 1-2: Towne 
(gB type 1), AD169 (gB type 2); Lanes 3 – 5: CMV isolates types 1 – 
3, respectively, Lane 6: mixed infection (types 2 and 3); Lane L, 
AmpliSize molecular ruler. 
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1 2 3 4 Mixed types 
 
Cohort A: Pediatric solid organ transplant subjects (n=17) 
Liver transplant (n = 5); 15 clinical samples 5 (33.3) 5 (33.3) 4 (26.7) 0 (0 1 (6.7) 
Renal transplant (n = 12); 89 clinical samples received 
but 82 samples typed (see text)
46 (56.0) 18 (21.9) 12 (14.6) 0 (0) 6 (6.7) 
 Total: 97 (100%) 51 (52.5)* 23 (23.7) 16 (16.5) 0 (0) 7 (7.2) 
 
Cohort B: Clinical isolates of CMV (n = 96, non-transplant subjects) 
 Total: 96 (100%) 62 (64.5)* 14 (14.5) 11 (11.5) 0 (0) 9 (9.4) 
 Overall Total: 193(100%) 113 (58.5)* 37 (19.1) 27 (14.1) 0 (0) 16 (8.3)  
* P = 0.03  





3.3.1 Cytomegalovirus seroprevalence in healthy young adults and 
pediatric solid organ transplant subjects 
 
In populations with good socioeconomic status, the seroprevalence of 
CMV is approximately 40% in adolescents, increasing thereafter by 
about 1% annually (Griffiths and Baboonian, 1984).  Approximately 
70% of adults in good socioeconomic conditions eventually become 
infected with CMV.  In contrast, most children in developing 
countries acquire CMV infection early in life, with adult 
seroprevalence approaching 100% by early adulthood.  
 
The overall seroprevalence of CMV infection for young adults in 
Singapore (mean age = 18.6 ± 1.5  years), on the basis of CMV IgG 
antibody status, is 46.36%.  This is not significantly different from 
the results of a recent study of 12 to 19 year-olds (Staras et al, 2006) 
in the United States (41.7%, P = 0.23). 
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A recent survey by Wong et al (2000) of Singapore’s antenatal 
population (mean age = 29.2 years) revealed that 87% of 200 patients 
tested positive for CMV IgG, suggesting that CMV is endemic in 
Singapore.  The percentage obtained is, however, a significant (P  = 
0.03) drop from the 99% of 100 expectant mothers who tested 
positive in Sng and Tobin’s 1971 survey, reflecting the improvement 
in socioeconomic conditions and in standards of public health in 
Singapore.  But Singapore’s CMV seroprevalence is still high 
compared to that for Europe (51.5% in France (P  = 0.03), 54.4% in 
London, UK (P  = 0.03)), reflecting the high rates seen in the tropics, 
as also seen in countries like Thailand (100%).  
 
Of the 73 male and 78 females in the study cohort, 42.47% (31/73) of 
males and 50.0% (39/78) of females were positive for CMV IgG 
antibody.  However, gender and CMV IgG seropositivity were found 
to be independent of each other (P = 0.18), as was also seen in a 
study of the blood donor population in Taiwan by Lu et al (1999). 
 
In contrast to the 46.36% seropositive rate in young adults obtained in 
this study, the pre-transplant CMV seropositive rate of the 17 
pediatric solid organ transplant subjects was only 23.52% (Table 3.3).  
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The trend is similar to that seen in the West, where CMV IgG 
seropositivity increases with age (Griffths and Baboonian, 1984, 
Staras et al, 2006).   
 
CMV seronegative patients who receive kidneys from seropositive 
donors are at highest risk of developing CMV-associated disease (Ho, 
1982).  Symptomatic disease occurs in 60-80% of these patients with 
a mortality of 10%.  Seropositive patients are not immune from the 
disease, as up to 30% of them can develop clinical disease, either 
from reactivation or reinfection. 
  
McLaughlin et al (2005) showed recently that CMV seronegative 
recipients of renal allografts from CMV seropositive donors (D+/R-) 
have an increased risk of early allograft loss due to acute rejection 
even if the D+/R- group does not appear to have poorer renal allograft 
function 3 years post-transplant.  In another study of the incidence 
and risk factors for CMV disease during the first post-transplant year 
in a cohort of liver transplant recipients who received antiviral 
prophylaxis with oral ganciclovir, late CMV disease developed in a 
substantial proportion of D+/R- recipients after prophylaxis was 
discontinued and was associated with increased mortality (Limaye et 
al, 2004).  With the majority of the transplant recipients likely to be 
CMV seropositive (R+), Singh et al (2005) has shown CMV infection 
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developed in 32.5% of 177 R+ liver transplant recipients, and, in the 
same study, donor CMV seropositivity is identified as the major risk 
factor in R- patients.  
 
 
The increasing trend of CMV seropositivity with age has implications 
for the management of both seropositive and seronegative, 
immunocompromised recipients in Singapore.  Our data suggests that 
pediatric transplant recipients, majority of whom is CMV 
seronegative, are likely to receive organs from adults, who are CMV 
seropositive donors.  In fact, the seropositivity rate of CMV in kidney 
donors in Singapore is 89.1% (Table 6.2).   
 
 
3.3.2 Molecular epidemiology of cytomegalovirus infection in 
Singapore  
 
The CMV envelope glycoprotein B, encoded by UL55, is a major 
target of neutralizing antibodies as well as cell-mediated immune 
responses (Britt, 1984, Hopkins et al, 1996).  In addition, it has been 
shown to be involved in the viral entry into cells, cell-to-cell viral 
transmission and fusion of infected cells (Navarro et al, 1993).  
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Several studies have been conducted to find a correlation between the 
gB genotype and the occurrence of CMV-associated disease in 
immunocompromised patients because it has been observed that in 
hosts with comparable levels of immunosuppression, some CMV 
infections result in symptomatic CMV disease while others are 
limited to asymptomatic virus shedding with no discernible clinical 
consequences.  But it remains unclear whether certain gB genotypes 
are associated with an increased frequency of disease.  Although an 
earlier study had suggested an association between gB type 2 and 
development of CMV retinitis in patients with AIDS (Shepp et al, 
1996), data from recent studies have not supported this (Gilbert et al, 
1999; Drew et al, 2002).  Also, Humar et al (2003) have shown that 
gB genotype did not affect the rate of disease recurrence or 
occurrence of tissue-invasive disease in solid-organ transplant 
recipients with CMV disease.  Candidate genes other than UL55 and 
their biological activities should be studied for their contribution to 
virulence. 
 
On the basis of CMV strains obtained in Singapore (from a cohort of 
pediatric solid organ transplant patients, and from the two clinical 
microbiology laboratories in Singapore performing isolation and 
culture of CMV from non-solid organ transplant patients), the overall 
frequency distribution (Table 3.3) for gB types 1, 2, 3 and 4 are  
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58.5%, 19.1%, 14.1% and 0%, respectively; 8.3% of the isolates 
studied contained mixed types.  The percentage of gB type 1 strains 
isolated is found to be statistically significant from the other types 
using pairwise comparisons of proportions (P < 0.05) for the overall 
frequency distribution.   
 
This study showed that CMV gB type 1 is also the predominant CMV 
strain for the pediatric solid organ (both cohorts of liver and renal) 
transplant subjects in Singapore (P = 0.03).  This observation is in 
agreement with other Asian reports of renal transplant recipients in 
Hong Kong (Woo et al, 1997) and also in immunocompetent patients 
with CMV infection in Japan (Kashiwagi et al, 2002), whereas gB 
type 2 CMV strains were more frequently recovered in Brazilian renal 
transplant recipients (Carraro and Granato, 2003).   
 
A predominance of gB type 1 genotype has also been observed in the 
majority of American studies of solid organ transplant population 
(Fries et al, 1994; Rosen et al, 1998; Humar et al, 2003; Carraro and 
Granato, 2003) although gB type 3 was the mostly frequently 
observed in liver transplant patients in a Canadian study (Sarcinella et 
al, 2002).  Another exception is the predominance of type 2 among 
bone marrow transplant recipients (Wada et al, 1997; Woo et al, 
1997).  A recent study of CMV strains isolated in the pediatric 
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population, equal numbers of gB types 1 and 3 were obtained 
(Xanthankos, 2003).  Therefore, it remains unclear whether or not gB 
genotype is a specific CMV-virulence factor with respect to 
association with a particular type of organ transplantation.   
 
In the Singapore context, our finding was likely a reflection of gB 
type 1 strain as the predominant CMV genotype in circulation in the 
population as gB type 1 strains were isolated in 64.5% (versus 14.5%, 
11.5% and 9.4% of gB types 2, 3 and mixed types, respectively (P < 
0.05)) in the non-transplant population (Table 4.3),  
Different mechanisms of the response to CMV infection, rather than 
different degrees of virulence associated with certain gB types might 
be at work, as shown by the dominance of different gB types in 
different types of transplant patients (Woo et al, 1997).  The 
pathological damage caused by CMV in renal transplant recipients is 
believed to be a result of the viral lysis following replication 
associated with gB type 1.  The induction of a strong cell-mediated or 
cytotoxic immune response may be more strongly associated with gB 
type 2 CMV strains in bone marrow transplant patients (in whom 
disease is immunopathological) rather than in renal transplant 
recipients in whom the immune response is likely to be protective.   
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The fact that gB is the principal target of neutralizing antibodies 
towards CMV in humans and is the most highly conserved envelope 
glycoprotein of human herpesviruses (Marshall et al, 2000) has made 
it the target of CMV vaccine development.  CMV gB vaccines using 
recombinant gB protein expressed from plasmid DNA and gB 
expressed in several different viral vectors have been investigated 
with animal models (Endresz et al, 2001; Wang et al, 2004).  
Evaluations in humans have been based on a live attenuated gB type 1 
(Towne) strain of CMV (Adler et al, 1998; Pass et al, 1999), more 
specifically its envelope glycoprotein B.  The initial safety data from 
a Phase 1 clinical trial of a CMV immunotherapeutic vaccine by Vical 
Inc, USA were reported at the Interscience Conference on 
Antimicrobial Agents and Chemotherapy in November 2004. 
 
More recent clinical trails have shown that the Towne vaccine 
induced neutralizing antibodies and cell-mediated immunity (both 
antigen-specific CD4+ and CD8+ T cell responses) mitigated CMV 
disease in seronegative renal transplant recipients and protected 
against a low-dose virulent CMV challenge in normal volunteers 
although it did not prevent infection in mothers of children excreting 
CMV (Gonczol and Plotkin, 2001; Jacobson et al, 2006). 
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While CMV gB type 4 isolates were not found in this study (they 
were also relatively rare in previously published reports), the overall 
frequency distribution of gB types 2 and 3 in Singapore adds up to 
33%.  Whether or not the gB type 1 (Towne) vaccine is sufficient to 
generate cross protection against gB types 2 and 3 strains of CMV 
remains unknown and warrants investigation.  
 
In 8.3% of all the clinical samples typed, mixtures of at least two 
different CMV strains were found. This has also been also reported 
elsewhere for renal transplant recipients (Aquino and Figueiredo, 
2000; Coaquette et al, 2004) although there was no association of gB 
genotypes with the development of symptomatic CMV infection in 
these two reports.  As only select clinical samples for each patient in 
the cohort of pediatric transplant recipients were available for gB 
genotyping we were thus unable to determine if there is indeed an 
association of viral genotype with the development of CMV disease 
in our local solid organ transplant population.   
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CMV infections are a major cause of morbidity and mortality among 
immunocompromised patients, especially recipients of bone marrow 
and solid-organ transplants and patients with AIDS.  In severely 
immunocompromised patients who develop CMV disease, prolonged 
antiviral therapy is often necessary.  To prevent CMV disease in the 
transplant population, typically one of two approaches are taken: 
prophylactic regimens (initiated in all transplant patients, regardless 
of risk) and pre-emptive regimens (administered only to high risk 
individuals).  Studies have shown that both strategies are effective in 
decreasing the incidence of CMV disease in solid organ transplants 
and hematopoietic stem cell transplants (Razonable and Paya, 2003) 
though there is debate as to which strategy is optimal (Emery, 2001; 
Hart and Paya, 2001).  Antiviral prophylaxis has also been shown to 
reduce other clinically relevant and indirect CMV-related outcomes 
such as graft rejection (Lowance et al, 1999).  
 
Preventive strategies via the use of antiviral prophylaxis and pre-
emptive therapy have, however, resulted in changing the natural 
course of CMV infection (‘late-onset CMV disease’) (Razonable and 
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Paya, 2003).  Also, widespread and prolonged use of antiviral drugs 
have lead to the emergence of ganciclovir- (and other drug)-resistant 
CMV infections.   
 
Risk factors for ganciclovir-resistant CMV infection include lack of 
CMV-specific immunity (i.e. donor CMV-seropositive and recipient 
CMV-seronegative), high viral replication and a high viral load, 
multiple episodes of CMV disease, receipt of potent 
immunosuppression, prolonged antiviral drug administration, and 
suboptimal tissue-plasma antiviral drug concentration (Limaye et al, 
2000). 
 
The majority of infections caused by drug-resistant CMV have been 
found in patients with AIDS (Erice, 1999).  The frequency of these 
infections has varied among different studies. In one study that 
analyzed the prevalence of infections caused by ganciclovir-resistant 
CMV strains in 31 patients with AIDS and CMV retinitis, 5 (38%) of 
13 patients who were treated with intravenous ganciclovir for more 
than 3 months were excreting ganciclovir-resistant CMV strains in 
their urine (Drew et al, 1991).  This represented an overall incidence 
of ganciclovir resistance of 7.8% in this patient population.  A 1997 
randomized trial conducted by Studies of Ocular Complications of 
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AIDS (SOCA), in collaboration with the AIDS Clinical Trials Group, 
comparing intravenous ganciclovir and foscarnet found ganciclovir-
resistant CMV in 5.3% of 207 patients who remained viremic after 
being treated with ganciclovir for a minimum of 2.5 months.  
Ganciclovir-resistant CMV infections in AIDS patients who had 
received prophylaxis or preemptive therapy with oral ganciclovir was 
4.8% (Smith et al, 1998). In that study, the detection of these UL97 
mutations in plasma was associated with clinical progression. 
 
CMV drug resistance represented a major problem in patients with 
AIDS until the recent introduction of highly active antiretroviral 
combination therapy, which dramatically decreased the incidence in 
this clinical setting (Baldanti et al, 2004).  However, CMV resistance 
to antiviral drugs remains a major problem in the transplantation 
setting. 
 
The incidence of ganciclovir-resistant CMV infections varies 
according to the type of organ transplant, with the highest incidence 
observed in lung and combined kidney-pancreas transplant recipients 
(9% and 13%, respectively) (Bhorade et al, 2002; Limaye, 2002; 
Limaye et al, 2002).  Studies in the United States indicate that CMV 
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ganciclovir resistance occurs in 0%, 0.3% and 1% of liver, heart and 
kidney transplant recipients, respectively (Limaye et al, 2000; Limaye 
et al, 2002; Bhorade et al, 2002).  A Western Australian retrospective 
study of orthotopic liver transplant patients on universal ganciclovir 
prophylaxis did not find antiviral resistance in this type of organ 
transplant (Leong et al, 2004).   
 
Until recently, there were only sporadic cases of ganciclovir-resistant 
CMV infection among hematopoietic stem cell transplant recipients 
but it may be an emerging problem in pediatric transplantation.  In a 
case report by Springer et al (2005), two such recipients died with 
persistent CMV infection complicated by resistance to antivirals, with 
resistance detected after only 6 weeks of foscarnet treatment in the 
first patient and after 11 weeks of ganciclovir treatment in the second.  
Other reports have also suggested that resistance may develop more 
rapidly in severely immunocompromised children (Wolf et al, 1998). 
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4.2 Characterization of mutations conferring cytomegalovirus 
resistance to ganciclovir 
 
Antiviral agents for the treatment of CMV infections include 
ganciclovir, foscarnet, and cidofovir. All three compounds inhibit 
CMV DNA synthesis by inhibiting the viral DNA polymerase.  
Valganciclovir, an orally administered prodrug of the standard drug 
ganciclovir, is also used for the treatment of AIDS-related CMV 
retinitis and as prophylaxis of CMV infection and disease in high-risk 
solid organ transplant recipients (Baliga et al, 2004; Cvetkovic, 
2005). 
 
Ganciclovir (9-[1,3-dyhydroxy-2-propoxymethyl]guanine) is a 
deoxyguanosine analogue that must be phosphorylated to ganciclovir 
triphosphate to exert its antiviral activity (Crumpacker, 1996).  The 
CMV UL97 gene of CMV encodes a viral protein kinase that 
phosphorylates ganciclovir to ganciclovir monophosphate, with 
cellular kinases carrying out further phosphorylations to ganciclovir 
di- and triphosphate.  Ganciclovir triphosphate is a competitive 
inhibitor of the natural substrate (deoxyguanosine triphosphate) for 
the CMV DNA polymerase. Also, incorporation of ganciclovir 
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triphosphate into viral DNA inhibits CMV DNA chain elongation 
(Crumpacker, 1996; Field et al, 1983). 
 
The evidence that CMV could become resistant to antiviral 
compounds was initially obtained in the laboratory by selecting a 
ganciclovir-resistant CMV strain after passaging a susceptible 
reference virus (laboratory CMV strain AD169) in the presence of 
increasing concentrations of ganciclovir (Biron et al, 1986).  Initial 
studies of resistant laboratory and clinical CMV strains related 
ganciclovir resistance to inadequate intracellular phosphorylation of 
the compound in cells infected with ganciclovir-resistant viruses.  
Although experimental evidence at that time suggested that 
ganciclovir phosphorylation was controlled by a CMV-encoded 
function, the mechanism by which ganciclovir is phosphorylated in 
CMV-infected cells was eventually confirmed by two independent 
reports providing biochemical, immunological, and genetic evidence 
that the phosphorylation of ganciclovir in CMV-infected cells is 
controlled by a protein kinase homologue encoded by the UL97 open 
reading frame of the virus (Littler et al, 1992; Sullivan et al, 1992). 
 
Analyses of UL97 sequences in clinical CMV isolates resistant to 
ganciclovir have also demonstrated the presence of point mutations or 
deletions in this region of the viral genome.  To date, the majority of 
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the ganciclovir-resistant isolates of CMV contained mutations at 
codon 460, 520, 594 or 595 (Erice, 1999).  In fact, resistance 
mutations are all within a region of about 150 codons or 450 base 
pairs making genotyping a viable method for antiviral testing.  
Sequencing of the UL54 gene is much more cumbersome since 
resistance-conferring mutations occur over a region of about 600 
codons or 1800 base pairs. 
 
The aforementioned isolates contained mainly single UL97 mutations, 
with few isolates containing two mutations in this region (Table 5.1).  
Marker transfer experiments have shown that the mutations confer 
ganciclovir resistance when introduced into the genome of 
recombinant viruses.  Similar to the studies done with ganciclovir-
resistant laboratory CMV strains, anabolism studies with ganciclovir-
resistant clinical CMV isolates have demonstrated that the functional 
consequence of these UL97 mutations is an impaired intracellular 
phosphorylation of ganciclovir into ganciclovir monophosphate, with 
the subsequent lack of synthesis of ganciclovir di- and triphosphate. 
 
A study by Lurain et al (2001) has also demonstrated that, in the 
complete sequences of the UL97 phosphotransferase genes in 28 
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phenotypically ganciclovir-sensitive CMV clinical isolates, the gene 
was highly conserved, with nucleotide sequence identity among 
strains ranging from 98.6 to 100% and amino acid sequence identity 
of >99%.  Mutations in the UL97 gene eventually lead to decreased 
levels of the active (tri-phosphorylated) form of ganciclovir so that 
the CMV polymerase is no longer inhibited.   
 
The CMV DNA polymerase is also the target of the antiviral agents 
such as ganciclovir.  Fully activated ganciclovir is a competitive 
inhibitor of the DNA polymerase (UL54 gene) and also causes a 
slowing and then cessation of chain elongation (Arens, 2001).  
Mutations in the UL54 gene can also directly result in resistance of 
the virus to these drugs (Table 5.1).  Sequence analysis of the DNA 
polymerase of ganciclovir-resistant CMV strains selected in the 
laboratory has shown the presence of mutations in this region of the 
viral genome (Lurain et al, 1992; Sullivan et al, 1993).  Recent 
marker transfer studies by Chou et al (2003) have confirmed CMV 
DNA polymerase resistance mutations at both conserved and 
nonconserved loci.  It has been postulated that these DNA polymerase 
mutations could be involved in substrate recognition and could cause 
drug resistance by decreasing the affinity of the viral polymerase for 
antiviral compounds.   
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4.3 Laboratory methods for the diagnosis of ganciclovir-resistant 
cytomegalovirus  
 
Diagnosis of ganciclovir resistance requires the demonstration of 
reduced susceptibility of a clinical CMV isolate to ganciclovir in 
vitro.  Methods used in the laboratory to determine susceptibilities of 
CMV isolates to antiviral compounds may be classified as phenotypic 
or genotypic.  
 
Phenotypic methods are designed to determine the concentration of an 
antiviral agent that would inhibit the virus in culture. In general, these 
are culture-based methods in which a known amount of infectious 
virus is grown in the presence of different concentrations of the 
antiviral agent.  
 
The plaque reduction assay (PRA) is considered the gold standard for 
antiviral susceptibility testing of CMV and other viruses (Biron et al, 
1986).  In this assay, a standardized amount of a stock virus 
(previously subjected to titer determination in cell culture) is 
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inoculated into cultures and incubated in the presence of the antiviral 
agent.  The cultures are then observed for the presence of viral 
plaques. On the basis of the results of phenotypic assays, viruses are 
classified as susceptible or resistant to a given antiviral compound.  
Phenotypic assays require a viral isolate, thus prolonging the time 
necessary for their completion and are not therapeutically useful 
(Lurain et al, 2001). 
 
Genotypic assays are designed to determine whether mutations known 
to confer antiviral resistance are present in the genome of the viruses 
being studied.  Generally, genotypic methods involve the use of 
molecular technologies to obtain sequence information concerning 
target regions of the viral genome.  The clustering of mutations at 
specific UL97 codons in ganciclovir-resistant CMV isolates has led to 
the development of diagnostic screening assays based on restriction 
digest analysis of selected PCR products amplified from CMV-
infected cell cultures or directly from clinical specimens (Wolf et al, 
1995).  These assays are useful when the genetic basis for antiviral 
resistance has been identified and when there is a predictable 
relationship between the presence and absence of a genetic variant 
and measurable antiviral resistance.  The significance of mutations 
found in genotypic studies must be further evaluated by assessing the 
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effect of each mutation on the phenotype of recombinant viruses and 
on the structure and function of mutated viral proteins (Chou et al, 
2002).  
 
Genotypic assays for resistance to anti-CMV drugs examine two 
CMV gene products which are implicated in resistance: the CMV 
UL97 and the UL54 gene products.  Point mutations or deletions of 
portions of UL97 can lead to ganciclovir resistance.  To date, the 
most common mutations conferring ganciclovir resistance are at 
codons 460, 520, 594, 595 and deletions 595 to 607 (Chou et al, 
1995a; Chou et al, 1995b; Erice et al, 1989; Handson et al, 1995; 
Spector et al, 1995; Wolf et al, 2001 and Wolf et al, 1995).  
 
Ganciclovir-resistant strains can be classified into two groups: those 
with low resistance to ganciclovir with mutations on the UL97 gene, 
but wild-type for the UL54 gene; and those with high resistance to the 
drug, with mutations on both viral genes (Uwe-Vogel et al., 1997).   
 
UL54 mutations, depending on their locations, can confer resistance 
to one or more antivirals (Chou et al, 2003).  The majority of 
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genotypic assays are PCR-based methods involving restriction digest 
analysis and/or DNA sequencing analysis.  They may be more 
sensitive than phenotypic assays but may be limited by incomplete 
characterization of all the mutations that confer resistance either by 
lack of marker transfer experiments or recombinant virus data.  
 
The main aim of this chapter is to determine the frequency of CMV 
mutant strains in (i) CMV isolates (“live” cultures) sent to the 
Virology Laboratories of NUH and the Singapore General Hospital 
(SGH), where the active programs for solid organ transplantations in 
Singapore are located and (ii) CMV DNA isolated directly from 
clinical samples such as blood, saliva and urine for a cohort of 
pediatric solid organ transplant patients from NUH.  Different 
laboratory methods currently available, including conventional drug 
susceptibility assay (plaque reduction assay) and previously published 
genotypic assays (PCR-RFLP, DNA sequencing) would be employed. 
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Table 4.1.  CMV UL97 and UL54 gene mutations and phenotype 
analysis (adapted from Erice, 1999) 
 
 




UL97 (confirmed by marker transfer 
experiments) 
 
M460V, M460I, H520Q, 591-594 




Additional UL97 mutations (found in 
resistant clinical isolates) 
 
N510S, A590T, A591D, A591V, 
C592G, A594T, L595T, L595W, 
E596G, E596D, N597I, G598V, K599M, 
600 deleted, C503Y, C606D
R 
 
UL54 (confirmed by marker transfer 
studies/recombinant virus data) 
 
F412C, D413E, L501I, A809V R 
L802M S or R 
 
Additional UL54 mutations (found in 
resistant clinical isolates) 
 
N408D, F412V, L501F, T503I, P522S, 
L545S, G678S, I722V, Y751H, V781I, 
T821I, V812L, A987G, K513R
R 
* S, Sensitive; R, Resistant 
 





4.4.1 Drug susceptibility testing by plaque reduction assay (PRA) 
 
Laboratory strains of clinical isolates originally propagated in human 
foreskin fibroblasts (MRC-5) and saved in frozen (-70°C) storage 
were subjected to plaque reduction assay (Figure 4.1). Of the total of 
96 clinical isolates of CMV re-cultured to prepare stock virus 
concentrations for the assay, seven (7.3%) either did not show CPE 
characteristic of CMV (confirmed negative by direct 
immunofluorescence staining using FITC-conjugated monoclonal 
anti-CMV (Dako A/S, Denmark)) or failed to produce the requisite 
90% cytopathology of the infected cell layer.   
 
IC50 values obtained for PRA for the wild type control (laboratory 
CMV strain AD169) ranged from 1.6 to 2.2µM (mean IC50 = 1.9µM, 
CV% = 72.4), which were within the expected sensitive range (≤ 6µM 
of ganciclovir).  The 89 laboratory strains of clinical isolates of CMV 
that were tested by PRA had also IC50 values below the 6.0uM value 
for sensitivity, and ranged from 0.95 to 2.4µM (Table 4.2). 
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4.4.2 Genotypic analysis of the CMV UL97 and UL54 genes 
 
Examination of the extracted DNAs from the 96 clinical isolates of 
CMV by (a) PCR-RFLP did not reveal any of the UL97 mutations at 
codons 460, 594, 595 and 520 that were known to confer ganciclovir 
resistance, and by (b) DNA sequencing of the codons 300 to 1000 
region of the CMV polymerase (UL54) gene also did not reveal any 
mutation, when compared against results obtained for the wild type 
laboratory CMV strain AD169 (Table 4.2).  
 
As shown in Table 4.2, of the 12 renal transplant patients (comprising 
a total of 89 clinical samples) screened by PCR followed by 
restriction analysis, three patients (Patients R1, R2 and R3) harbored 
CMV strains with mutations in the UL97 gene that were known to 
confer ganciclovir resistance by clinical studies as well as marker 
transfer experiments (Chou et al, 1995a; Chou et al, 1995b).  These 
mutations (either as single mutant strain or a mixture of wild type and 
mutants) were at codons 594 and 595, and were confirmed by DNA 
sequencing (Table 4.2, Figures 4.2 and 4.5).  CMV DNAs from the 
rest of the patients were wild type genotypes with respect to both 
UL97 and UL54 genes. 
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Using the same screening strategies to examine a cohort of five liver 
transplant patients (with a total of 15 clinical samples comprising 
blood and liver, colon and sigmoid biopsies), mutant CMV genotypes 
were obtained for the UL97 gene (in codons 460 and 594) in two 
patients, Patients L1 and L2 (Table 4.2, Figures 4.2, 4.4 and 4.5).  
The remaining patients’ CMV DNAs exhibited only wild type 
genotypes for both the UL97 and UL54 genes.   
 
While CMV disease such as retinitis and pneumonitis was found to 
occur in all transplant patients in this study cohort irregardless of 
presence or absence of mutant CMV genotypes, all five patients with 
CMV resistant genotypes also had peripheral blood or 
bronchoalveolar lavage cellular CMV DNA copy numbies of > 1000 
µg DNA, compared to one kidney and one liver transplant patient 
with > 1000 µg DNA but with wild type CMV genotype.  Viral copy 
number of > 1000 µg DNA has been shown to associate with 
recrudescence of CMV retinitis in pediatric solid organ transplant 
recipients (Aw et al, 2000).   
.
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Ganciclovir 0uM                             1.5uM                3.0uM
 
 
Figure 4.1.  Cytomegalovirus susceptibility to ganciclovir by plaque 
reduction assay.  Plaques (cells stained with methylene blue) 
produced by a laboratory strain from a clinical isolate grown in 
monolayers of human embryonic fibroblasts under agarose overlay 
medium with increasing concentrations of ganciclovir. 
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Table 4.2.  Screening results for CMV mutations conferring ganciclovir resistance in (a) pediatric renal and liver 
transplant patients, and (b) clinical isolates of CMV in Singapore  
 
Cohort A: Pediatric solid organ transplant subjects (n = 17)  
Ganciclovir resistant CMV detected in 3/12 subjects by PCR-RFLP 
UL97 changes*  
Renal transplant 
subjects (n = 12; 89 
clinical samples 
assayed) Position(s); Amino 
acid(s) changes 
Nucleotide change(s) Remarks 
 Patient R1 L595S T to C mutants or mixture of wild type and mutants 
 Patient R2 A594V C to T mixture of wild type and mutants 
 Patient R3 A594V, L595S C to T (codon 594), T 
to C (codon 595) 
mixture of wild type and mutants 
Ganciclovir resistant CMV detected in 2/5 subjects by PCR-RFLP 
UL97 changes*  
Liver transplant 
subjects (n = 5, 15 
clinical samples 
assayed) Position(s); Amino 
acid(s) changes 
Nucleotide change(s) Remarks 
 Patient L1 M460V A to G mutants or a mixture of wild type and mutants 
 Patient L2 A594V C to T mixture of wild type and mutants 
*No simultaneous UL54 mutations noted in the clinical samples received for all patients with UL97 mutants at time 
of screening; UL54 mutation was detected in additional samples received for Patient R1 (see Chapter 6) 




Table 5.2.  (continued)   
Cohort B: Clinical isolates of CMV (n = 96)  
 
7/96 of isolates did not show CPE or produce 
90% cytopathology of infected cell layer; 
89/96 of isolates tested by plaque reduction 
assay (PRA).  No ganciclovir resistance 
demonstrated.  IC50 values = 0.95 – 2.4µM 
(mean IC50 = 1.9µM, CV% = 72.4).  IC50 
values for laboratory CMV strain AD169 = 1.6 
– 2.2µM.   
Laboratory strains of clinical isolates (“live” cultures) originally 
propagated in human foreskin fibroblasts (MRC-5) and saved in 
frozen (-70°C) storage 
 
 
Extracted DNAs from 96/96 clinical isolates 
tested by PCR-RFLP and DNA sequencing for 
ganciclovir resistance.  No UL97 or UL54 
mutations conferring ganciclovir resistance 
detected. 
 














NlaI HhaI                             TaqI 




Figure 4.2. Genotypic analyses of CMV UL97 gene by PCR-RFLP for 
M460V, A594V and L595S mutations that confer ganciclovir 
resistance. (a) NlaIII restriction digests of PCR amplified CMV UL97.  
Lanes 1, 2 and 3 contain CMV strains from a patient who harboured 
wild type CMV, patient L1 (M460V mutant) and wild type laboratory 
control CMV AD169, respectively.  Lane L, AmpliSize molecular ruler 
(Bio-Rad Laboratories, Hercules, CA, USA); (b) HhaI restriction 
digests of PCR amplified CMV UL97.  Lanes 1, 2 and 3 contain CMV 
strains from a patient has wild type CMV, patient R3 (both A594V 
mutant and wild type CMV) and wild type laboratory control CMV 
AD169, respectively.  Lane L, 20bp EZ Load molecular ruler (Bio-Rad 
Laboratories, Hercules, CA, USA); (c) TaqI restriction digests of PCR 
amplified CMV UL97.  Wild type CMV strains isolated from a patient 
with wild type CMV and the laboratory control (AD169, wild type) are 
shown in lanes 1 and 4, respectively.  CMV strains present in patient 
R1 are either a mixture of wild type and L595S mutant strains (lane 2) 
or mutant strains alone (lane 3).  Lane L, AmpliSize molecular ruler 
(Bio-Rad Laboratories).  








L         1         2         3                 L        1  2         3
 
 
Figure 4.3. Genotypic analyses of CMV UL97 gene codons by PCR-
RFLP for H520Q and L595F mutations. (a) AluI restriction digests of 
PCR amplified CMV UL97.  Lanes 1, 2 and 3 contain CMV strains 
from two patients with the wild type and the laboratory control CMV 
AD169 strain, respectively.  Lane L, AmpliSize molecular ruler; (b) 
MseI restriction digests of PCR amplified CMV UL97.  Lanes 1, 2 and 
3 contain CMV strains from two patients with the wild type and the 
laboratory control CMV AD169, respectively.  .  Lane L, AmpliSize 
molecular ruler (Bio-Rad Laboratories). 












Figure 4.4. Genotypic analyses of CMV UL97 gene codons by NlaIII 
restriction digests of PCR amplified CMV UL97 for M460V mutations.  
Lanes 1, 2, 3 and 4 contain CMV strains from a patient with wild type 
variant, a patient with the wild type, laboratory control CMV AD169, 
and patient L1 with the mutant CMV, respectively.  Lane L, AmpliSize 
molecular ruler (Bio-Rad Laboratories). 




Figure 4.5. CMV UL 97 gene in the vicinity of codons 460, 594 and 
595.  Sequence of reference (laboratory control CMV strain AD169) is 
shown, aligned with sequence of mutant strains M460V, A594V and 
L595S. 
 
               460                 594 595 
AD169 ACACCCATGAACGTG …… TGCCGCGCGTTGGAGAAC 
               Met  Cys  Arg  Ala  Leu Glu  Asn 
M460V               GTG ……  
               Val   
A594V  ……                 GTG 
                  Val 
L595S  ……                        TCG 
                           Ser 





Plaque reduction assay has been considered the gold standard for 
antiviral susceptibility testing (Wentworth and French, 1970) and is 
used successfully for rapidly growing, cell-free clinical isolates of 
herpes simplex virus.  CMV presents a more challenging problem 
because clinical isolates are often slow growing and cell associated.  
This study illustrates several of its limitations.  Time required for viral 
isolation (in particular in CMV, noted for its slow growth) and 
subsequent performance of the assay typically required several weeks 
at a minimum to perform, itself a disadvantage in guiding clinical 
decisions.   
 
In the preparation of viral stocks for the PRA assay in this study, 7.3% 
(7/96) of the clinical isolates of CMV either did not show CPE 
characteristic of CMV or failed to produce the requisite 90% 
cytopathology of the infected cell layer in spite of multiple passages in 
culture.  As adequate amounts of virus were not achieved, the PRA 
assays were therefore not carried out for these clinical isolates.  This 
inherent difficulty in CMV drug susceptibility testing has been noted 
elsewhere by Landry et al (2000) and Jabs et al (1998a; 1998b).   
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Nevertheless, the 89/96 laboratory strains of clinical isolates of CMV 
examined by this in vitro method were all phenotypically non-resistant 
to ganciclovir.  The IC50 values obtained were in the range of 0.95 to 
2.4µM of ganciclovir, against the non-ganciclovir resistant laboratory 
control CMV strain AD169’s average value of 1.9µM.  The expected 
sensitive range is ≤ 6µM of ganciclovir. 
 
However, it has been demonstrated that certain CMV viruses that were 
susceptible in phenotypic assays actually contained UL97 or UL54 
mutations conferring antiviral resistance.  One study reported a clinical 
isolate of the CMV virus with a A594V mutation in the UL97 gene that 
was susceptible to ganciclovir by PRA (Wolf et al, 1995), and, in 
another study, a CMV isolate with a similar UL97 codon 594 mutation, 
obtained from a bone marrow transplant recipient, was also susceptible 
to ganciclovir using a genotypic assay for ganciclovir resistance (Erice 
et al, 1998).  Resistance mutations affect the growth rate of the CMV 
virus and growth attenuation has been reported elsewhere for mutant 
strains (Baldanti et al, 1996).  Thus, slow growing mutant viruses may 
affect phenotypic assays such as the PRA, whereby the delayed 
appearance of plaques may be misinterpreted as drug susceptibility.  
 
The two genotypic methods (namely PCR-RFLP and DNA sequencing) 
adopted in this study were also utilized for ganciclovir resistance 
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screening of CMV DNAs extracted from these clinical isolates.  
However, no mutations known to confer resistance were detected by 
these methods.   
 
In contrast, screening CMV DNAs extracted directly from blood of a 
cohort of pediatric solid organ transplant subjects revealed the 
presence of UL97 gene mutations conferring ganciclovir resistance in 
three of 12 (25%) renal and two of five (40%) liver transplant patients 
(Table 4.2).  Owing to the small sample numbers per transplant type, it 
is not possible to draw comparisons between the percentages obtained 
and data from previously studies.  Nonetheless, the mutations detected 
all occurred in the two strongly clustered sites (at codons 460 and 594 
and 595, corresponding to subdomains VI and IX, respectively) in the 
UL97 phosphotransferase gene where all known UL97 mutations occur 
(Table 4.1).   
 
This study confirms the presence of ganciclovir resistance in CMV 
strains in Singapore.  It also demonstrates – in the mutations at UL97 
codons 460, 594 and 595 that were detected in CMV strains obtained 
locally - that the majority of the types of mutations in ganciclovir-
resistant isolates of CMV were genotypically similar to those occurring 
in the West, particularly from the immunocompromised patients (Erice, 
1999). 
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It was also noted that either mutant or mutant and wild type strains of 
the CMV virus were isolated from the cohort screened.  As was also 
observed by Erice et al (1998), immunocompromised patients such as 
transplant patients can harbor multiple isolates, including the mixed 
populations of mutant and wild type strains.   
 
The fact that mutant CMV strains were not detected by the PRA assay 
but by the genotypic screening method could be attributed to the 
improved sensitivity of the PCR based method.  In a previous study, 
mutants could be detected only when they reach 10% of the viral 
population in a clinical isolate of CMV (Chou et al, 1995b).   
 
The discrepancy between a resistant genotype (with a mutant UL97 or 
UL54 sequence) as determined by a method such as PCR-RFLP and a 
susceptible phenotype, as demonstrated by the PRA assay, could also 
be explained by the fact that in vitro anti-viral susceptibility assays 
have a lower sensitivity than that for PCR-based amplification methods 
for specific amplification and detection of antiviral resistance 
mutations.   
 
Additionally, the co-existence of multiple isolates of the virus in a 
patient may make it possible that culture-based susceptibility assays 
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will select a different virus population from that selected by PCR, 
thereby producing different sets of results. . 
 
A disadvantage of this PCR-RFLP method is that specific mutations 
involving base changes that do not result in a change in the restriction 
enzyme pattern may not be detected.  Also, strain variation at NlaIII 
sites other than codon 460 occasionally resulted in a variant restriction 
pattern but this was easily distinguished from that of the M460V 
mutation (Figure 4.4).  In this study, the wild type variant CMV strain 
was observed in patients who harbored CMV that were either 
ganciclovir resistant or sensitive or both, and thus, there did not appear 
to be any association between their occurrence and susceptibility or 
resistance to ganciclovir. 
 
Resistance of CMV to antiviral agents is a well-documented 
complication of long-term antiviral therapy.  This problem has been 
observed mostly in patients with AIDS and CMV retinitis, in whom 
drug-resistant CMV infections have been associated with clinical 
progression and therapeutic failure.  Currently available data suggest 
that the incidence of infections caused by drug-resistant CMV in bone 
marrow and solid organ transplants is low.  In a study by Boivin et al 
(1993), none of 33 blood or tissue CMV isolates recovered from solid-
organ transplant recipients who developed CMV viremia after receiving 
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prophylaxis and or treatment with intravenous ganciclovir were 
resistant to this drug.  Gilbert et al (2001) showed that following 
preemptive ganciclovir therapy in allogeneic stem cell transplant 
recipients, there was no emergence of CMV UL97 mutations conferring 
ganciclovir resistance  
 
Nevertheless, with the extensive use of ganciclovir as prophylaxis and 
or prolonged preemptive therapy and the use of oral ganciclovir, 
reports of emergence of drug-resistant mutants in the various transplant 
populations have accumulated in recent years (Chou, 1999; Singh, 
2001; Limaye, 2002).   
 
In a 2000 retrospective study by Limaye et al of solid organ transplant 
recipients who had received oral ganciclovir and highly potent 
immunosuppression, ganciclovir-resistant CMV disease developed in 
five (7%) of 67 seronegative recipients of CMV-seropositive organs 
(D+/R-) compared with none of 173 seropositive recipients (P = 
0.002).  Among the 25 (10.4%) patients who developed CMV disease 
within one year after transplantation, five had ganciclovir-resistant 
CMV disease.   
 
We have also demonstrated the presence of CMV ganciclovir 
resistance in Singapore in three of 12 (25%) renal transplant recipients.  
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A retrospective study of all the clinical samples received from the first 
such case (Patient R1, Appendix A) showed emergence of the 
ganciclovir resistant CMV approximately seven months post-
transplantation (Figure 7.1).  Wild type strains of CMV were 
eventually replaced by a mixture of both resistant and wild type strains 
in a renal transplant recipient on long-term anti-CMV prophylaxis and 
treatment in immunocompromised patients.  The patient experienced 
several episodes of severe CMV disease, leading to the administration 
of repetitive courses of antiviral therapy.  Selective pressure allowed 
for strains of CMV with a point mutation (TTG-to-TCG; Leu-to-Ser at 
codon 595 of the UL97 gene) to co-circulate with wild type CMV.   
 
Our data also showed that ganciclovir resistance is also extended to 
CMV strains associated with liver transplantation with clinical samples 
from two of five (40%) of liver transplant patients containing CMV 
strains with UL97 gene mutations.   
 
To date, on the basis of a PubMed index search, no molecular studies 
on CMV resistance to ganciclovir have been conducted in Singapore or 
in the region.  There is a single Japanese report (Harada et al, 1997) of 
a clinical isolate of CMV exhibiting ganciclovir resistance, in the 
UL54 polymerase gene.   
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Our findings confirm the presence of ganciclovir-resistant CMV strains 
in Singapore.  That they are found in a cohort of transplant patients 
who are on ganciclovir prophylaxis (and not in the non-transplant 
population) warrants the adoption of antiviral screening assays for 
these patients as the assays have the potential to guide therapy and 
assist in the confirmatory diagnosis of clinical antiviral resistance. 
 
Based on our own experience, a culture-based susceptibility assay such 
as the PRA was laborious compared to the relative ease of use and 
shorter turnaround time of the PCR-RFLP test.  Of particular 
usefulness will be molecular assays that can be performed on DNA 
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5 DEVELOPMENT OF RAPID NUCLEIC ACID TESTS FOR 





Traditional methods for detection of microbial drug resistance follow 
the basic paradigm of isolation of a microorganism in pure culture 
followed by detection of phenotypic drug resistance by one or more 
methods, for example, plaque reduction assay for resistance to antiviral 
agents.  These methods are invariably labor intensive and time-
consuming.  Delays in providing timely results for effective patient 
management and treatment can be substantial.   
 
CMV resistance studies have been limited by the difficulty and lack of 
standardization of antiviral susceptibility assays although efforts are 
being made towards the development of a standardized plaque 
reduction assay for CMV cell-associated clinical isolates (Landry et al, 
2000).  The recognition that specific mutations in the UL97 and UL54 
genes of CMV are associated with different antiviral susceptibility 
patterns has prompted the development of molecular laboratory 
methods for detection of mutant viral sequences in viral isolates and 
directly in clinical specimens.  The incorporation of these methods in 
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the routine of diagnostic virology laboratories have contributed to a 
more rapid and sensitive detection of drug-resistant CMV strains. 
 
 
5.2 Current and new strategies for the genotypic detection of 
mutations conferring ganciclovir resistance in cytomegalovirus 
 
While phenotypic assays have the advantage of measuring the growth 
characteristics of a virus even in the context of a complex assortment 
of mutations in which it may be very difficult to sort out and identify 
their individual actions and collective interactions.  Genotyping, on the 
other hand, can be a fairly simple, straightforward procedure that 
yields clinically useful information at a reasonable cost and in a short 
amount of time and is routinely performed on the nucleic acid 
extracted from patient plasma, thus precluding the necessity of an in 
vitro culture.  The major requirement for interpretation of genotypes 
for resistance testing is that the location of mutations that confer 
resistance must be known and there should be some concept of which 
mutations confer what level of resistance. 
 
For all practical purposes, there are only four viruses for which a 
genotypic analysis is clinically useful, HBV, HCV, CMV and HIV.  
This is mostly a function of the fact that there are not many viral 
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infections that can be treated with antiviral drugs and thus there are 
few opportunities for viruses to become resistant to antiviral drugs 
(Arens, 2001). 
 
Currently the majority of genotypic screening tests for ganciclovir 
resistance are based on PCR, entailing amplification of the region of 
UL97 gene surrounding specific codons where mutations are known to 
occur, followed by restriction digest analysis of the PCR products.  
Mutations at specific UL97 codons in conserved regions of the gene in 
ganciclovir-resistant CMV isolates are in the form of amino acid 
deletions and or substitutions, and result either in the loss or 
acquisition of naturally occurring restriction enzyme sites.  Distinctive 
restriction patterns can be visualized by gel electrophoresis and 
ethidium bromide staining (Table 2.1).  This screening method can 
detect mutants when they reach 10% of the viral population in a 
clinical isolate; in one study, it identified 78% of the isolates resistant 
to ganciclovir in phenotypic assays (Chou et al, 1995b).  A major 
advantage of this restriction digestion analysis is that preliminary 
results can be obtained in less than 48 hours (compared to a minimum 
of six to seven weeks for the plaque reduction assay).  This method 
(using a nested PCR format) can be applied directly to clinical samples 
such as leukocytes, plasma and cerebrospinal fluid.  In addition, direct 
genotypic detection of a mutant strain of the virus indicates that the 
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mutation is not due to in vitro phenotypic selection.  A limitation of 
phenotypic methods for sensitivity testing of CMV strains is that the 
selection process during growth in cell culture may lead to changes in 
the features of the virus present in the original clinical sample.  Also, 
the virus in blood or urine may be different from the virus causing the 
disease (for example, in the case of CMV retinitis) and it is thus 
questionable how representative a virus isolated in cell culture is for 
the disease causing virus in the retina.   
 
However, a drawback of this PCR-RFLP method is that specific 
mutations involving base changes that do not result in a change in the 
restriction enzyme pattern may not be detected.  Also, it does not 
detect ganciclovir-resistant CMV isolates containing DNA polymerase 
mutations but wild-type UL97 sequences (Erice et al, 1997).  In other 
words, while a positive result is virtually diagnostic of ganciclovir 
resistance, a negative result does not necessarily indicate that a virus is 
susceptible to ganciclovir.  
 
Confirmed ganciclovir resistance mutations on the CMV DNA 
polymerase gene occur at both conserved and nonconserved loci (Chou 
et al, 2004).  These are mainly point mutations with the exception of a 
two-codon (codons 981 and 982) deletion (Chou et al, 2000).  At 
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present, the method of choice for detection of these mutations is by 
sequencing the relevant portions of the UL54 gene.   
 
The aims of this chapter were to (a) improve on existent PCR-RFLP 
methods for mutation analysis in the CMV UL97 gene and (b) develop 
assays for analysis of mutations in the CMV UL54 gene that obviate 
the need for DNA sequencing.  A secondary aim of this chapter was to 
discover novel mutations that may also confer ganciclovir resistance.  
 
For mutation analysis in the CMV UL97 phosphotransferase gene, we 
sought to develop rapid PCR-based methods using the current 
conventional PCR assay as well as the more recently available real 
time PCR platforms.  PCR-RFLP as a screening method can detect 
mutants when they reach 10% of the viral population in a clinical 
isolate (Chou et al, 1995b); we sought to improve on this rate of 
detection as well as the turnaround time for reporting of results by 
simultaneous and direct detection of mutant and wild type genotypes in 
the same clinical samples.   
 
Although DNA sequencing is now less costly than in the past, there is 
still the need to invest in and maintain an automated DNA sequencer.  
In Singapore and neighboring countries, this facility is usually only 
available in research laboratories.  Thus, routine analysis of CMV 
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UL97 DNA polymerase to detect ganciclovir resistance is not often 
possible.  To date, there is a limited number of publications on the use 
of non-DNA sequencing methods such as restriction enzyme analysis 
of PCR fragments for mutation analysis in the CMV UL54 polymerase 
gene (Harada et al, 1997; Chou et al, 1998).  We therefore also aimed 
to develop PCR-based screening assays that did not necessitate the use 
of DNA sequencing.   
 





5.3.1 CMV UL97 mutation analysis by discriminatory PCR 
 
We developed rapid molecular assays for the detection of these point 
mutations by a novel discriminatory PCR assay strategy involving two 
sets of amplifications, one each for detection of wild type and of 
mutant sequences.  The first set of primers, designed using the Primer 
3 software program, was a pair (CMV_594R and CMV_594LW for 
analysis of codon 594, CMV_595R and CMV_595LW for codon 595, 
Table 2.2), corresponding to the sequence of the reference strain 
AD169.  This allowed for amplification and therefore detection of wild 
type sequences (amplification product size 269 bp and 161 bp, 
respectively) but not A594V or L595S mutants that contain a single 
nucleotide substitution (C to T or T to C) at positions 1781 and 1784, 
respectively.  The second set of primers (CMV_594R and 
CMV_594LM for codon 594, CMV_595R and CMV_595LM for codon 
595) included either a 3’ substitution of A for G nucleotide on primer 
CMV_594LM or a 3’ substitution of G for A to enable detection of the 
L595S mutant sequence but not the wild type for the respective codons 
(Figures 6.1 and 6.2).  Therefore, by simultaneously performing two 
PCR reactions for each unknown clinical sample, this assay can 
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differentiate between wild type and mutant genotypes, and, if 
amplification products are detected in both reactions, the detection of 
mixed populations of wild type and mutant CMV strains.   
 
In order to reduce the turnaround time, a two-step protocol (versus the 
standard three-step) was devised, combing the annealing and 
elongation step of the PCR cycle.  Selection of the optimal annealing 
temperature is often the most critical component in the optimization 
phase of PCR assay development to achieve increased specificity and 
minimize mispriming and amplification of non-target sequences (Harris 
and Jones, 1997).   
 
During the assay development, the thermal gradient functionality of the 
iCycler thermal cycler – which allowed programming of a temperature 
gradient in increments of 0.5°C across the thermal cycling block - was 
exploited to determine the best annealing/extension temperature for 
amplification of the desired sequence (for example, the wild type) but 
not the non-specific product (for example, the mutant genotype) or 
artefacts and secondary products such as primer-dimers.   
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These newly developed PCR assays were performed on 40 clinical 
samples randomly selected from our study cohort of renal and liver 
transplant recipients.  There was complete concordance with the results 
obtained previously by PCR-RFLP methods for ganciclovir resistance 
with respect to detection of wild type, mutant or a mixture of wild type 
and mutant genotypes (Table 6.1).   
 
 
5.3.2 CMV UL97 mutation analysis by real time PCR using molecular 
beacons 
 
Nucleic acids isolated from 40 blood samples (from the same study 
cohort of solid organ transplant recipients) were subject to real-time 
PCR molecular beacon analysis for the presence of the A to G mutation 
in codon 460 of the UL97 CMV gene.  Each sample was 
simultaneously analyzed in two separate reaction wells, each well 
containing PCR reaction mixture with either the wild-type beacon or 
the mutant beacon.  Fluorescence was measured during every cycle of 
the PCR using the 490 and 530 filters for FAM and HEX, respectively.  
Comparison of the multiple amplification curves was made following 
normalization of the fluorescence for each molecular beacon as 
previously described (Smit et al, 2001).  In brief, the formula (F – 
Fmin)/(Fmax – Fmin) is used, where F is the measured fluorescence, and 
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Fmin and Fmax are the minimum and maximum fluorescence, 
respectively.  
 
Figure 5.3 shows the amplification curves obtained, after normalization 
of fluorescence, with PCR amplifications using both molecular beacons 
of three different patient samples that harbor wild-type strains of CMV 
(sample a), both wild type and mutant strains (sample b) or mutant 
strains alone (sample c) with respect to codon 460 of the UL97 gene.   
 
The results indicate that PCR amplification of CMV in each sample 
produced an increase in the fluorescence of only the molecular beacon 
that was complementary to the intended target DNA.  For instance, 
there was increase in fluorescence when wild-type beacon was tested 
against samples a and b (containing wild-type CMV and a mixed 
population, respectively) but not against sample c (which contained no 
wild-type CMV).  When the mutant beacon was tested against the same 
samples, only samples b and c (which contained the mixed population 
and mutant CMV, respectively), displayed increase in fluorescence.  
Simultaneous fluorescence of both molecular beacons in sample b 
indicated the presence in sample c of both wild-type and mutant strains 
of the virus.  Thus the genotypes of different combinations of CMV 
genomes could be correctly predicted by this strategy.  It was also 
observed that samples negative for CMV DNA as well as negative 
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(nuclease-free water) controls did not generate any fluorescence for 
either beacon.   
 
Analysis of the scatter plot of fluorescence values received in the last 
PCR cycle for each clinical sample tested against both wild type and 
mutant molecular beacons (Figure 5.4) show three distinct clusters, 
reflecting the three possible combinations of wild type and mutant 
CMV strains in any given sample with CMV DNA. . 
 
Table 5.2 summarizes the results obtained by both PCR-RFLP and real-
time PCR analysis by molecular beacons for the detection of wild-type 
and mutant strains in clinical samples.  With one exception, the results 
obtained by molecular beacon analysis show general concordance with 
the other molecular approach for the clinical samples tested with the 
exception of one sample which was genotyped as mixture of wild-type 
and mutant strains by molecular beacons but as wild type only by PCR-
RFLP. 
 
To further evaluate the ability of the molecular beacon assay to 
discriminate genotype artificial mixtures of different percentages of 
M460V mutant and wild-type (AD169) strains of the virus of known 
copy numbers were prepared and assayed in triplicates.  The M460V 
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mutants were generated by mismatched primer mutagenesis using wild 
type CMV AD169 as template and newly designed primers.   
 
The results are comparable to PCR-RFLP and indicate that a sample 
with approximately 10% or more of the mutant strains against a 
background population of wild type virus can also be correctly 
clustered in the wild type/mutant group (Figure 5.4).  However, 
molecular beacon assay was able to identify artificial mixtures at a 
ratio of 95:5 wild-type to mutant strains in two out of the triplicate 




5.3.3 Analysis of CMV UL54 F412C mutation by PCR-RFLP 
 
We designed primers for PCR amplification of the CMVL UL54 gene 
region surrounding codon 412 yielding a 318 bp amplicons, to be 
followed by its digestion by MboII to produce a single fragment (318 
bp) for wild type CMV and two fragments (134 and 184 bp) for mutant 
strains (Table 2.5).   
 
Screening 52 clinical samples using this PCR-RFLP assay, two of three 
samples containing a mixture of wild type and F412C mutant CMV 
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strains were correctly genotyped when compared with the results 
obtained by DNA sequencing (Table 5.3, Figure 5.7).  Arrow (bottom 
figure) indicates the 1235 position (T) of the UL54 gene and shows a T 
to C substitution (resulting in an amino acid change from 
phenylalanine to cysteine in codon 412.  
 
 
5.3.4 Analysis of CMV UL54 F412C mutation by discriminatory PCR 
 
Applying a strategy similar to that of the discriminatory PCR-based 
assay for detection of CMV UL97 gene mutations, we designed primers 
for and developed a discriminatory PCR assay for direct, rapid 
detection of the F412C mutation in the UL54 gene from clinical 
samples.  Primer set CMV_412FW1 and CMV_412RW1 were designed 
to only anneal to and amply wild type sequences whereas primer set 
CMV_412FW1 and CMV_412RM2 contain, in the3’ end of latter 
primer, a ‘wobble’ sequence (TG) which allowed for annealing to 
complementary mutant sequence but not to the wild type owing to the 
mismatch sequence (Table 2.5).  As shown in Figure 5.6, this assay 
allowed for discrimination between wild type and mutant templates as 
well as for identification of templates with mixed populations of 
viruses.   
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Compared with results obtained by DNA sequencing of 52 samples 
from the same cohort of transplant patients that was also screened 
using the PCR-RFLP method, there was complete agreement between 
DNA sequencing and this newly developed PCR method.  And unlike 
the PCR-RFLP method, where the restriction patterns were ambiguous 
and the genotype for 13 samples could not be determined, this 
discriminatory PCR assay was able to correctly identify wild type 
strains and to distinguish them from samples with mixed populations of 
wild type viruses and viruses with the F412C mutation, previously 
confirmed by DNA sequencing (Table 5.3, Figure 5.7). 
 










Nested PCR (codon 594)






Figure 5.1. (a) HhaI restriction digests of PCR amplified CMV UL97.  
Lanes 1, 2 and 3 contain CMV strains from patient X (wild type), 
patient L2 (both A594V mutant and wild types) and control (AD169, 
wild type) strain, respectively.  Lane L, AmpliSize molecular ruler. (b)  
Products of discriminatory PCR assay for wild type and A594V mutant 
CMV UL97. CMV strains from patient X, patient L2, positive control 
(AD169) plus a negative control (water) are present in lanes 1, 2, 3 and 
4 and lanes 5, 6, 7, 8, respectively. Lane L, EZ Load 100 bp molecular 
ruler (Bio-Rad Laboratories, Hercules, CA, USA) 
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Figure 5.2. (a) TaqI restriction digests of PCR amplified CMV UL97.  
Wild type CMV strains isolated from patient X and the control 
(AD169) are shown in lanes 1 and 4, respectively.  CMV strains 
present in patient A are either a mixture of wild type and L595S mutant 
strains (lane 2) or mutant strains alone (lane 3).  Lane L, AmpliSize 
molecular ruler.  (b) Products of discriminatory PCR assay for wild 
type and L595S mutant CMV UL97. CMV strains from patient X (wild 
type), patient R1 (mixed population), patient R1 (mutant alone) and 
positive control (AD169) plus a negative control (water) are present in 
lanes 1, 2, 3, 4 and 5 and lanes 6, 7, 8, 9 and 10, respectively.  Lane L, 
EZ Load 100 bp molecular ruler. 
 
 Cytomegalovirus infections in solid organ transplant recipients 
 135 
 
Table 5.1.  Comparison of PCR-RFLP and novel two-step 
discriminatory PCR (D-PCR) assays for codons 594 and 596 UL97 
























    
 
 Wild-type strain only 37 37 38 38 
 Mixed (both mutant & 
wild type strains) 
3 3 1 1 




















































Figure5.3. Real-time PCR amplification plots of three different viral 
genotypes with respect to codon 460 of the UL9 CMV gene: sample a 
(wild-type CMV only), sample b (both wild-type and mutant CMV, 
sample c (mutant CMV only).  All samples were probed with both 
wild-type and mutant molecular beacons (top and bottom graphs, 
respectively).  Normalized fluorescence of both the wild-type and 
mutant beacons is plotted on the y-axis and the number of PCR cycles 
on the x-axis. 























Figure 5.4. Scatter plot of 40 clinical samples based on fluorescence 
values obtained at the last PCR cycle when analyzed by real-time PCR 
using both wild-type and mutant molecular beacons.  The three clusters 
obtained correspond to the three possible genotypes.   
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Table 5.2. Comparison of two DNA-based methods (PCR-RFLP and 
real-time PCR using molecular beacons) for codon 460 UL97 CMV 








A. Clinical samples 
  
 Wild-type strain only 31 30 
 Mixed (both mutant & 
wild type strains) 
3 4 
 Mutant strain only 6 6 
Total number 40 40 
   
B. Artificial mixtures  
(% CMV AD169 wild 
type to mutant strains, 
each combination 






 100:0 Wild-type (3/3) Wild-type (3/3) 
 95:5 Wild-type (3/3) Mixed (2/3) Wild-
type (1/3) 
 90:10 Mixed (3/3) Mixed (3/3) 
 80:20 Mixed (3/3) Mixed (3/3) 
 70:30 Mixed (3/3) Mixed (3/3) 
 0:100 Mutant (3/3) Mutant (3/3) 
 












Figure 5.5. MboII restriction digests of PCR amplified CMV UL54 for 
codon 412 mutation analysis.  Lanes 1, 2 and 3 contain CMV strains 
from patient X (wild type), patient R4 (both F412C mutant and wild 
types) and control (AD169, wild type) strain, respectively.  Lane L, 
AmpliSize molecular ruler. 
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Table 5.3. Comparison of DNA sequencing analysis with newly 
developed PCR-RFLP and discriminatory PCR assays for F412C 













   
 Wild-type strain only 49 37 49 
 Mixed (both mutant & 
wild type strains) 
3 2 3 
 Mutant strain only 0 0 0 
 ‘Indeterminate’ - 13 - 
Total number 52 52 52 
 








L    1     2    3    4   5     6    7      
 
 
Figure 5.6. Products of discriminatory PCR assays for CMV UL54 
codon 412 mutation analysis. CMV strains from patient 1 (wild type), 
patient 2 (mixed of wild type and mutant populations) and wild type 
positive control (AD169) are present in lanes 1, 2, 3, respectively for 
PCR using wild type primer set (CMV_UL54FW1 and 
CMV_UL54RW1), and also in lanes 4, 5 and 6, respectively, for PCR 
using primer set (CMV_UL54FW1 and CMV_UL54RM2) for 
amplification of mutants.  Lane 7 is a negative (water) control.  Lane 
L, EZ Load 100 bp molecular ruler. 
 






Figure 5.7. DNA sequence alignment using Jellyfish software version 
1.4 for CMV UL54 codon 412. ul54 refers to published UL54 sequence 
for wild type CMV AD169; A is wild type patient sample.  Arrow (top 
figure) indicates the 1235 position (T) of the UL54 gene.  E is patient 
sample with mutant F412C genotype.  Black color arrow (bottom 
figure) indicates the 1235 position (T) of the UL54 gene and shows a T 
to C substitution.  Red color arrow (bottom figure) points to G to A 
change at position 1237.  
 





5.4.1 CMV UL97 mutation analysis by discriminatory PCR 
 
The most common CMV UL97 codons 594 and 595 mutations 
conferring ganciclovir resistance involve single nucleotide substations 
at positions 1781 and 1784 (Erice, 2000) which result in amino acid 
changes from Ala to Val and from Leu to Ser, respectively.  
 
A novel discriminatory PCR assay strategy was devised for detection 
of these point mutations.  This involves two sets of newly designed 
primers, the first set of which allowed for amplification and therefore 
detection of wild type sequences (amplification product size 269 bp 
and 161 bp, respectively) but not A594V or L595S mutants that contain 
a single nucleotide substitution (C to T or T to C) at positions 1781 and 
1784, respectively.  The second set of primers enables detection of the 
L595S mutant sequence but not the wild type for the respective codons 
(Figures 5.1 and 5.2).  Furthermore, a two-step protocol (versus the 
standard three-step) was devised, combing the annealing and 
elongation step of the PCR cycle.  Selection of the optimal annealing 
temperature via use of the thermal gradient functionality of the iCycler 
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thermal cycler was an important component in the optimization phase 
of PCR assay development to achieve increased specificity and 
minimize mispriming and amplification of non-target sequences.  
Complete concordance was observed with the results obtained 
previously by PCR-RFLP methods for ganciclovir resistance with 
respect to detection of wild type, mutant or a mixture of wild type and 
mutant genotypes (Table 5.1).   
 
Mismatches resulting in non-authentic priming events in these assays 
were controlled in our assay by optimising the annealing/extension 
temperature for mutation analysis of each UL97 codon by gradient 
PCR selection to allow for reliable analysis of CMV strains of 
unknown status.  This carefully selected temperature allowed for 
maximal stringency in the pairing between, for instance, a reverse 
primer (CMV_594LW) designed for wild type codon 594 sequences but 
a strongly destabilized 3’ terminal guanosine when this primer is 
paired with a mutant sequence containing thymidine instead of cytosine 
in position 1781 of the UL97 gene.   
 
 
Alain et al (1997) described the use of a conventional three-step 
discriminatory PCR protocol for detection of the M460V mutation in 
 Cytomegalovirus infections in solid organ transplant recipients 
 145 
the CMV UL97 gene without the necessity of restriction analysis.  
With the two-step discriminatory PCR protocol for detection of A594V 
and L595S mutations, we have expanded on the repertoire of PCR-
based assays available for rapid detection of ganciclovir resistance 
directly on clinical samples.  
 
 
5.4.2 CMV UL97 mutation analysis by real time PCR using molecular 
beacons 
 
A rapid real-time PCR assay using molecular beacons for the 
simultaneous detection of wild-type and mutant CMV viruses with 
respect to codon 460 of the UL97 gene has been developed.  The 
molecular beacons were designed to complement the wild-type codon 
460 or the mutant sequence arising from ATG to GTG change 
(methionine to valine amino acid substitution).  We elected to perform 
the detection of wild type and mutant CMV strains in each sample 
simultaneously but in separate reaction tubes in order to avoid 
competition and other problems inherent in multiplex PCR assays 
(Elnifro et al, 2000).   
 
Discrimination between wild-type and mutant templates was 
demonstrated as the beacons did not generate fluorescence with their 
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respective mismatch targets but only with those that they were 
designed to perfectly anneal with (Figure 5.3).  In fact, samples that 
harbor mixed populations of wild type and mutant viruses could also be 
recognized by examining the amplification curve (Figure 5.3) or by a 
scatter plot (Figure 5.4).  The mixed genotypes are indicated by a 
separate (central) cluster hat is distinguishable from the clusters of 
wild type and mutant genotypes when the fluorescence values of the 
last PCR cycle obtained using either wild type or mutant molecular 
beacon were plotted. 
 
Applied to a small number of clinical samples, the retrospective 
mutation screening results generated by the molecular beacons real-
time PCR assays are in general concordance with that obtained by 
PCR-RFLP.  Using molecular beacons strategy, codon 460 mutation 
was detected in ten out of the total number of 40 samples, whereas the 
latter method identified nine samples as containing the mutation.   
 
The discrepant result arose from the genotyping of one of the clinical 
sample as mixed (containing both wild-type and mutant CMV Strains) 
by molecular beacons but as wild-type by PCR-RFLP.  It has been 
reported that PCR-RFLP is able to detect mutant CMV templates only 
when the percentage of mutants in the viral population reaches 10% 
(Chou et al, 1995a).  Hence, genotyping by use of a more sensitive 
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probe-based PCR amplification method such as molecular beacons is 
probably more accurate.  
 
In a separate experiment using artificial mixtures of wild-type and 
mutant CMV templates of varying percentages (Table 5.2), we 
demonstrated that the molecular beacons used in this study were able 
to correctly and reproducibly genotype samples that contained 10% or 
more mutant templates against a wild-type background.  However, we 
observed that two out of three samples in the triplicates containing 
mixtures of 5% mutant CMV DNA templates could also be 
unambiguously genotyped by this method.   
 
The improved sensitivity of real-time over conventional PCR for the 
detection of viruses in routine and research laboratories has been 
documented and attributed mainly to improved detection by 
fluorogenic chemistries such as molecular beacons as well as advances 
in instrumentation (Mackay et al, 2002; Abravaya et al, 2003; Poddar, 
2000).  Our data is also in support of this observation, and indicate that 
the molecular beacons assay is possibly more sensitive for mutation 
analysis of codon 460 mutations than PCR-RFLP.   
 
As real-time PCR also allows for quantitation of the copy number or 
amount of starting template, an area for further investigation with this 
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new technology is the determination of the exact percentage of mutants 
in the viral population in an isolate that is correspondent to the 
appearance of clinical resistance to ganciclovir.  
 
 
5.4.3 Analysis of CMV UL54 F412C mutation by PCR-RFLP and 
discriminatory PCR 
 
Published data (reviewed by Erice, 1999) indicate that susceptibility 
patterns of CMV to antiviral agents are dependent upon whether the 
CMV strain contains mutations only in UL97, only in UL54, or in both 
genes.  The general observation is that CMV strains with only UL97 
mutations are resistant to ganciclovir but susceptible to foscarnet and 
cidofovir, whereas CMV strains with certain UL54 mutations are cross-
resistant to ganciclovir and cidofovir, and CMV strains containing 
UL97 and UL54 mutations (double-mutant strains) are highly resistant 
to ganciclovir on the basis of IC50 values obtained for the 
corresponding clinical isolates (Smith et al, 1997).   
 
The mutation in codon 412 consists of a single-base change at position 
1893(G to T) of the UL54 gene, which results in a change from 
phenylalanine to valine at residue 412 (F412C mutation).  This 
mutation is located in the conserved region IV, and it has been 
 Cytomegalovirus infections in solid organ transplant recipients 
 149 
suggested this DNA polymerase mutation could be involved in 
substrate recognition and could cause drug resistance by decreasing the 
affinity of the viral polymerase for antiviral compounds (Lurain et al, 
1992; Sullivan et al, 1993).  Antiviral susceptibility studies have 
revealed that these CMV strains were resistant to ganciclovir, 
susceptible to foscarnet, and resistant to cidofovir (Chou et al, 1997; 
Smith et al, 1997).  
 
A survey of published data revealed that DNA sequencing is 
extensively and almost exclusively used for detection of mutations in 
codons within the CMV UL54 gene.  Whilst automated DNA 
sequencers are now available and the cost per run is reduced, its utility 
remains limited to research institutes or clinical laboratories with 
adjunct research and development facilities.   
 
Chou et al (1999) have recommended that genotypic assays for UL54 
resistance should focus on the codon ranges 379 to 421, 492 to 545, 
696 to 845, and 978 to 988, based on confirmed marker transfer 
experiments.  However, to date, there have only been two publications 
citing a PCR-based method (Harada et al, 1997; Chou et al, 1998) for 
mutation analysis in the UL54 gene at codons 501 and 809, 
respectively.  It is with these reasons in mind that the study aimed to 
develop PCR-based methods which are rapid and relatively less 
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complex to perform for the detection of mutations in other regions of 
the UL54 genes.   
 
PCR-RFLP entails PCR amplification followed by restriction analysis 
of the amplified product at specific recognition sites that may or may 
not be affected by changes such as point mutation, inversion and 
deletion.  The presence and absence of fragments resulting from 
changes in recognition sites are used identifying wildtype and mutant 
strains.   
 
Analysis of the published sequence of the UL54 gene at codon 412 
where a known mutation (F412C) exists showed a potential MboII 
recognition site (v(N) 7 TCTTC) for the mutant sequence (TCT) but not 
in the wildtype (TTT).  The T to C substitution results in amino acid 
change from phenylalanine to cysteine.  We therefore designed primers 
for PCR amplification of the gene region surrounding codon 412 
followed by MboII digestion to produce distinguishable electrophoretic 
patterns, namely a single fragment (for wild type CMV and two 
fragments for mutant strains, distinguishable u (Figure 5.5).   
 
The mutant F412C genotype was detected in two samples (sputum) 
belonging to patient R1, a renal transplant recipient whom we have 
previously also shown, in screening of his blood samples, to harbor 
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mixed populations of wild type CMV strains and a L595S mutation in 
the UL97 gene by PCR-RFLP and DNA sequencing (Chapter 3) as well 
as the discriminatory PCR assay we had developed.  UL54 polymerase 
mutations usually appear after prolonged therapy and may increase the 
drug resistance beyond that conferred by a preexisting UL97 mutation 
(Smith et al, 1997).  The detection of the F412C in the sputum of 
patient R1 approximately a year after ganciclovir treatment had been 
initiated and the earlier appearance of a UL97 mutation in codon 595 
confirms this observation.   
 
DNA sequencing of the region surrounding codon 412 of the UL54 
gene also revealed nucleotide change (G to A) at position 1237 (Figure 
5.7), one codon downstream of codon 412, leading to a change in 
amino acid from aspartic acid (GAC, for wild type genotype) to 
asparagine (AAC).   
 
This appears to be a novel mutation.  A D413E mutation (aspartic acid 
to glutamic acid) had previously been reported (Erice et al, 1997) in a 
blood isolate for an AIDS patient with CMV colitis and retinitis and 
shown by marker transfer studies to confer ganciclovir resistance 
(Chou et al, 2004).  There have been no other reports of any codon 413 
changes in this conserved region IV of the viral DNA polymerase.   
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This mutation was seen in the sample of Patient R1 who demonstrated 
clinical resistance to ganciclovir, in addition to CMV disease markers 
such as pneumonitis and retinitis (Appendix A).  But whether or not 
this particular mutation confers ganciclovir resistance can not be 
ascertained at this juncture as it appeared in clinical samples that also 
contained CMV strains with other, known ganciclovir-resistant markers 
(namely L595S in the UL97 gene and F412C in the UL54 gene).  
Multiple mutations may occur in a viral genomes as large as that of 
CMV (230 kb) so new mutations suspected of conferring drug 
resistance requires validation experimentally by a process of marker 
transfer whereby the mutation is transferred to a drug-susceptible CMV 
laboratory strain (Chou et al, 2003).   Marker transfer study of this new 
mutation is thus warranted.   
 
In the screening of 52 clinical samples, randomly selected from our 
study cohort of renal and liver transplant recipients, by this PCR-RFLP 
method, non-specific restriction of PCR products yielding DNA 
fragment sizes other than the expected 134 bp and 184 bp was 
encountered for 13 of the clinical samples, rendered as ‘indeterminate’ 
(Table 5.3).  For these samples, it was difficult to distinguish between 
a true mutation, a mixed population (both mutant and wild type strains 
present) and non-specificity owing to restriction sites resulting from 
polymorphism in this particular region of the UL54 gene.   
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Harada et al (1997) have also reported unusual restriction digest 
patterns in the assay they had developed for genotyping codon 501.  
Indeed it has been shown that while no amino acid variation exists for 
codon 412 other than the F412C mutation, interstrain variations exist 
for the polymerase gene, with a total of 282 variant nucleotides, of 
which greater than 80% produce silent mutations (Chou et al, 1999).  
Changes within the region amplified by PCR which produce additional 
recognition sites for MboII will therefore result in variant restriction 
digest patterns.   
 
Difficulties encountered by this PCR-RFLP approach to genotyping 
prompted us to seek an alternative PCR-based method.  
 
We had previously developed rapid, discriminatory PCR assays for 
detection UL97 mutations conferring ganciclovir resistance (see 
Section 6.4.1).  Screening samples obtained from a cohort of paediatric 
solid organ transplant patients for A594V and L595S mutants, we have 
also shown complete concordance with results obtained by published 
PCR-RFLP methods (Tables 5.1 and 5.2).   
 
Applying a strategy similar to that of the discriminatory PCR-based 
assay for detection of CMV UL97 gene mutations, we designed primers 
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for and developed a discriminatory PCR assay for direct, rapid 
detection of the F412C mutation in the UL54 gene from clinical 
samples.  As shown in Figure 5.6, this assay allowed for discrimination 
between wild type and mutant templates as well as for identification of 
templates with mixed populations of viruses.   
 
We compared results obtained by DNA sequencing of 52 samples from 
the same cohort of transplant patients and by the PCR-RFLP method, 
there was complete agreement between DNA sequencing and this 
newly developed PCR method (Table 5.3).  Restriction patterns were 
ambiguous for the PCR-RFLP method and the genotype for 13 samples 
could not be determined whereas this newly developed discriminatory 
PCR assay was able to correctly identify wild type strains and to 
distinguish them from samples with mixed populations of wild type 
viruses and viruses with the F412C mutation, previously confirmed by 
DNA sequencing (Table 5.3, Figure 5.7). 
 
A major problem with PCR, however, is that all polymerases invariably 
generate errors during amplification (Fujimura et al, 1990).  
Polymerase misincorporations invariably become disguised as 
mutations and result in false positives (Reiss et al, 1990).  To this end, 
we have attempted to minimize amplification errors by developing 
PCR-based assays that allow for direct detection from clinical samples 
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in addition to confirmation of positive results by RFLP (restriction 
digests) and DNA sequencing.  RFLP-based methods used for detection 
of known mutations examine few sites for mutations relative to 
mutation scanning methods such as denaturation gradient gel 
electrophoresis (DGGE).  Therefore, in principle they are less affected 
by PCR errors since at the particular DNA position the polymerase is 
likely to cause less misincorporation (Makrigiorgos, 2004).  This is 
also valid for real-time PCR-based detection of known mutations 
(Neoh et al, 1999).   
 
To this end, we propose a strategy for laboratory detection of CMV 
ganciclovir resistance using a variety of molecular assays.  Following 
detection of total CMV by PCR in whole blood (and other sample 
types) screening of the common mutations in the UL97 gene using 
PCR-RFLP, discriminatory PCR or real-time PCR strategies, or a 
combination of strategies to detect select mutations rather than all 
possible mutations simultaneously will – with its short, same-day 
turnaround time – enable correlation with clinical suspicion of antiviral 
resistance.  Laboratory confirmation of the mutation detected can 
subsequently be made by DNA sequencing, utilizing Sanger or dye 
terminator sequencing or even pyrosequencing. 
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Renal transplantation has become the preferred treatment modality for 
patients with end-stage renal disease.  Over the past two decades, the 
success rates of renal transplantation have improved with the 
introduction of a number of new and effective immunosuppressive 
agents into clinical use, particularly in the 1990s.  Short-term outcomes 
have improved with decline in the incidence of early graft failures and 
the number of acute rejection episodes but, despite these advances, 
evidence exists that long-term outcomes have not improved in a similar 
manner (Hariharan et al, 2000).  Recent studies by Meier-Kriesche et al 
(2003; 2004) have shown that there is little or no impact in the 
improvement in long term outcomes.   
 
Chronic rejection is currently the most prevalent cause of renal 
transplant failure (Joosten et al, 2005).  While studies have shown that 
episodes of acute rejection are major risk factors for chronic rejection, 
various nonimmunologic factors have been found to be important as 
well (Pascual et al, 2002).  As multiple factors are now known to play 
a part in chronic rejection, the term “chronic allograft nephropathy 
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(CAN)” has been introduced (Halloran et al, 1999).  In fact, CAN 
remains the most common cause of late graft loss in renal 
transplantation (Joosten et al, 2005; Mekeel et al, 2006, Pascual et al, 
2002).  
 
Clinically, chronic rejection is characterized by a slow loss of function 
(demonstrated by a reduction in the glomerular filtration rate or, more 
commonly, rising serum creatinine levels), often accompanied by low-
grade proteinuria and hypertension, usually occurring months or years 
after transplantation (Halloran et al, 1999; Morris, 1999).  A biopsy is 
often obtained to help determine the etiology of graft dysfunction.  The 
histopathology is not specific in most cases but transplant arteriopathy, 
chronic transplant glomerulopathy, tubular atrophy, and interstitial 
fibrosis are characteristic (Colvin, 1996). 
 
The pathogenesis of CAN involves both immunologic (antigen-
dependent) and nonimmunologic (antigen-independent) mechanisms 
(Table 7.2).  CAN develops in grafts that undergo intermittent or 
persistent damage from cellular and humoral responses resulting from 
indirect recognition of alloantigens.  Poggio et al (2004) examined 
alloreactivity in renal transplant recipients with and without CAN and 
concluded that persistent cell-mediated and humoral alloimmunity 
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contribute to the development of CAN, and that direct, donor-specific 
cellular immunity predominated in patients with CAN.   
 
Nonimmunologic factors also have a role in the development of CAN.  
At the tissue level, acute peri-transplantational injuries causing delayed 
graft function and the role of senescence conditioned by 
ischemia/reperfusion may contribute to the development of chronic 
allograft nephropathy (Halloran, 1999; Joosten et al, 2005).  The age of 
the donor, the quality of the graft, and the number of nephrons in the 
donor organ have been implicated as important predictors of the long-
term survival of the graft (Halloran, 1999).  Histopathologic findings 
from 2-year protocol biopsies from a U.S. multicenter kidney 
transplant trial comparing tacrolimus versus cyclosporine suggest that 
drug-induced toxicity resulting from long-term treatment with 
calcineurin inhibitors – in addition to other nonimmunologic factors 
such as CMV infection in the first year – may also play a part in CAN 
(Solez, 1998).   
 
Infection by CMV in the allograft recipient continues to be a serious 
complication of transplantation owing to long term use of 
immunosuppressive regimes to prevent rejection of the transplanted 
kidney from the host’s immune system.  While the newer 
immunosuppressive agents have been able to induce a greater degree of 
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tolerance for the allograft, their use has also resulted in the 
undermining of the body’s ability to contain opportunistic infections 
such as CMV.  Polyomavirus-associated nephropathy is an emerging 
disease in renal transplant patients with variable prevalence of 1-10% 
and graft loss up to 80%; BK virus is the primary etiologic agent, but 
JC virus and possibly simian virus SV40 may account for some cases 
(Hirsch et al, 2006).  
 
While CMV infection has been shown to have a high association with 
chronic rejection in extra renal transplants such as heart/lung 
transplants, there is conflicting evidence on the role of CMV infection 
in chronic allograft rejection in renal transplantation.   
 
The proposed mechanisms by which CMV induces an alteration of the 
cellular and humoral responses to the allograft include upregulation of 
HLA class I and II-like antigens, and production of anti-endothelial 
cell antibodies (AECA), shown previously to be deleterious to the 
allograft (Jordan et al, 1988; Yap et al, 1988).  Assessment of CMV 
infection of the renal allograft as well as identification of other 
contributory factors to the process of chronic rejection is therefore 
important.   
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In this chapter, we sought to determine if CMV infection in the renal 
allograft contributes significantly to chronic allograft dysfunction in 
renal transplant recipients by:  
 
1. Examining the potential factors that may be associated with 
chronic allograft dysfunction in a cohort of renal transplant 
recipients at one year post transplant, including the presence of 
CMV DNA in the blood of transplant recipients within the first 
five month post transplant using logistic regression analysis, 
and; 
2. Determining the relationship between anti- endothelial cell 
antibodies (AECA) and CMV infection in the same post 
transplant period. 
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Table 6.1.  Putative risk factors for chronic allograft nephropathy 
(adapted from Sahadevan and Kasiske, 2005) 
 
 
Immunologic risk factors 
 
 









Non-immunologic risk factors 
 
 
  Ischemic injury and delayed graft function 
Older donor age 

















6.2.1 Clinical characteristics of the study group 
 
A total of 119 consecutive renal allograft recipients were enrolled in 
the study.  The population characteristics of the patients in the study 
are shown in Table 6.2.  The mean age (± SD) at the time of renal 
transplantation was 41.5 years (± 9.4 years).  In terms of transplant 
type, 79.4% (94/119) had a cadaveric donor transplant while 20.6% 
(25/119) underwent live (related and unrelated) donor transplant.  Of 
the study population 20.7% (25/119) received either ATG or OKT3 in 
addition to the standard induction immunosuppression regimen of 
methyl prednisolone, azathioprine or mycophenolate mofetil and 
cyclosporin A.  At least one acute rejection episode was observed in 
35.7% (42/119) of the patients. Twenty-seven percent (32/119) of the 
study population also received intravenous ganciclovir either 
prophylactically or as a form of treatment in CMV infection.  Donor 
and recipient CMV seropositivity were 89.1% (106/119) and 95.8% 
(114/119), respectively.  Mean serum creatinine of the study group at 
one year post-transplant was 136 µmol/L (± 45 µmol/L).  Defining 
chronic allograft dysfunction at one-year post transplant as serum 
creatinine greater than 150 µmol/L, 38.6% (46/119) of the study 
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6.2.2 CMV DNAemia in the pre- and post-transplant periods 
 
The detection of CMV DNA in blood by quantitative PCR was 
monitored for 119 renal allograft transplant recipients who had whole 
blood drawn consecutively during pre-transplant and at day one, 
months one, three and five post-transplant.  Negative CMV DNAemia 
was interpreted as CMV levels at less than 100 copies, and positive 
CMV DNAemia as CMV levels at 100 or more copies of CMV 
DNA/µg of total DNA in whole blood.  Percentages of recipients with 
or without CMV DNAemia were plotted against time (in the pre- and 
post-transplant periods) for recipients grouped according to status of 
renal allograft function at one year post-transplant (as defined by (a) 
serum creatinine <150 µmol/L and (b) serum creatinine ≥150 µmol/L) 
(Table 6.3 and Figures 6.1).  As shown in Figure 7.1 (a), patients 
classified as having a normal functioning allograft at one year post-
transplant were able to clear CMV DNAemia by five months post-
transplant; on the other hand, there was an increasing trend in the 
percentages of patients with allograft dysfunction who were positive 
for CMV DNA in blood, with 61.9% having positive CMV DNAemia 
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at five months post-transplant, compared to 38.1% in the subgroup of 
patients without allograft dysfunction (P < 0.01) (Figure 6.1 (b)).  
 
 
6.2.3 Statistical analysis of risk factors for development of chronic 
allograft rejection at one year post-transplant 
 
Univariate analysis employing chi-square test showed a significant 
correlation between chronic allograft dysfunction at one year post-
transplant and presence of CMV DNAemia at five months post-
transplant (P < 0.01) but not the other periods pre or post-transplant 
(Table 6.4).  There was no significant association between renal 
allograft dysfunction and transplantation type, previous acute rejection 
episodes, or the administration of anti-CD3 monoclonal antibody, anti-
thymoglobulin, mycophenolate mofetil and ganciclovir (Table 6.3). 
 
With chronic allograft dysfunction as the dependent variable in a 
multivariate logistic regression analysis, positive CMV DNAemia was 
again a significant risk factor (P = 0.04; OR 2.864, 95% CI 1.046-
7.839). 
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6.2.4 Anti-endothelial cell antibodies (AECA) activity in sera 
 
Fifty one of the renal allograft recipients had sera available at five 
months post-transplant for the EIA assay for AECA.  Twenty-four 
percent (12/51) of these patients’ sera were positive for IgG specific 
AECA activity as compared to 6% of controls (P < 0.01), and 29% 
(15/51) of sera were also positive for IgM specific AECA activity, 
compared to 9% of controls (P < 0.01).  The levels of AECA activity in 
the transplant recipient and control groups, expressed as the 
standardized score, are shown in Figure 6.2.   
 
Chi square analysis of these patients, re-grouped as recipients who 
were positive or negative for CMV DNAemia at five months post-
transplant, versus AECA activities revealed a significant association 
between the presence of CMV DNAemia and presence of IgG specific 
activity (P < 0.01) (Table 6.5).  There was, however, no statistically 
significant association with IgM specific AECA activity (P = 0.31). 
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Mean age at transplantation (years) (± SD) 
 










Acute rejection episodes  
 
i. No rejection episodes 












Mean serum creatinine at one year post-
transplant (150 µmol/L) (± SD) 
 
 




i. Donor seropositive 
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Table 6.3 Potential risk factors that may be associated with chronic 
allograft dysfunction in a cohort of renal transplant recipients at one 
year post transplant. 
 
  
Renal allograft function at one 














 i. Cadaveric 



















 i. No rejection 
episodes 
























 i. Anti-CD3 
monoclonal 
antibodies (OKT3) 
 ii. Anti-thymocyte 
globulin (ATG) 
 iii. OKT3 and/ or 
ATG 
















































*Univariate analysis using chi square test 
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Table 6.4  CMV DNAemia in the pre- and post-transplant periods for 
renal allograft recipients, grouped according to graft function at one 
year post-transplant, as measured by (a) serum creatinine <150 µmol/L 
and (b) serum creatinine ≥150 µmol/L.  
 
  
Renal allograft function at one 



























































































*Univariate analysis using chi square test 
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Negative for CMV DNAemia
Positive for CMV DNAemia
 
 



















Negative for CMV DNAemia
Positive for CMV DNAemia
 
 
Figure 6.1. Serial CMV DNAemia in the pre- and post-transplant 
periods for renal allograft recipients, grouped according to graft 
function at one year post-transplant: (a) Patients without allograft 
dysfunction (serum creatinine <150 µmol/L), and (b) Patients with 
allograft dysfunction (serum creatinine ≥150 µmol/L).  Negative CMV 
DNAemia is interpreted as CMV levels at <100 copies, and positive 
CMV DNAemia as CMV levels > 100 copies of CMV DNA/µg of total 
DNA in whole blood. 








































































Figure 6.2. Distribution of IgG and IgM specific anti-endothelial cell 
antibodies (AECA) activity in renal allograft transplant recipients and 
controls.  AECA activity is expressed as a standard score.  Dashed 
lines represent the upper 95th percentile confidence limit of the normal 
population. (*P < 0.01). 
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Table 6.5.  Anti-endothelial cell antibodies (AECA) activity in sera 
versus CMV DNAemia of renal allograft recipients (n = 51) at five 
months post-transplant.   
 
     
  
CMV DNAemia at five 
months post-transplant  
    Negative Positive 
% of 
Total 
Negative 61.5% 38.5% 75% 
 
IgG specific 
AECA activity Positive 16.7% 83.3%* 24% 
     
Negative 55.6% 44.4% 71% IgM specific 
AECA activity Positive 40% 60%** 29% 
    
*P < 0.01; **P = 0.31 
 
 




6.3.1 Cytomegalovirus infection and chronic allograft nephropathy 
 
CAN is said to represent the cumulative and incremental damage to the 
kidney from time-dependent immunologic and non-immunologic 
causes (Nankivell et al, 2004; Table 6.1) but its pathophysiology 
remains poorly understood.  Despite the implementation of new 
antiviral agents and practice guidelines addressing CMV infection in 
organ transplantation, CMV remains an important cause of morbidity 
in renal transplantation.  Becker et al (2002) showed that while 
ganciclovir was associated with trends toward lower rates of infection 
and disease, 9% of renal transplant and 13.4% of simultaneous 
pancreas-kidney transplant recipients still experienced symptomatic 
CMV infection or CMV disease.  CMV seronegative recipients of an 
organ from a seropositive donor are at the highest risk, with a 25.2% 
rate of CMV infection or CMV disease in that study, although a 60% to 
80% incidence of subsequent CMV infection has been reported 
elsewhere (EBPG Expert Group on Renal Transplantation, 2000).  In 
Singapore the incidence of CMV disease in pediatric transplant 
recipients is 28.6% (Aw et al, 2000).   
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Several studies have shown a definite link between CMV-related 
disease and risk of acute rejection in renal transplant recipients.  In a 
historical cohort study of 192 consecutive renal transplant recipients by 
Toupance et al (2001), transplant patients with CMV disease had a 
significant likelihood of developing acute rejection after CMV 
infection or reactivation (P < 0.01, OR 5.98, CI 1.21-29.40).  In a 
multiple time-dependent Cox analysis of data from 477 consecutive 
renal allograft recipients CMV infection (RR = 1.6 (1.1-2.5, P = 0.02) 
and CMV disease (RR = 2.5 (1.2-5.1, P = 0.01) were independent 
significant predictors for clinical acute rejections (Sageda et al, 2002).  
The impact of CMV infection and disease on long-term outcome of 
kidney transplantation is less clear.   
 
Clinical evidence for the association between CMV infection and 
disease in CAN and graft loss have come from studies by Humar et al 
(1999), Sola et al (2003), Nett et al (2004) and Sagedal at al (2004).  
However, contradictory data have also been reported (Dickenmann et 
al, 2001; Ricart et al, 2005).  CMV has additionally been associated, 
after kidney transplantation, with increased cardiac complications 
(Humar et al, 2000), increased gastrointestinal complications (Sarkio et 
al, 2005) and new onset diabetes mellitus (Hartmann A et al, 2006).   
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In this chapter, we prospectively examined the potential factors that 
may be associated with chronic allograft dysfunction (on the basis of 
serum creatinine) at one year post-transplant in a cohort of adult renal 
transplant recipients from the local population.  Serum creatinine 
measured at varying stages post-transplant (usually at six months and 
one year) as a predictive marker of long-term outcome and graft 
survival (Prommool et al, 2000; Sahadevan and Kasiske, 2005; 
Boratynska et al, 2006).   
 
Univariate analysis employing a chi-square test for interdependence 
showed no significant association between allograft dysfunction at one 
year post-transplant and transplantation type, previous acute rejection 
episodes, or the administration of anti-CD3 monoclonal antibody, anti-
thymoglobulin, mycophenolate mofetil and ganciclovir (Table 6.2).  
There was, however, a significant correlation between allograft 
dysfunction and presence of CMV DNAemia at five months post-
transplant (P < 0.01) but not the other periods pre or post-transplant 
(Table 6.4).  Similarly using a logistic regression method, with chronic 
allograft dysfunction at one year post-transplant as the dependent 
variable, post-transplant CMV DNAemia was also a significant risk 
factor (P< 0.01; OR 3.578, 95% CI 1.417-0.031).   
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CMV infection in the organ transplant recipient is frequently identified 
by serological CMV IgM status or CMV IgG seroconversion, viral 
culture, CMV early antigen detection (pp65 antigenaemia) or PCR to 
detect CMV DNA.  While quantitative PCR methods for CMV DNA 
have emerged as the most clinically useful method to (a) detect CMV 
infection in kidney transplant recipients (Sola et al, 2005), (b) monitor 
viral load during antiviral treatment (Piiparinen et al, 2006), and (c) 
predict risk for development of CMV diseases such as retinitis in 
patients with AIDS (Rasmussen et al, 1997) or in paediatric solid organ 
transplant patients (Aw et al, 2000), there are few studies employing 
molecular detection of genomic CMV as an index to define active 
CMV infection in allograft dysfunction.   
 
Sebakova et al (2005) recently showed, in biopsies that were performed 
as protocol biopsies or when renal function deteriorated, that tissue 
viral DNA is associated with chronic allograft nephropathy.  In this 
study we have demonstrated, by means of quantitative PCR detection 
of CMV DNA in blood, that CMV infection is a significant 
independent prognosticator for renal allograft dysfunction (Table 6.4).  
This finding agrees with a study by Geddes et al (2003) who, in 
monitoring CMV PCR positivity for the first three months in 
consecutive renal transplants and analyzing renal function at one year 
post-transplant, found a mean estimated creatinine clearance at one 
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year of 70.0 mL/minute in patients who experience no CMV infection, 
47.7 mL/minute in patients who experienced infection but no disease 
and 39.6 mL/minute in patients who experienced CMV disease (P 
<0.01).  Our data also supports similar findings in studies which 
utilized pp65 antigenaemia as a marker for CMV infection (Sola et al, 
2003; Sagedal et al, 2004).   
 
Our data also revealed a time-dependent relationship between presence 
of CMV infection and development of renal allograft dysfunction.  By 
monitoring CMV DNAemia in the transplant recipients in the pre- and 
post-transplant periods and subdividing the study cohort into those 
with or without allograft dysfunction, we showed that inability to clear 
CMV DNAemia by five months post-transplant was a characteristic of 
recipients who eventually developed allograft dysfunction one year 
post-transplant (Figure 6.1(b)).  Conversely, there was a decline in the 
percentage of recipients with positive CMV DNAemia in the subgroup 
without allograft dysfunction to 38.1% at five months post-transplant 
(compared to 61.9% in the subgroup with allograft dysfunction)(Figure 
6.1(a), Table 6.3).  This is in spite of the 83.3% positive for CMV 
DNAemia pre-transplant (compared to 16.7% in the subgroup with 
allograft dysfunction), indicating that these patients were adequately 
immunocompetent to clear the virus.   
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6.3.2 Correlation between anti-endothelial cell antibodies and 
cytomegalovirus infection related chronic allograft nephropathy 
 
Although acute rejection and immunosuppression, putative risk factors 
known to affect long term kidney transplant outcome, were not 
significantly associated with allograft dysfunction in this study, it is 
possible that other causal factors, whether in addition to, or in 
association with or consequential to CMV infection, are also involved 
in the development of chronic allograft dysfunction.   
 
Also, as histological data were not available in this study (protocol 
biopsies were not performed during this time period), we were not able 
to show whether CMV infection as defined by renal allograft 
histopathologic changes were associated with CAN.  It has become 
increasingly apparent that examination of graft histology can help to 
identify some of the specific factors involved in damaging the allograft 
in an individual recipient (Nankivell et al, 2001; Nickerson et al, 2001)   
 
Recent studies examining the impact of CMV infection on 
histopathologic changes in protocol biopsy specimens of kidney 
allografts have revealed that the presence of CMV proteins or genome 
in the kidney allograft, together with a previous history of acute 
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rejection episodes, was associated with increased vascular changes 
(Helantera et al, 2003).  Persistent CMV infection has also been 
associated with the increased expression of fibrogenic molecules in the 
development of CAN (namely transforming growth factor-β (TGF- β) 
and platelet-derived growth factor (PDGF)) and the increased 
expression of intercellular adhesion molecule-1 (ICAM-1) (Helantera 
et al, 2005).  In a model of rat kidney allograft, prolonged, increased 
expression of ICAM-1 and vascular cell adhesion molecule-1 (VCAM-
1) in the CMV-infected vascular endothelium was associated with 
accelerated chronic allograft nephropathy (Kloover et al, 2000).   
 
Jeannet et al (1970) first observed that post-transplant, de novo, donor-
specific antibodies are associated with a poor outcome in human renal 
transplantation.  More recently, deposition of C4d, the cleavage 
product of the complement component C4 in the peritubular capillaries 
of the graft has been demonstrated in patients, including paediatric 
transplant recipients, with chronic renal allograft rejection and CAN, 
permitting the recognition of a form of ongoing antibody-mediated or 
humoral mechanism in the pathology (Mauiyyedi et al, 2001; Aiello et 
al, 2004, Herman et al, 2005).   
 
CMV infection after transplantation has been associated with the 
occurrence of various autoantibodies and monoclonal gammopathies 
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(Hebart et al, 1996; Mengarelli et al, 2000). Among these, high levels 
of AECA have been demonstrated in 80% of renal and heart and in 
43% of liver transplant recipients with CMV infections and to play a 
role in the development of antibody-mediated rejections (Jordan et al, 
1988; Dunn et al, 1992; Toyoda et al, 1997; Fredrich et al, 1999; 
Toyoda et al, 1999; Varani et al, 2002.  Toyoda et al (1999) have 
shown that AECA induced by CMV infection are primarily 
autoantibodies that were also able to react with multiple cell types such 
as human fibroblasts, keratinocytes, peripheral blood mononuclear 
cells and platelets.  They suggested that the elevated AECA levels seen 
in CMV-infected transplant recipients represent a polyclonal activation 
of humoral immune responses by CMV.   
 
The exact role of AECA in the pathogenesis of CAN has not been fully 
elucidated.  Poggio et al (2004) have shown that direct and indirect 
cellular immunity as well as humoral immunity (by detection of post-
transplant anti-HLA antibody by flow cytometry) are significantly 
associated with renal allograft transplant recipients with CAN, 
suggesting that persistent cell-mediated and humoral alloimmunity 
contribute to its development.   
 
In our study IgG specific AECA activity was observed in 24% of renal 
transplant recipients (n = 51) versus 6% of the non-transplant control 
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population (P < 0.01); IgM specific AECA activity was also present in 
29% of the recipients compared to 9%, of controls (P < 0.01).  In our 
study we also sought to evaluate the correlation between the presence 
of AECA and CMV DNAemia monitored at various periods pre- and 
post-transplant periods in the cohort of renal allograft recipients with 
CAN or normal renal function.  At five months post-transplant, 
presence of IgG specific (P < 0.01) but not IgM specific (P = 0.31) 
AECA activity was significantly associated with CMV DNAemia.  We 
have shown, in the first part of the study, that CMV DNAemia 
monitored five months post-transplant was significantly associated 
with abnormal renal function at one year post-transplant.  However, we 
did not find a statistically significant direct correlation between AECA 
activity and abnormal renal function at one year post-transplant (P = 
0.85).  We noted that Fault et al (1999) found a significant association 
of anti-endothelial antibodies with transplant-induced coronary artery 
disease, a primary cause of graft failure in cardiac allograft recipients 
after the first year of transplantation.  In that study, serum antibodies 
to endothelial cells were detectable by flow cytometry, enzyme-linked 
immunosorbent assay and immunoblotting techniques but only 
significant associations were found for the amount of antibody 
identified by Western immunoblotting. 
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The association between AECA and CMV DNAemia post-transplant 
suggests that CMV-induced endothelial damage leads to the production 
of AECA.  While these alloantibodies may represent a marker of cell 
injury, their detection in sera – unlike positive CMV DNAemia – does 
not correlate directly with the development of chronic allograft 
dysfunction.  Perhaps it is the actual binding of AECA to the renal 
vascular endothelium and the bystander effect of subsequent 
complement activation via the classical pathway that contributes to 
chronic allograft injury.  Further studies are required to examine the 
correlation between CMV infection, presence of AECA in sera and 
renal histological evidence of CAN and the presence or absence of 





Our data suggests that current strategies to improve long term 
outcomes after renal transplantation should also include serial post-
transplant assessment of CMV infection by means of PCR 
amplification of viral DNA in sera.  Both immunologic and 
nonimmunologic factors contribute to long term graft outcome.  The 
genesis and progression of chronic allograft dysfunction and CAN 
involves more than a single pathogenic mechanism.   
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We speculate that humoral mediated insult to the allograft may involve 
AECA via CMV induction in association with some other 
immunological process such as complement activation.  Although 
protocol biopsies were not routinely performed during the period of 
this study, histological assessment of donor kidneys – at various post 
transplant intervals – to correlate viral tissue DNA, presence of AECA, 
evidence of antibody-mediated injury and renal function may serve to 
elucidate the role of virus-induced immune injury to the allograft. 
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7. CONCLUDING REMARKS 
 
 
This thesis has addressed several issues relating to the clinical 
challenges that CMV infections pose to immunocompromised patients 
from a Singapore perspective.  In a previously reported series of 
children with renal transplantation, 30.8% had complications of CMV 
disease (Sim et al, 1997).   
 
We had hypothesized that the high incidence of active CMV disease 
was due to ganciclovir-resistant CMV mutant strains.  By determining 
the frequency of CMV mutant strains in CMV isolates from the non-
transplant population and CMV DNA isolated directly from clinical 
samples from a small cohort of pediatric solid organ transplant patients 
from NUH, and employing different laboratory methods currently 
available, we have demonstrated the presence of CMV ganciclovir 
resistance in Singapore in three of 12 (25%) renal transplant recipients 
two (40%) of the five patients who underwent liver transplantation. 
 
There was no genotypic evidence of ganciclovir resistance in our 
screen of CMV isolates from the non-transplant population.  Clinical 
information from the latter was not made available in our study so it 
was not possible to establish a clear relationship between laboratory 
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resistance and clinical unresponsiveness.  Nevertheless, our laboratory 
analyses confirm the presence of ganciclovir-resistant CMV strains in 
Singapore.  That they are found in a cohort of transplant patients who 
were on ganciclovir prophylaxis and who had active CMV disease 
which were relatively resistant to treatment is of significance.   
 
As antiviral screening assays have the potential to guide therapy and 
assist in the confirmatory diagnosis of clinical antiviral resistance – 
and the fact that resistant CMV strains are found in the local 
population - we advocate that these tests be made available for testing 
of patients who are positive for CMV and, in particular, those 
undergoing kidney and lung transplantation.   
 
We have developed molecular assays that can be directly performed on 
clinical samples, that are with greater sensitivities than currently 
available methods in their ability to detect low copy number of mutant 
CMV strains (against a high background of wild type CMV, mixed 
viral populations being a feature of the cohort in our study) and with 
short turnaround time.  These new assays have enabled us to discover a 
novel codon 413 mutation in one of the renal transplant patients with 
CMV disease.   
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A potential area for further research is the quantitative determination 
of mutant strains.  This has application in ascertaining the exact 
percentage of mutants in the viral population in an isolate that is 
correspondent to the appearance of clinical resistance to ganciclovir.  
Modifications of existing PCR techniques or novel methods are 
necessary in order to ensure that mutant and wild type sequences 
amplify with near equal efficiency, so that they are eventually present 
in proportions representative of the starting material.   
 
We have begun to prospectively evaluate the clinical utility of these 
novel assays – in tandem with conventional PCR testing - for the 
laboratory detection of ganciclovir  resistance and correlating presence 
or absence of clinical features suggestive of ganciclovir resistance, such as 
the need for an alternative antiviral agent or the development of late CMV 
disease 
 
Although ganciclovir-resistance in CMV strains exist in Singapore and 
this has now to be considered a risk factor in patients with CMV 
infections – at least in the paediatric transplant population, as we have 
demonstrated – follow up studies are necessary to better define whether 
this particular immunologically impaired group has an increased risk of 
CMV infection or disease.  One option is to employing recently 
available immunological assays to determine the number and 
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functionality of CMV specific lymphocytes (by flow cytometry or 
enzyme-linked immunospot technique) in subsets of adult, paediatric 
and non-transplant subjects.  An investigation into the kinetics of 
cellular immune responses (early versus late lymphocyte proliferation) 




In an attempt to correlate CMV infection and other risk factors with 
allograft outcome, a prospective study of a cohort of renal transplant 
recipients pre- and post-transplantation was carried out in this study.  
 
In renal transplantation, there is conflicting evidence on the role of 
CMV infection in chronic allograft rejection.  This could be because 
previous retrospective and prospective studies have only looked at the 
relationship between CMV antibody positivity and allograft function.  
CMV antibody positivity reflects not only possible active CMV 
infection, but also host immunity and latent infection. Therefore, CMV 
antibody status may not be the best index to use to define the role of 
active CMV infection in allograft rejection.  Detection of CMV 
genome by PCR has been shown to correlate well with CMV 
antigenemia which occurs in acute CMV disease.  Both univariate and 
multivariate analyses of clinical data from a prospective study of 119 
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consecutive renal transplant patients at the two major transplant centers 
in Singapore revealed a significant correlation between allograft 
dysfunction and presence of CMV DNAemia at five months post-
transplant.   
 
Our data also revealed a time-dependent relationship between presence 
of CMV infection and development of renal allograft dysfunction.  Our 
results indicated that inability to clear CMV DNAemia by five months 
post-transplant was a characteristic of recipients who eventually 
developed allograft dysfunction one year post-transplant, a feature not 
observed in the group of patients with normal renal function.  Our data 
provides argument that current strategies to improve long term 
outcomes after renal transplantation should also include serial post-
transplant assessment of CMV infection by means of PCR 
amplification of viral DNA in sera.   
 
CMV infection after transplantation has been associated with the 
occurrence of various autoantibodies and monoclonal gammopathies, 
including high levels of AECA in solid organ transplant recipients who 
had CMV infections.  We noted a relationship between AECA and 
CMV infection in the same post transplant period by demonstrating 
that at five months post-transplant, presence of IgG specific AECA 
activity was significantly associated with CMV DNAemia.  We 
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propose the histological assessment of donor kidneys to elucidate 
immunopathogenic mechanisms involving CVM mediated AECA 
injury. 
 
With the emergence of ganciclovir resistance CMV infections remain 
an important infectious complication after solid organ transplantation.  
Rapid genotypic analysis of clinical isolates of CMV for 
characterization of mutations known to confer antiviral resistance as 
well as the monitoring of novel mutations is also warranted in order to 
effectively guide therapy and patient management.  CMV DNAemia 
has also been identified as a significant risk factor in the development 
of long term renal allograft dysfunction.  The laboratory detection and 
quantitation of CMV should be part of pre- and post-transplant 
strategies to prevent the recipient from returning to end stage renal 
disease and dialysis.
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APPENDIX A CASE REPORT: GANCICLOVIR –
RESISTANT CYTOMEGALOVIRUS INFECTION IN A 




This report describes the first documented laboratory-confirmed case 
of ganciclovir resistant CMV infection in Singapore. 
 
A 16-year-old boy first presented (in 1998) at two years old with renal 
impairment and was diagnosed to have congenital dysplastic kidneys.  
He developed end stage renal failure at 12 years old, requiring 
peritoneal dialysis and later, at 15 years old, haemodialysis due to 
recurrent peritonitis.  The patient, who was CMV seronegative, 
underwent a renal transplant from a cadaveric CMV seropositive 
donor.   
 
The immunosuppressants given post transplant included anti thymocyte 
globulin and methylprednisolone, followed by prednisolone, 
cyclosporin and mycophenolate mofetil.  
 
The patient was given prophylactic ganciclovir at a dose of 5mg/kg 
twice daily, with adjustment for renal function and total white cell 
count.  Ganciclovir, as an intravenous preparation, was given for a 
period of 21 days post transplant followed by oral ganciclovir for three 
months.   
 
At three months post transplant, the patient developed CMV retinitis 
(diagnosed by indirect ophthalmoscopy through dilated pupils) which 
showed some clinical resolution after two months of treatment with 
ganciclovir.  However, the retinitis flared up again at seven months 
post transplant while the patient was on ganciclovir prophylaxis.  He 
also developed CMV pneumonitis (demonstrated by instititial infiltrate 
and CMV DNA by PCR of bronchoalveolar lavage cells) at three 
months post transplant which improved clinically initially but 
developed recurrences at six months, 17 months and 20 months post 
renal transplant despite ganciclovir prophylaxis.   
 
During each infectious episode, he was treated with a four-month 
course of intravenous ganciclovir, as well as intravenous hyperimmune 
CMV immunoglobulin for four weeks followed by intravenous gamma 
globulin 0.5g/kg twice weekly for a further three months.  
 
He developed chronic allograft dysfunction at 18 months post 
transplant and finally allograft rejection when he stopped his 
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medication at 33 months post transplant.  Allograft nephrectomy was 
performed, and this did not show any evidence of CMV renal disease.  
All immunosuppressants were stopped post nephrectomy, and two 
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Figure 7.1.  Summary of the paediatric renal transplant patient’s post 
transplant history and clinical course of CMV disease.  
 
 
Virus isolation and genetic analysis 
Serial samples (whole blood) obtained from the patient were subjected 
to PCR for detection and quantitation of CMV DNA as previously 
described (Aw et al, 2000).  
 
Analyses of CMV UL97 phosphotransferase coding sequences for 
mutations conferring ganciclovir resistance were carried out by nested 
PCR- restriction enzyme digest protocols as previously described 
(Chou et al 1995; Hanson et al, 1995).  CMV DNA was subjected to an 
initial round of PCR to amplify the entire UL97.  Subsequently, 
regions within the UL97 gene flanking frequently encountered UL97 
resistance mutations at codons 460 (Met to Val), 594 (Ala to Val), 595 
(Leu to Ser, or Leu to Phe) and 520 (His to Glu) were further amplified 
by PCR with relevant primers.  PCR products obtained were then 
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digested separately with restriction enzymes (NlaIII, HhaI, TaqI, MseI 
and AluI) in order to identify mutations in codons 460, 594, 595 (two 
different mutations) and 520, respectively.  Restriction digest patterns 
were visualized upon electrophoresis on 8% or 15% polyacrylamide 
gels and ethidium bromide stained, and compared against wild type 
CMV reference strain AD169 (American Type Culture Collection, 
Manassas, VA, USA).   
 
The specific identification of a mutation was confirmed by DNA 
sequence analysis of the PCR products using BigDye Terminator Cycle 
Sequencing kit (Applied Biosystems, Foster City, CA, USA) and the 
ABI Prism 310 genetic analyzer (Applied Biosystems). 
 
To assess the genetic relatedness of serial CMV DNAs recovered from 
the patient, genotyping of part of the CMV envelope glycoprotein B 
was also performed as previously described (Chou and Dennison, 
1991). 
 
As shown in Figure 7.1, in the patient’s initial blood samples, only 
wild type strains of CMV were recovered.  The presence of a Leu-to 
Ser mutation at codon 595 of the CMV UL97 gene was first detected – 
approximately seven months post-transplantation - as part of a mixture 
of wild type and mutant CMV strains.  DNA sequence analysis 
confirmed the TTG-to-TCG base change.  The L595S mutation was 
noted in all subsequent blood samples.  Other known UL97 gene 
mutations were not detected in the patient. 
 
Genotyping of the gB gene revealed that CMV strains (whether 
wildtype or mutant) in blood samples collected serially were either a 




The first three cases of clinical resistance to ganciclovir were 
described in 1989 although a resistant strain of CMV was isolated in 
the laboratory in 1986 (Erice et al, 1989).  More recently, mutations in 
clinical isolates of CMV which confer ganciclovir-resistance have been 
elucidated.  Ganciclovir-resistant CMV strains selected in the 
laboratory have amino acid deletions or substitutions in conserved 
regions of the UL97 gene region and/or point mutations in the DNA 
polymerase gene of the virus (Erice, 1999).  
 
It has been observed that the majority (94%) of ganciclovir-resistant 
CMV strains contain specific UL97 mutations (Chou et al, 1995; Smith 
et al, 1997).  By combining PCR and restriction enzyme digestion 
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methods, it has been shown to be possible to detect 78% of 
ganciclovir-resistant CMV isolates containing the most common UL97 
mutations (Chou et al, 1995). 
 
There is a high incidence of CMV disease (28.6%) in the National 
University Hospital’s paediatric solid organ transplant recipients, with 
a mortality rate of 3.5 % (Sim et al, 1997; Aw et al, 2000).  This is the 
first documented case of ganciclovir resistant CMV infection due to 
UL97 mutation but not necessarily the first occurrence as mutation 
analysis was not performed in Singapore prior to inception of our 
study.   
 
Wild type strains of CMV were first observed in the blood of the 
patient, to be replaced by a mixture of both resistant and wild type 
strains.  This supports the observation by Drew (2000) and Erice 
(1999) of emergence of antiviral drug-resistant CMV in patients on 
prolonged and or long-term anti-CMV prophylaxis and treatment in 
immunocompromised patients.  The patient experienced several 
episodes of severe CMV disease, leading to the administration of 
repetitive courses of antiviral therapy.  Selective pressure allowed for 
strains of CMV with a point mutation (TTG-to-TCG; Leu-to-Ser at 
codon 595 of the UL97 gene) to co-circulate with wild type CMV.   
 
It was observed that the appearance of CMV strains resistant to 
ganciclovir coincided with high levels of CMV DNA in the patient’s 
blood as well as with CMV pneumonitis and retinitis.   
 
CMV gB genotypes 1 and 2 or gB genotype 1 alone was detected in 
blood samples collected serially – the occurrence of mixed genotypes 
agrees with the findings in Coaquette et al (2004)’s recent study of a 
group of 64 transplant patients (22 patients received kidney transplant), 
in whom 46.9% of the patients showed multiple strains of the virus.  
Similar to that study, infection with a mixture of gB genotypes for this 
patient appeared to be associated with a higher virus load (> 100 copies 
of CMV DNA/µg of total DNA), while infection with a single genotype 
(gB type 1) was seen when copy numbers were less than 100.   
 
Coaquette et al have hypothesized that patients with mixed infection 
are more heavily immunosuppressed, compared with patients with 
single gB genotype infection. Post-transplantation immunosuppressants 
given this patient included anti thymocyte globulin, 
methylprednisolone, oral prednisolone, cyclosporin and mycophenolate 
mofetil.  The patient had chronic allograft dysfunction, resulting in 
slow tapering of the immunosuppressive doses, thus predisposing him 
to CMV infection.  In addition, specific treatment of CMV disease 
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probably contributed to the mixed infection seen in the patient, 
probably by preventing virus-specific cellular immune responses to 
infection with diverse CMV gB genotypes. 
 
Based on genotyping of CMV DNAs recovered serially from the 
patient, there were two different strains of CMV from the onset of 
infection.  Mixed infection and the subsequent detection of 
ganciclovir-resistant mutant CMV strains meant that the patient 
harboured multiple gB genotypes in the heterogeneous population of 
wild type viruses and anti-viral resistant strains.  Given the limitation 
of current molecular methods such as PCR-RFLP (where detection of 
ganciclovir-resistant mutant CMV strains is possible only when the 
mutant population reaches 10% or more (Chou et al, 1995; Erice et al, 
1999), it was not possible to ascertain whether resistance arose from 
mutation of wild type strains as a result of ganciclovir therapy or from 
a mutant strain already present when the patient was infected.  
 
Also, it was fortuitous that the patient’s CMV DNAemia was 
eliminated two weeks post nephrectomy –probably a result of cessation 
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APPENDIX B Clinical data for the study population (n = 119) of renal allograft recipients (see Chapter 7) 
       


































MFF MFF MPL GAN 
CV 01 0 0 0 0 1 0 0 1 1 0 1 0 0 0 0 0 0 0 
CV 02 1 1 0 2 1 - 1 0 1 1 1 0 0 0 0 0 1 0 
CV 03 0 0 0 0 2 3 0 0 0 0 2 0 0 0 1 1 0 1 
CV 04 0 2 1 1 1 1 0 0 0 0 1 0 0 0 0 0 1 0 
CV 05 0 1 1 2 3 1 0 0 0 0 1 0 0 0 0 0 0 0 
CV 06 0 0 0 1 3 1 0 0 0 1 1 0 1 1 1 0 1 1 
CV 07 0 0 0 2 2 0 1 0 1 0 1 0 0 0 0 0 0 0 
CV 08 0 1 1 3 2 2 1 1 1 0 1 0 0 0 0 0 0 0 
CV 09 0 0 2 1 5 1 1 0 1 0 3 0 1 1 1 0 0 0 
CV 10 0 0 1 0 0 0 1 0 1 0 2 0 0 0 0 0 0 0 
CV 11 0 0 0 0 3 0 1 0 1 0 1 0 0 0 0 0 0 0 
CV 12 0 0 3 1 1 3 1 0 1 0 1 0 0 0 0 0 0 0 
CV 13 1 1 1 2 3 3 1 1 1 1 2 1 0 1 1 1 1 1 
CV 14 0 0 - 3 1 1      0 1 0 0 0 1 1 0 0 
CV 15 0 1 1 5 1 3 0 0 0 1 1 0 0 0 0 0 1 0 
CV 16 1 1 1 2 2 3 1 0 1 0 1 0 0 0 0 0 0 0 
CV 17 1 5 1 2 1 5 0 1 1 1 1 0 0 0 0 0 1 0 
CV 18 1 0 1 0 0 5      0 1 1 0 1 1 0 1 1 
CV 19 1 0 0 0 0 4      1 1 0 0 0 0 0 0 0 
CV 20 1 0 0 0 2 3 0 0 0 0 1 1 0 1 1 1 1 1 
CV 21 0 1 0 1 1 1 0 0 0 1 1 0 0 0 0 0 0 0 
CV 22 0 0 0 0 3 3      1 1 0 0 0 0 0 1 0 
CV 23 0 1 1 3 3 2 0 0 0 1 1 0 0 0 0 0 1 0 
CV 24 0 1 1 1 - - 0 0 0 1 1 0 0 0 1 1 1 1 
CV 25 0 0 0 5 - - 1 1 1 1 1 1 0 1 1 1 1 1 
CV 26 0 0 0 0 - - 0 1 0 0 2 0 1 1 1 0 0 1 
CV 27 1 0 0 0 - - 1 1 1 0 1 0 0 0 0 0 0 0 
CV 28 0 0 0 3 1 1 0 0 0 1 2 1 0 1 1 0 1 1 
CV 29 1 0 0 0 1 0      1 1 1 0 1 1 0 1 1 
CV 30 1 0 0 0 5 5      0 1 0 1 1 1 0 0 1 
CV 31 0 1 0 0 0 - 1 0 1 0 1 0 0 0 0 0 0 0 
 Cytomegalovirus infections in solid organ transplant recipients 
 215
CV 32 1 0 1 3 0 - 1 1 1 1 1 0 1 1 1 0 1 1 
CV 33 1 0 3 0 2 2      0 1 0 1 1 1 0 0 1 
CV 34 0 - 0 0 1 0 1 1 1 1 1 0 1 1 1 0 1 0 
CV 35 0 5 1 3 - - 1 1 1 1 1 0 0 0 0 0 0 0 
CV 36 0 0 0 0 0 0      1 2 1 0 1 1 1 1 1 
CV 37 0 2 1 0 - - 0 0 0 1 1 0 0 0 0 0 1 0 
CV 38 1 1 1 3 5 5      1 1 0 0 0 0 0 1 0 
CV 39 1 0 1 1 1 0 0 0 0 1 1 0 0 0 0 0 1 0 
CV 40 0 0 0 0 4 0      0 1 0 0 0 0 0 0 0 
CV 41 1 1 1 3 3 1      1 1 1 0 1 1 0 1 1 
CV 42 0 1 1 3 4 1      0 1 0 0 0 0 0 0 1 
CV 43 0 0 0 0 3 0 0 1 1 0 1 0 0 0 0 0 0 0 
CV 44 1 2 2 2 5 0 0 0 0 0 1 0 0 0 0 0 0 0 
CV 45 0 2 0 5 - - 1 1 1 0 1 0 0 0 1 1 0 0 
CV 46 1 2 3 2 2 0 0 1 1 0 1 0 0 0 0 0 0 0 
CV 47 0 0 0 0 0 0      0 2 0 0 0 0 0 1 0 
CV 48 0 0 0 0 0 0      0 1 0 0 0 0 0 0 0 
CV 49 0 0 0 3 2 2 0 0 0 0 1 0 0 0 0 0 0 0 
CV 50 0 0 0 5 0 - 1 0 1 0 1 0 0 0 0 0 0 0 
CV 52 1 0 0 1 0 1      0 1 0 0 0 0 0 0 0 
CV 55 0 1 2 2 2 4      0 1 1 0 1 1 1 1 1 
CV 59 0 1 0 2 3 0      0 1 0 0 0 1 1 0 1 
CV 60 0 2 0 1 5 5      0 3 0 0 0 0 0 1 0 
CV 61 0 1 0 3 5 2      0 2 0 1 1 1 0 0 1 
CV 62 1 0 0 3 3 0      0 1 0 0 0 1 1 0 0 
CV 63 0 0 0 0 0 0 1 1 0 0 1 0 0 0 0 0 0 0 
CV 65 0 0 0 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 
CV 66 0 0 0 0 0 - 0 0 0 1 1 0 0 0 1 1 0 0 
CV 67 0 0 1 0 1 2      0 1 0 0 0 1 1 0 1 
CV 68 0 0 1 0 3 4      0 1 0 0 0 0 0 0 0 
CV 69 0           0 2 0 1 1 1 0 0 1 
CV 71 0 0 0 2 3 0      0 1 0 0 0 0 0 0 0 
CV 72 0 1 3 0 1 0      0 1 1 0 1 1 1 1 1 
CV 73 0 3 4 0 0 3      0 1 0 0 0 0 0 0 0 
CV 75 1 0 0 0 0 2      0 2 0 0 0 1 1 0 0 
CV 76 1 0 1 5 3 1      0 1 0 0 0 1 1 0 0 
CV 77 1 0 1 2 - - 1 1 1           
CV 79 1 0 0 0 3 2      0 1 0       
CV 80 1 1 0 0 2 0 0 0 0 0          
CV 81 1 0 1 3 1 3      0 1 0 0 0 0 0 0 0 
CV 82 0 0 0 3 0 0      1 1 0 0 0 1 1 0 0 
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CV 83 0 3 0 3 0 0 0 0 0 0 2 0 0 0 0 0 0 0 
CV 84 0 0 0 0 5 0 0 0 0 1 3 1 1 1 1 0 1 1 
CV 85 1 0 0 0 0 3      0 1 0 0 0 1 1 0 0 
CV 87 1 0 0 0 5 5 0 0 0  1 0  0 0    
CV 88 1 0 1 1 0 1      0 1 0 0 0 0 0 0 0 
CV 89  1 0 5 0 0 0      0 2 0 0 0 0 0 0 0 
CV 90 1 0 1 1 1 1 1 0 1 0 2 0 1 1 1 0 0 1 
CV 92 1 1 1 0 1 3 0 0 0 0 2 0 0 0 0 0 0 0 
CV 95 0 0 0 0 0 1 0 0 0 1 1 0 0 0 1 1 0 0 
CV 96 1 2 2 3 5 3      1 1 0 0 0 1 1 0 0 
CV 97 1 0 0 3 3 2 0 0 0 1 3 0 0 0 0 0 1 0 
CV 98 0 0 0 1 3 0 0 1 1 1 3 1 0 1 1 0 1 1 
CV 100 0 0 0 2 1 0 0 1 1 0 3 0 0 0 0 0 0 0 
CV 107 0 0 4 5 0 0      0          
CV 109 0 3 3 3 3 0      0 2 0 1 1 1 0 0 1 
CV 112 0 1 0 5 1 0      1 1 0 0 0 1 1 0 0 
CV 115 0 0 0 1 1 0      0 1 0 0 0 0 0 0 0 
CV 119 0 0 0 0 0 0      0          
CV 120 0 0 0 0 0 0      1 1 0 0 0 1 1 1 0 
CV 126 1 1 1 1 1 0      1 1 0 0 0 1 1 1 0 
CV 127 1 0 0 0 0 0      1 1 0 0 0 1 1 0 0 
CV 128 0 0 0 0 0 0      0 1 0 0 0 1 1 0 0 
CV 129 0 0 0 1 0 0      0 1 0 0 0 1 1 0 0 
CV 130 1 1 2 1 - - 1 1 1 0          
CV 136 1 1 1 3 4 - 0 0 0 1 1 0 0 0 0 0 1 1 
CV 147 1 0 0 4 1 0 1 1 1 1 1 0 0 0 1 1 1 1 
CV 154 0 0 0 1 0 1 0 0 0 0          
CV 168 1 0 0 0 0  0 0 0 0 1 0 0 0 1 1 0 0 
CV 170 0 0 2 1 0 2 0 0 0 1 1 0 0 0 0 0 0 0 
                       
 
0 :  <150 
µmol/L 
0 : no 
rejection 
0: 




0: no AECA activity; 1: 
activity present 
1: ≥1 
episode        
                
   
CMV DNAemia measured at levels 0 - 5; 
levels 0 - 2: < 100 copies of CMV 
DNA/µg of total DNA in whole blood; 
levels 3 - 5: ≥ 100 copies 




       
 





1 Yeo AC, Yeo WS, Liang AW, Seah CC, Vathsala A, Lee EJC, 
Yap HK (2006).  Post-transplant CMV DNAemia but not CMV-
induced anti-endothelial cell antibodies predisposes to chronic 
renal allograft dysfunction.  Submitted 
 
With the use of newer immunosuppressive protocols, allograft 
survival rates have improved tremendously due to the marked 
reduction in incidence of graft loss to acute rejection.  However, 
chronic rejection still remains a problem. This study aimed to 
assess the impact of cytomegalovirus (CMV) infection on 
chronic renal allograft dysfunction.  A total of 126 new renal 
allograft recipients transplanted either at National University 
Hospital or the Singapore General Hospital were recruited over 
a two year period, with 4 withdrawals and 3 deaths before 
completion of the study.  Post-transplant parameters recorded 
included transplantation type, rejection episodes, type of 
immunosuppression and ganciclovir adminstration.  Blood 
samples were obtained pre-transplantation and subsequently at 
monthly intervals for five months post-transplant, and the 
presence of CMV DNA was determined by quantitative 
polymerase chain reaction.  Statistical analysis of risk factors 
for development of chronic allograft rejection at one year post-
transplant, defined as serum creatinine >150 µmol/L was 
performed using SPSS for Windows 13.0.  Univariate analysis 
employing chi-square test showed a correlation between chronic 
allograft dysfunction at one year post-transplant and 
cytomegalovirus DNAemia at five months post-transplant (P < 
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0.01) but not previous acute rejection episodes, type of 
transplantation or type of immunosuppression or ganciclovir 
administration.  With chronic allograft dysfunction as the 
dependent variable in a multivariate logistic regression analysis, 
only cytomegalovirus DNAemia was significant (P< 0.01; OR 
3.578, 95% CI 1.417-0.031).  CMV infection in the post-
transplant period was a significant risk factor for long-term 
renal allograft dysfunction. Further studies will address possible 
mechanisms by which the virus affects immune responses. 
 
 
2 Yeo AC, Chan KP, Kumarasinghe G, Yap HK. (2005) Rapid 
detection of codon 460 mutations in the UL97 gene of 
ganciclovir-resistant cytomegalovirus clinical isolates by real-
time PCR using molecular beacons. Mol Cell Probes 19(6):389-
93. 
 
A rapid real-time polymerase chain reaction (PCR) assay using 
molecular beacons has been developed for the simultaneous 
detection of wild-type and mutant strains of cytomegaloviruses 
(CMV) with respect to codon 460 of the UL97 gene has been 
developed. The molecular beacons were designed to complement 
the wild-type codon 460 or the mutant sequence arising from a 
single base-pair difference (point mutation). Discrimination 
between wild-type and mutant templates was demonstrated as 
the beacons did not generate fluorescence with their respective 
mismatch targets but only with those that they were designed to 
perfectly anneal with. Samples that harbor mixed populations of 
CMV could also be readily recognized. Applied to a small 
number of clinical samples, results from the retrospective 
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screening by this assay are in general concordance with that 
obtained by PCR-RFLP. Using molecular beacons strategy, 
codon 460 mutation was detected in ten out o the total number 
of 40 samples, whereas the latter method identified nine samples 
as containing the mutation. The discrepant result arose from the 
genotyping of one clinical sample as mixed (containing both 
wild-type and mutant CMV strains) by molecular beacons but as 
wild-type by PCR-RFLP, suggesting that this real-time strategy 
is possibly more sensitive for mutation analysis. 
 
 
3 Yeo A, Aw M, Seah CC, Liang AW, Chan KP, Kumarasinghe G, 
Yap HK. PCR-based detection of gene mutations conferring 
ganciclovir resistance in cytomegalovirus.  In Abstracts of 10th 
International Congress of Infectious Diseases (11-14 March 
2002), Singapore. 
 
Use of ganciclovir to treat cytomegalovirus (CMV) infections 
and diseases or as prophylaxis has led to the emergence of 
resistant strains.  Mutations in several regions of the CMV 
UL97 phosphotransferase as well as the UL54 DNA polymerase 
genes have been shown to confer resistance to ganciclovir both 
clinically and in vitro by conventional plaque reduction assay.  
We describe PCR-based strategies for the detection of CMV 
strains with mutant UL97 and UL54 sequences that are rapid, 
non-culture dependent and directly from blood samples.  PCR-
Restriction Fragment Length Polymorphism (RFLP) assays 
using newly developed primers were used to screen for 
mutations in the UL54 gene. To discriminate between CMV 
strains with and without mutations in the UL97 gene, primers 
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sets were designed to specifically amplify either one but not 
both.  Thirty-six blood samples from a cohort of solid-organ 
transplant recipients, which were PCR positive for CMV and 
which contain either wild type, mixed population or mutant 
strains (with UL97 mutations in codons 594 and 595), were 
correctly identified, and confirmed by the standard PCR-RFLP 
assays.  PCR-based detection methods are an alternative to 
culture for detection of CMV ganciclovir resistance, and their 




4 Lim DL, Yeo AW, Liang AW, Seah CC, Yeo AC, Koay E, Yap 
HK.  Improved prediction of active cytomegalovirus (CMV) 
infection in high risk patients.  In Abstracts of 10th International 
Congress of Infectious Diseases (11-14 March 2002), Singapore.   
 
Background: CMV infection is a major cause of morbidity and 
mortality in allograft recipients, bone marrow transplant 
recipients and in patients with immunodeficiencies.  Preemptive 
therapy is a promising strategy in the prevention of serious 
CMV infection.  We have shown in our previous study that 
>1000 copies of CMV DNA/mg DNA tested gives a positive 
predictive value (PPV) of 70%, with a sensitivity and specificity 
of 63% and 87% respectively.  The presence of CMV late 
mRNA as pp67 is thought to reflect active viral replication.  The 
aim of this study was to determine if the addition of pp67 to the 
semi-quantitative polymerase chain (PCR) would improve the 
predictive value of detecting active disease. 
 
 Cytomegalovirus infections in solid organ transplant recipients 
 221 
Methods: From May 2001 to July 2001, blood was taken for at-
risk patients with suspected CMV disease.  CMV DNA was 
detected using semi-quantitative PCR amplification and pp67 
mRNA was detected via nucleic-acid sequence-based 
amplification (NASBA).  Active CMV disease was defined as 
either (i) proven organ involvement, eg. involvement of the lung 
as proven by CMV detection in bronchoalveolar lavage 
specimen, or (ii) a presumptive viral syndrome, eg. unexplained 
fever for at least 72 hours with associated leucopenia. 
 
Results: From May 2001 to July 2001, 117 samples were 
received from 79 patients.  Sixty percent were transplant 
recipients.  Of these samples, 20 were positive for both CMV 
>1000 copies and pp67.  Nineteen had active CMV disease, 
giving a significantly increased positive predictive value of 
95.0% (P = 0.031) as compared to CMV PCR alone (PPV = 
70%).  CMV pp67 alone gave a positive predictive value of 
72.9% and this was also significantly lower (P = 0.042) than the 
predictive value of the combined tests.  The sensitivity of the 
combined test was 63.0% and the specificity was 98.9. 
 
Conclusion: The combination of CMV PCR and pp67 provides a 
clinician with a highly predictive tool that is also very specific 
for active CMV disease.  Anti-viral therapy has its inherent risks 
and hence this combination is extremely useful when deciding 
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5 Yeo A, Yeap SY, Yap HK.  PCR-based detection of UL97 gene 
mutations conferring ganciclovir resistance in cytomegalovirus  
In Abstracts of The Institute of Biomedical Science Congress 
2001 (25-27 September 2001), Birmingham, England, UK  
 
Use of ganciclovir to treat cytomegalovirus (CMV) infections or 
as prophylaxis has led to the emergence of resistant strains.  
Mutations in several regions of the CMV UL97 
phosphotransferase as well as the UL54 DNA polymerase genes 
have been shown to confer resistance to ganciclovir both 
clinically and in vitro by conventional plaque reduction assay.  
We describe a PCR-based strategy for the detection of CMV 
strains with mutant UL97 sequences that is rapid, non-culture 
dependent and directly from blood samples.  To discriminate 
between sensitive and resistant CMV strains, primer sets were 
designed to specifically amplify either one but not both.  In a 
preliminary study, which was carried out prospectively, 32 
blood samples, which were PCR positive for CMV and which 
contain either wild type, mixed population or mutant strains 
(with UL97 mutations in codons 594 and 595), were correctly 
identified, and confirmed by the standard PCR-Restriction 
Fragment Length Polymorphism (RFLP) assays.  
 
 
6 Yeo A, Lee CY, Aw M, Seah CC, Liang AW, Chan KP, 
Kumarasinghe G, Yap HK. Detection of cytomegalovirus UL97 
gene mutations conferring ganciclovir resistance in local 
allograft recipients.  In Abstracts of 7th Asian Congress of 
Pediatric Nephrology (4-6 November 2000), Singapore.  
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Use of ganciclovir to treat cytomegalovirus (CMV) infections or 
as prophylaxis has led to the emergence of resistant strains.  
Mutations in several regions of the CMV UL97 
phosphotransferase as well as the UL54 DNA polymerase genes 
have been shown to confer resistance to ganciclovir both 
clinically and in vitro by conventional plaque reduction assay.  
The aim of this study was to devise a nested PCR-RFLP strategy 
for the rapid, direct detection in blood of CMV strains with 
mutant UL97 sequences.  Analysis of UL97 phosphotransferase 
coding sequences was carried out by restriction enzyme 
digestion using NlaIII, HhaI, TaqI, MseI and AluI.  A total of 50 
blood specimens from 11 transplant recipients were studied.  In 
two local paediatric transplant recipients with CMV infections, 
ganciclovir-resistant CMV strains were detected.  The mutations 
were present at either codon 594 or codon 595 of the UL97 
gene.  In both cases, a mixed population of CMV mutant and 
wild type strains was observed although genotyping of part of 
the CMV envelope glycoprotein B (gB) revealed the presence of 
only one (gB1) of four defined gB types.  In conclusion, 
diagnosis of ganciclovir-resistant CMV infection can be 
performed rapidly using a nested PCR-RFLP strategy on 
patients’ blood specimens. 
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chlamydial keratoconjunctivitis. Invest Ophthalmol Vis Sci. 
41(7):1818-22.  
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PURPOSE: To develop a multiplex polymerase chain reaction 
(PCR) for the detection of adenovirus, herpes simplex virus, and 
Chlamydia trachomatis in conjunctival swabs. METHODS: 
Oligonucleotide primers for detection of the 3 agents were 
combined in one reaction and evaluated for optimal performance 
using control DNAs of adenovirus type 2, herpes simplex virus, 
and C. trachomatis plasmid. The multiplex PCR was evaluated 
prospectively against its corresponding uniplex PCRs, virus 
isolation, Chlamydia Amplicor PCR, and an immunoassay 
technique (immune dot blot test) in a total of 805 conjunctival 
swabs from patients with suspected viral and chlamydial 
keratoconjunctivitis. RESULTS: The multiplex PCR was as 
sensitive as uniplex PCRs for the detection of the agents in 
clinical specimens. In the prospective study, 48 of 49 (98%) 
clinical specimens were positive for adenovirus by the multiplex 
PCR compared with 26 of 49 (53%) by adenovirus isolation. For 
herpes simplex virus detection, the multiplex PCR had a 
sensitivity of 92% (34/37) compared with 94.5% (35/37) by cell 
culture. The multiplex PCR produced identical results to the 
Amplicor PCR (21/21; 100%) compared with 71% (15/21) by 
the immune dot blot test. CONCLUSIONS: With clinical 
specimens the multiplex PCR was as sensitive as its respective 
uniplex PCRs but more sensitive than adenovirus isolation and 
as sensitive as herpes simplex virus isolation or C. trachomatis 
Amplicor PCR. It has the potential to replace several diagnostic 
tests with consequent savings in cost. The test also reduces the 
risk of misdiagnosis by the clinicians. 
 
